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ABSTRACT 
Multimorbidity, Management of COPD and Health Outcomes among Medicaid Beneficiaries 
Mayank Ajmera, B.Pharm., M.S. 
 
Chronic Obstructive Pulmonary Disease (COPD) is characterized by persistent and progressive 
airflow limitation caused due to chronic inflammation in the lungs. Approximately 15 million adults 
in the United States (U.S.) are estimated to be diagnosed with COPD and an equal number may have 
undiagnosed COPD. Challenges to COPD management include high prevalence of inflammation-
related multimorbidity among individuals with COPD. The association between multimorbidity, 
existing COPD management and role of novel therapies with anti-inflammatory properties (e.g. 
statins) in improving COPD-specific outcomes is not well researched. Therefore, the purpose of this 
study was to use real-world observational data to provide a comprehensive understanding of the 
relationship between multimorbidity and COPD management as well as assess the effectiveness and 
safety of statins in terms of COPD management. The specific aims of three studies were to: (1) 
examine the association between inflammation-related multimorbidity and COPD management in 
terms of COPD medication receipt, long-acting bronchodilators persistence and COPD-specific 
outcomes; (2) assess the effectiveness of novel statin therapy in improving COPD-specific 
outcomes; (3) evaluate the safety of statins and other commonly used medications (antidepressants 
and inhaled corticosteroids) in terms of new-onset diabetes. This study used a retrospective 
longitudinal dynamic cohort design using data extracted from multiple years (2005-2008) of 
Medicaid Analytic eXtract (MAX) files to identify Medicaid beneficiaries with newly diagnosed 
COPD (n = 19,060). Findings from the first study documented very high prevalence of 
inflammation-related multimorbidity and indicated that it was significantly associated with reduced 
COPD-medication utilization and decreased persistence on long-bronchodilators.  Our study findings 
suggest that COPD medication management may be poor due to competing demands arising from 
the presence of inflammation-related multimorbidity. The results from the study on effectiveness of 
statins revealed that any statin use improved COPD-specific outcomes compared to no statin use.  A 
closer examination of the data revealed that only those with long-term statin use had better outcomes 
as compared to those with no statin use. We also found that beneficiaries with inflammation-related 
multimorbidity and statin use had better COPD-specific outcomes compared to those with 
multimorbidity and no statin use.  From the third study, we found that association between statin use 
and risk of new-onset diabetes was no longer significant in analyses that controlled for selection bias 
in unobserved characteristics. Collectively, these findings indicate poor COPD management among 
those with multimorbidity and emphasize the need for novel therapies to effectively manage COPD. 
In this context, the current study underscores the advantage of statins in improving COPD-specific 
clinical and economic outcomes. This study indicate the need of randomized clinical trials and long-
term observational studies to establish the efficacy, effectiveness, and safety of novel therapeutic 
agents in management of COPD.
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CHAPTER 1: BACKGROUND AND SIGNIFICANCE 
 
Definition 
Chronic Obstructive Pulmonary Disease (COPD) is characterized by persistent and 
progressive airflow limitation caused due to chronic inflammation in the lungs. The inflammation of 
airways in the lungs is usually a result of persistent exposure to noxious substances such as tobacco 
smoke. (GOLD, 2013)  As per the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 
definition of COPD, airflow limitation can be mainly attributed to small airways diseases 
(obstructive bronchiolitis) and parenchymal destruction (emphysema). (GOLD, 2013) The most 
common symptoms of COPD include dyspnea, chronic cough, sputum production, wheezing and 
chest tightness. (Kessler, 2011; Espinosa, 2011)  
Epidemiology and Burden of COPD 
Approximately 15 million adults in the United States (U.S.) are estimated to be diagnosed 
with COPD and an equal number may have undiagnosed COPD. (CDC, 2012; Ford et al., 2013) 
Specifically, COPD is highly prevalent among young adults (<65 years old) as well. The extent of 
COPD among young adults ranges from 3.2% (18-44 year) to 9.2% (55-64 year). (CDC, 2012) 
COPD is associated with high clinical, economic and humanistic burden. It is the third leading cause 
of death (133,965 deaths due to COPD in 2009) in the U.S. with age adjusted death rate of 41.2 per 
100,000 individuals. (NHLBI, 2009)  The overall management of COPD accounts for $49.5 billion, 
with maximum healthcare expenditures attributed towards exacerbation management. Healthcare 
utilization, specifically inpatient healthcare utilization among COPD has increased over the 
years.(Brown et al, 2010)  Furthermore, COPD has high humanistic or social burden as well. 
Globally, COPD account for 3.1 % of disability adjusted life-years (DALYs) lost; and is projected to 
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be the seventh leading cause of DALYs lost. (GOLD, 2013) In addition to the burden associated 
with COPD, those with COPD also have high rates of multimorbidity; specifically inflammation-
related multimorbidity. The high prevalence of inflammation-related multimorbidity adds to the 
burden of COPD. In this context, it is important to systematically study the relationship between 
inflammation-related multimorbidity, management of COPD and health outcomes.  
Inflammation-related Multimorbidity and COPD-specific Outcomes  
COPD is mainly characterized as an inflammatory disease (Rabe et al., 2007) and therefore, 
it has been suggested that individuals with COPD may have high prevalence of other inflammation-
related chronic conditions. Investigators from a study using National Health and Nutrition 
Examination Survey (NHANES) have reported that individuals with COPD have high rates of 
inflammation-related chronic diseases such as (54.6% vs. 36.9%), diabetes (16.3% vs. 12.8%) , 
depression (20.6% vs. 12.5%), osteoporosis (16.9% vs. 8.5%), coronary heart disease (12.7% vs. 
6.1%), congestive heart failure (12.1% vs. 3.9%), and stroke (8.9% vs. 4.6%) as compared to those 
without COPD. (Schnell et al., 2012) Indeed, researchers have suggested that COPD should be 
deemed as part of “chronic systemic inflammatory syndrome”. (Barnes & Celli, 2009; Fabbri, 2008) 
Evidence exists with regards to challenges to COPD management that may occur due to presence of 
inflammation-related multimorbidity. However, no study till now has assessed its impact on COPD 
management, specifically treatment patterns among individuals with COPD. Furthermore, only a few 
studies have examined the role of co-existing chronic conditions on COPD-specific outcomes. The 
findings from these studies point towards negative impact of multimorbidity on COPD-specific 
outcomes; however, none of the studies until now have systematically evaluated the impact of 
inflammation-related multimorbidity on COPD-specific outcomes.  
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This leads to the rationale for the Aim1, which examines the association between 
inflammation-related multimorbidity and COPD treatment patterns (management) and COPD-
specific outcomes such as COPD-specific healthcare utilization and healthcare expenditures among 
Medicaid beneficiaries with newly-diagnosed COPD.  
Inflammation-related Multimorbidity, Novel Statin Therapy and COPD-specific outcomes  
Currently, the treatment for Chronic Obstructive Pulmonary Disease (COPD) focuses on 
reducing the frequency of acute exacerbations and relieving the symptoms of COPD such as 
shortness of breath (GOLD, 2013) through acute and maintenance pharmacologic therapies as well 
as pulmonary rehabilitation. To date, no therapeutic options, which alter the prognosis of disease 
also known as disease modifying drugs for COPD treatment, have been established.  As the literature 
review from Aim 1 suggested that COPD is associated with high levels of systemic inflammation; it 
is plausible that treatments for reducing the systemic inflammation may have positive COPD-
specific outcomes. Indeed, new insights into the pathophysiology of the disease have opened up 
opportunities to use therapeutic regimens that are currently available for circulatory diseases to treat 
COPD. (M. Cazzola, Ciaprini, Page, & Matera, 2007; Fabbri & Rabe, 2007) 
Statins, a class of cholesterol lowering drugs have demonstrated their effectiveness in 
prevention and management of cardiovascular diseases. (Baigent et al., 2005) Based on the review of 
in vitro as well as in vivo studies Schönbeck and Libby (Schonbeck & Libby, 2004) concluded that 
statins also have anti-inflammatory functions. The evidence has also been supported by preclinical 
models that have revealed the pleiotropic/anti-inflammatory therapeutic benefits attributable to 
statins. (Takahashi et al., 2008) These facts derived from several mechanistic studies suggest that 
statin use has emerged as a novel therapeutic intervention for individuals with COPD. (Walsh, 2008)  
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Some studies have examined the beneficial effects of statins in improving lung function, 
health status and COPD-related exacerbations among those with COPD. Few studies have assessed 
impact of statin use and COPD-specific outcomes and reported lower rates of COPD-related 
hospitalizations with statin use. However, none of the studies are generalizable to US population and 
no study has systematically studied the role of inflammation-related multimorbidity on statin use and 
COPD-specific outcomes. Moreover, no study till now has examined the impact of statin use on 
healthcare expenditures among individuals with COPD. 
Therefore, the primary purpose of the Aim 2, is to examine the effectiveness of novel statin 
therapy in terms of clinical and economic outcomes among individuals with newly-diagnosed COPD 
in a real-world practice setting. The study estimates the extent of statin use among individuals with 
COPD and examined the factors associated with statin use. Furthermore, we also assessed the 
COPD-specific outcomes with statin use among those with COPD and inflammation-related 
multimorbidity.  
Inflammation-related Multimorbidity, Medication Use and New-onset Diabetes 
 Multiple medication use among individuals with COPD is very high due to the presence of 
high rates of inflammation-related multimorbidity. (Anecchino et al., 2007) Although, generally 
regarded as safe, concerns about adverse effects have been raised about some of the medications 
used to treat COPD and allied inflammation-related multimorbidities. Specifically, antidepressants, 
inhaled corticosteroids (ICS) and statins have been linked with new-onset diabetes. (Bhattacharjee, 
Bhattacharya, Kelley, & Sambamoorthi, 2013; O'Byrne et al., 2012; Sattar et al., 2010; Suissa, 
Kezouh, & Ernst, 2010) New-onset diabetes has been linked with medication use because some of 
these medications can increase insulin resistance and decrease insulin secretion and thereby affecting 
the overall glucose metabolism. (Carvalho et al., 2004; Colbert & Stone, 2012; Nielsen et al., 2004)  
 [6] 
 
 Medications such as ICS are integral to the management of individuals with COPD. 
Furthermore, new medications (statins) are being evaluated as disease modifying drugs for the 
treatment of individuals with COPD. Therefore, it is essential to generate evidence regarding 
multiple medication use and potential adverse effects like new-onset diabetes.  
 Thus, in the Aim 3, we comprehensively evaluated the association between commonly-used 
medications and new-onset diabetes among individuals with COPD and inflammation-related 
multimorbidity. This study specifically examined the safety of type of statins among Medicaid 
beneficiaries with COPD after controlling for comprehensive set of risk factors. 
Use of Medicaid Data 
To accomplish all the aims we selected Medicaid data for the following reasons: 1) 
Multimorbidity rates are increasing among the young adults and studies have reported negative 
impact of multimorbidity on economic outcomes among the young adults population. In the United 
States, Medicaid is the largest insurance provider for the young adults and thus it is important to 
examine the impact of multimorbidity on Medicaid enrollees. 2) Furthermore, Affordable Care Act 
through the Medicaid expansion policies is going to expand the coverage for young adults and thus 
will include a majority of young adults in the US. 3) Medicaid population also represents individuals 
in the lower socio-economic strata of the society. The effects of socio-economic status on lung 
functions have been extensively studied. It has been reported that low socio-economic status (SES) 
is associated with decreased lung function even after controlling for smoking status, occupational 
exposures and race. A review of literature by Hegewald et al. concluded that SES is an under-
recognized factor of pulmonary disease. (Hegewald, 2007) Many factors associated with low SES 
such as exposure to indoor and outdoor air pollutants, poor nutrition, tobacco smoke exposure etc. 
have been suggested to affect lung function. (Hegewald, 2007) Therefore, understanding the 
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management of COPD in a more vulnerable section of the society with greater risk factors is 
important.  4) Specifically, COPD management in Medicaid enrollees has been an understudied area. 
Few studies have examined healthcare utilization, economic burden and quality of care among 
Medicaid beneficiaries with COPD. The burden of COPD in high-risk Medicaid population (40-64 
years old) is greater when compared with other respiratory diseases (ORD) and non-respiratory 
diseases (NRD). (Shaya, 2006; Lin, 2010) In a study conducted by Shaya FT et al, it has been 
suggested that healthcare use i.e. hospitalization rates are more among COPD patients as compared 
to ORD and NRD patients within the Medicaid population. In the same study, it has been reported 
the office visits (indicator of better quality) were lower among COPD patients as compared to ORD 
patients. (Shaya, 2006) Studies have also shown that Medicaid beneficiaries with COPD have high 
rates of multimorbidity. Therefore, it is important to systematically study the management of COPD 
in the Medicaid population. (Lin, 2010) 
Purpose of this study 
The purpose of this study was to comprehensively understand the relationship between 
inflammation-related multimorbidity, COPD management and health outcomes associated with 
novel statin therapy among Medicaid beneficiaries observed in a real-world practice setting. This 
study used a retrospective longitudinal dynamic cohort design using data extracted from multiple 
years (2005-2008) of Medicaid Analytic eXtract (MAX) files to identify Medicaid beneficiaries with 
newly diagnosed COPD (n = 19,060). The specific aims and objectives of three studies are listed 
below. 
Aim 1: Examine the association between inflammation-related multimorbidity and COPD 
medication receipt, long-acting bronchodilators persistence and COPD-specific outcomes 
among Medicaid beneficiaries with COPD 
Objective 1.1: To examine COPD Medication receipt and long-acting bronchodilators persistence 
among Medicaid beneficiaries with COPD and inflammation-related multimorbidity defined by the 
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presence of arthritis, CVD, depression, diabetes and osteoporosis and depression compared those 
with COPD only. 
Hypotheses 1.1: We hypothesized that individuals with COPD and inflammation-related 
multimorbidity will have significantly lower likelihood of receiving inhaled medications and will 
also have lower rates of treatment persistence compared to those with COPD only. 
Objective 1.2: Compare COPD-specific (COPD-specific hospitalizations, COPD-specific 
Emergency Room visits and COPD-specific outpatient visits) and COPD-related healthcare 
utilization (COPD-related hospitalizations and COPD-related Emergency Room visits) among 
individuals with COPD and inflammation-related multimorbidity and those with COPD only.  
Hypotheses 1.2: We hypothesized that individuals with COPD and inflammation-related 
multimorbidity will have significantly higher healthcare utilization as compared to individuals with 
COPD only. 
Objective 1.3: Estimate and compare COPD-specific healthcare expenditures individuals with 
COPD and inflammation-related multimorbidity and those with COPD only.  
Hypotheses 1.3: We hypothesized that individuals with COPD and inflammation-related 
multimorbidity will have significantly higher COPD-specific healthcare expenditures as compared 
to individuals with COPD only. 
Aim 2: To examine the effectiveness of novel statin therapy in improving COPD-specific 
outcomes.   
Objective 2.1: To estimate the prevalence of statin therapy and examine the factors associated with 
statin therapy among individuals with COPD.  
Objective 2.2: To assess the effectiveness of statin therapy among Medicaid beneficiaries with 
COPD.  
 
Hypotheses 2.2.1: We hypothesize that adults with statin therapy will be less likely to have COPD-
specific hospitalizations, COPD-specific Emergency Room visits, and COPD-specific outpatient 
visits.  
Hypotheses 2.2.2:  We hypothesize that adults with statin therapy will be less likely to have COPD-
specific hospitalizations, COPD-specific Emergency Room visits, and COPD-specific outpatient 
visits among individuals with COPD and inflammation-related multimorbidity. 
Objective 2.3: To estimate and compare total healthcare and COPD-specific expenditures associated 
with statin therapy among individuals with COPD compared to no statin therapy. 
Hypotheses 2.3: We hypothesize statin therapy will be associated with statistically significant lower 
total healthcare expenditures and COPD-specific expenditures as compared to adults with no statin 
therapy.    
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Aim 3: To evaluate the association between commonly used medications (antidepressants, ICS, 
statins) and new-onset diabetes among adults with newly diagnosed COPD. 
Objective 3.1: To assess real world safety (new-onset diabetes) of any antidepressants, ICS and 
statin use among Medicaid beneficiaries with newly-diagnosed COPD after controlling for 
comprehensive set of risk factors.  
Hypotheses 3 1: We hypothesize that any antidepressants, ICS and statin use will increase the risk of 
new-onset diabetes among Medicaid beneficiaries with newly-diagnosed COPD compared to those 
with no antidepressants, no ICS and no statin use. 
Objective 3.2: To compare the safety (new-onset diabetes) of type of statins among Medicaid 
beneficiaries with newly-diagnosed COPD after controlling for comprehensive set of risk factors. 
Hypotheses 3.2: We hypothesize that lipophilic statins i.e. atorvastatin and simvastatin will be 
associated with higher risk of new-onset diabetes compared to non-lipophilic statins such as 
pravastatin.  
Objective 3.3: To examine the association between long-term use of antidepressants, statins and 
new-onset diabetes among Medicaid beneficiaries with newly-diagnosed COPD after controlling for 
comprehensive set of risk factors. 
Hypotheses 3.3: We hypothesize that long-term use of antidepressants and statins throughout the 
baseline period will be associated with increased likelihood of incident diabetes as compared to 
non-persistent use of statins.  
 Significance of the study 
This study aims to fill the knowledge gap and provide knowledge about real-world patterns 
of current pharmacologic management among those with inflammation-related multimorbidity and 
COPD. As there has been an increasing recognition for organizing care around the individuals rather 
than the disease (Kadam, 2012) an understanding of how care is delivered among individuals with 
multimorbidity will have important implications for the overall healthcare management of 
individuals with COPD. Our study also addresses the need to evaluate novel anti-inflammatory 
treatments for effective management of patients with COPD. As COPD is being increasingly 
recognized as a disease of systemic inflammation, it is highly important to measure the effectiveness 
of anti-inflammatory therapies in a real-world setting.  
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CHAPTER 2: INFLAMMATION-RELATED MULTIMORBIDITY AND COPD 
MANAGEMENT AMONG MEDICAID BENEFICIARIES WITH NEWLY-DIAGNOSED 
COPD 
 
INTRODUCTION 
Multimorbidity is defined as coexistence of two or more chronic conditions. (C. M. Boyd, 
Ritchie, Tipton, Studenski, & Wieland, 2008; M. Fortin, Soubhi, Hudon, Bayliss, & van den Akker, 
2007; Valderas, Starfield, Sibbald, Salisbury, & Roland, 2009) Agency for Healthcare Research and 
Quality suggests that multimorbidity affects care of each chronic condition by complications posed 
by each condition  on another such as interaction between medications or disabling impact of one 
condition on another.(AHRQ, 2007)  Multimorbidity is a major challenge among elderly individuals 
aged 65 or older. (Marengoni et al., 2011)  However, in recent years multimorbidity is no longer 
considered as just an older person’s issue due to its high prevalence among younger adults aged less 
than 65 years. (Naessens et al., 2011; Taylor et al., 2010)  The prevalence of multimorbidity in the 
Australian population is estimated to be 15% among younger adults in the age group 40-59 years. 
(Taylor et al., 2010) In the United States (US) among adults participating in the National Health 
Interview survey and in the age group 45-64 years, the prevalence of multimorbidity has been 
increasing and has grown from 24.5% in 2004 to 28.1% in 2010. (Ward & Schiller, 2013)A 
retrospective cohort study of 33,324 employees and dependents of the Mayo clinic (aged 18-64 
years) found that 54.3% of the total population had two or more chronic conditions and 16.5% had 
five or more chronic conditions. (Naessens et al., 2011) 
Multimorbidity and Young Adults 
Although multimorbidity is highly prevalent among younger adults, only a handful of studies 
have examined the impact of multimorbidity on health outcomes such as healthcare expenditures 
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(Naessens et al., 2011), and health-related quality of life (HRQol) (M. Fortin, Dubois, Hudon, 
Soubhi, & Almirall, 2007) among younger adults. In these few studies it has been suggested that 
adults with multimorbidity pose significant economic burden that persists over a long-term. 
(Anderson, 2010; Coughlin & Long, 2009; Naessens et al., 2011) A study conducted using data from 
employees of large self-funded health plan indicated that on a per-capita basis, younger adults with 
multimorbidity ($21,182 among those with 5 or more chronic conditions) had higher healthcare 
expenditures compared to those without multimorbidity ($3,952 among those with single chronic 
condition). (Naessens et al., 2011) Such higher healthcare expenditures also persisted over all four 
years of the study period. (Naessens et al., 2011) Similarly, in a report published by the Robert 
Wood Johnson Foundation, it has been indicated that more than three-fifths of healthcare spending 
on the overall US population is for individuals with multimorbidity. (Anderson, 2010)  These 
findings are in conclusion with another study on multimorbidity and healthcare expenditures among 
high-cost Medicaid beneficiaries. (Coughlin & Long, 2009)  Furthermore, the adverse impact of 
multimorbidity has also been observed in terms of healthcare utilization.  In 2009, of an estimated 
326 million physician office visits, 39.4% visits were made by adults in the age group 45-64 and 
with multimorbidity, suggesting that young adults had higher healthcare utilization compared to 
those without multimorbidity. (Ashman & Beresovsky, 2013)   In addition, almost a quarter of 
individuals in  age group 45-64 with multimorbidity delayed needed medical care due to cost 
considerations (Freid, Bernstein, & Bush, 2012), highlighting compromised access for individuals 
with multimorbidity. 
In addition to higher rates of healthcare utilization and expenditures, multimorbidity also 
affects the quality of life among younger adults. It has been reported that among younger adults with 
multimorbidity (cardiac and respiratory conditions) HRQoL was significantly lower when measured 
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in terms of SF-36 physical component summary compared to those without multimorbidity (mild or 
no problems with cardiac and respiratory disorders). (M. Fortin et al., 2007) 
 These studies highlight that there exists knowledge gap in terms of the comprehensive 
understanding of multimorbidity and its impact on management of specific chronic conditions, 
healthcare utilization and disease-specific outcomes among younger adults.   
Multimorbidity among Adults with Chronic Obstructive Pulmonary Disease (COPD) 
In many studies that estimate the prevalence and patterns of multimorbidity among adults 
aged over 55 years, COPD is often included as one of the chronic conditions (Britt, Harrison, Miller, 
& Knox, 2008) suggesting that multimorbidity may be a common problem among individuals with 
COPD.  It is important to analyze the impact of multimorbidity among individuals with COPD for 
many reasons. First, COPD is highly prevalent in the United States (US). As of 2011, approximately 
15 million Americans (6.3%) have diagnosed COPD; however, it has been reported that equivalent 
number of Americans may have undiagnosed COPD. (CDC, 2012; Ford et al., 2013) Second, COPD 
is a highly debilitating condition associated with significantly poor health-related quality of life 
(Ryynänen, Soini, Lindqvist, Kilpeläinen, & Laitinen, 2013) and is the third leading cause of 
mortality in the United States. In addition to the clinical burden of COPD, it is also associated with 
high economic (NHLBI, 2009) and social burden (Lopez & Mathers, 2006).  Third, the overall 
management of COPD accounts for $49.5 billion. (NHLBI, 2009)Fourth, compared to individuals 
without COPD, individuals with COPD are at a higher risk of having multimorbidity due to common 
inflammation-related pathways. (Fabbri, Luppi, Beghé, & Rabe, 2008)Therefore, an understanding 
of prevalence of multimorbidity and its impact on health outcomes among individuals with COPD is 
an important first step towards improving healthcare management of individuals with COPD.  
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Prevalence of Inflammation-related multimorbidity among individuals with COPD 
When examining multimorbidity among individuals with COPD, it is important to note that 
COPD is mainly characterized as an inflammatory disease that is associated with progressive and 
persistent airflow limitation. (Rabe et al., 2007)  Therefore, it has been suggested that there may be 
high prevalence of inflammation-related chronic conditions among individuals with COPD due to 
elevated levels of inflammatory mediators. Although, the exact mechanisms have yet not been 
established, researchers suggest that inflammation in COPD may either have a “spill-over” effect or 
the inflammation may be a part of “systemic” inflammation. (Fabbri et al., 2008)A review on 
systemic manifestations of COPD suggested that systemic inflammation in COPD may lead to 
various inflammation-related chronic diseases such as arthritis, cardiovascular diseases, depression, 
diabetes and osteoporosis. (Barnes & Celli, 2009; Nussbaumer-Ochsner & Rabe, 2011) Indeed, 
researchers have suggested that COPD should be deemed as part of “chronic systemic inflammatory 
syndrome”. (Barnes & Celli, 2009) 
Although there are no specific studies of inflammatory-related multimorbidity among 
individuals with COPD, a study using data from the National Health and Nutrition Examination 
Survey (1999-2008) reported that among individuals greater than 45 years old, those with COPD had 
significantly higher rates of coexisting arthritis (54.6% vs. 36.9%), diabetes (16.3% vs. 12.8%) , 
depression (20.6% vs. 12.5%), osteoporosis (16.9% vs. 8.5%), coronary heart disease (12.7% vs. 
6.1%), congestive heart failure (12.1% vs. 3.9%), and stroke (8.9% vs. 4.6%) as compared to those 
without COPD. (Schnell et al., 2012) These findings suggest that inflammatory conditions (arthritis, 
cardiovascular diseases, depression, diabetes and osteoporosis) may be highly prevalent among those 
with COPD.   
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Challenges to COPD Management 
 The management of individuals with COPD primarily revolves around pharmacologic 
treatments. The main medications used in the management of COPD include bronchodilators and 
corticosteroids. Primary goals of the COPD management comprise of reducing the symptoms of 
COPD and decreasing/minimizing the risk associated with COPD. (Rabe et al., 2007) 
Inflammatory-related multimorbidity among adults with COPD may complicate overall 
COPD management. (Tsiligianni, Kosmas, Van, & Tzanakis, 2013) One complication may arise 
because pharmacological therapies for COPD may interact or may have contraindications with 
therapies for inflammatory-related conditions. For example, beta blockers which are used to treat 
cardiovascular conditions may interact with beta agonists, main pharmacological therapy for COPD 
management. (van der Woude et al., 2005) Similarly, systemic corticosteroids to treat individuals 
with severe COPD have been linked to impairment in glucose metabolism process and thus may 
affect diabetes outcomes among individuals with COPD and diabetes. (Caughey, Preiss, Vitry, 
Gilbert, & Roughead, 2013) Another complication may arise because presence of some conditions 
such as CVD can affect metabolism of COPD-medications. For example, theophyline clearance is 
reduced among individuals with COPD and CVD and may lead to poor COPD-specific outcomes. 
(Ogawa, Stachnik, & Echizen, 2013) 
Although pharmacological therapy is the hallmark of COPD management, there are no 
clinical practice guidelines on how to manage COPD in the presence of multimorbidity. In fact, even 
among older adults with very high prevalence of multimorbidity there have been no established 
clinical practice guidelines. (C. M. Boyd et al., 2005)  
In the absence of clinical practice guidelines for individuals with multimorbidity the 
treatment for chronic conditions are at the discretion of clinical decision making by the healthcare 
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providers. Therefore, it is important to understand the current treatment practice among individuals 
with COPD and multimorbidity in order to improve their healthcare management.  
Impact on Overall Health Outcomes 
In addition to challenges in COPD management, inflammatory-related multimorbidity may 
also affect overall health and COPD-specific health outcomes of individuals with COPD. Although, 
the impact of inflammation-related multimorbidity has not been specifically studied among younger 
adults with COPD, some studies have evaluated overall mortality, healthcare utilization, and 
healthcare expenditures associated with multimorbidity among individuals with COPD of all ages. It 
has been reported that among individuals with COPD, inflammation- related multimorbidity are 
associated higher likelihood of all-cause mortality. (Antonelli Incalzi et al., 1997; McGhan et al., 
2007) 
 Higher overall healthcare utilization and expenditures have been observed among 
individuals with COPD compared to those without COPD.  Findings from a recent study suggest that 
presence of multimorbidity was associated with significantly higher overall medical utilization and 
costs among Medicaid beneficiaries with COPD (cases) as compared to matched controls. For 
example, the highest medical utilization as measured by number of service claims was higher among 
individuals with COPD and diabetes as compared to matched controls with diabetes (148.3 vs. 81.5, 
p < 0.001). (Lin, Shaya, & Scharf, 2010) Although, the impact of inflammation-related 
multimorbidity on general health outcomes has been studied, the relationship between inflammation-
related multimorbidity and COPD-specific outcomes is an understudied area.  
Effects on COPD-Specific Outcomes 
Only a few studies have examined the relationship between multimorbidity on COPD-
specific outcomes. One study evaluated the risk of COPD-related re-hospitalizations associated with 
co-morbidities among individuals of all ages with COPD. The results revealed that COPD related re-
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hospitalizations were higher among individuals with pulmonary hypertension (HR: 1.24; 95% CI: 
1.14 - 1.35). However, contrary to our understanding, presence of diabetes (HR: 0.76; 95% CI: 0.63 
– 0.91) or hypertension (HR: 0.77; 95% CI: 0.66 – 0.90) was associated with lower likelihood of 
COPD-related re-hospitalizations. (McGhan et al., 2007)  A study using data from 9,716 patients of 
all ages, admitted with COPD, across National Health Services Trusts in the United Kingdom (UK) 
evaluated the relationship between multimorbidity and COPD related outcomes. This study reported 
that other than the lung-related multimorbidity such as lung cancer, cardiovascular diseases and 
diabetes were significantly association with increased risk of 90-day readmissions. For example, 
individuals with ischemic heart disease had 20% increased risk of 90-day COPD readmission (RR: 
1.20, 95% CI: 1.12 – 1.27). (Roberts, Stone, Lowe, Pursey, & Buckingham, 2011) 
Need for the study 
 As suggested in the introduction section, studies related to impact of multimorbidity on 
health outcomes have mostly focused on elderly individuals; specifically, elderly Medicare 
beneficiaries. Evidence has accumulated that multimorbidity is common among young adults and it 
is important to understand the relationship between multimorbidity and health outcomes in this 
population.  
Among the younger adults population, enrollees in the Medicaid population due to their low 
socioeconomic status generally tend to have poor health outcomes. As confirmed by a recently 
conducted systematic review low socio-economic status is associated with higher rates of COPD 
prevalence and poor health outcomes such as mortality and higher healthcare utilization. (A. S. 
Gershon, Dolmage, Stephenson, & Jackson, 2012) In the United States, Medicaid is an important 
payer of a major part of young adult population. (KFF, 2011) Furthermore, it also represents 
individuals in the lower socio-economic strata of the society. (KFF, 2011) Studies have shown that 
multimorbidity has worse impact among individuals in the low SES category compared to those in 
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higher socioeconomic groups. (Sawa, 2011) In terms of Medicaid beneficiaries with COPD, 
investigators have indicated that individuals with COPD have more rates of multimorbidity 
compared to matched non-COPD counterparts. Utilizing the Maryland Medicaid database, Lin et al 
reported that beneficiaries with COPD had higher prevalence of diabetes mellitus (27.7%), 
congestive heart failure (17.9%) and cerebrovascular disease (10.7%). (Lin et al., 2010) The high 
prevalence of COPD and multimorbidity in the Medicaid population necessitates the examination of 
impact of multimorbidity on COPD-specific outcomes among Medicaid beneficiaries with COPD.  
 When considering individuals with multimorbidity, the Wagner chronic care model of 
structured care suggests that evidence based support for decision making and the use of clinical 
guidelines are key elements in providing high quality and effective care. (Wagner et al., 2005) 
Indeed, an expert review on guiding principles for care of adults with multimorbidity has highlighted 
the importance of availability of relevant evidence regarding important outcomes. (Guiding 
principles for the care of older adults with multimorbidity: An approach for clinicians: American 
geriatrics society expert panel on the care of older adults with multimorbidity.2012) Despite high 
prevalence of inflammation-related multimorbidity among individuals with COPD, no clear clinical 
guidelines for COPD have been established. Therefore, a systematic understanding of COPD and the 
relationship between inflammation-related multimorbidity and COPD-specific outcomes is required 
in order to provide evidence based care to individuals with COPD. Furthermore, a comprehensive 
understanding of the relationship will help in developing interventions which could further improve 
health outcomes among individuals with COPD. In fact, a systematic review of interventions for 
people with multimorbidity has suggested that interventions targeted at specific combinations of 
common conditions, or specific problems for patients with multiple conditions, may be more 
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effective. (Smith, 2012) Studies are therefore required to understand the impact of multimorbidity on 
COPD-specific outcomes.  
Only a few studies have assessed the impact of multimorbidity on COPD-specific outcomes. 
Moreover, there are several limitations present in these studies such as discrete approach followed in 
terms of assessing multimorbidity. (McGhan et al., 2007; Roberts et al., 2011) As COPD is 
increasingly being identified as a part of “chronic systemic inflammatory syndrome”, (Fabbri et al., 
2008) a holistic approach is required to understand the relationship between multimorbidity and 
COPD. In addition, the population included in one study had individuals with asthma which may 
have led to misdiagnosis of COPD.  Some of the other limitations of the studies presented in our 
introductions section include no adjustment of potential confounders such as co-medications.  
The high prevalence of inflammation-related multimorbidity among individuals with COPD 
and dearth of literature in terms of its impact on COPD-specific outcomes necessitates a 
comprehensive investigation. In addition, it is important to understand the relationship between 
inflammation-related multimorbidity and COPD among vulnerable Medicaid beneficiaries after 
extensively controlling for potential confounders. Therefore, our study aims to fill the critical 
knowledge gaps in the area of multimorbidity among younger adults with COPD. 
A unique contribution of our study is to have a better understanding of a relationship between 
inflammation–related multimorbidity and COPD-specific outcomes. COPD is often understood a 
disease with local inflammation. Therefore, most pharmacologic medications used in treating COPD 
focuses on reducing local inflammation and thereby improving only symptoms and not changing the 
course of disease progression. Recently, investigators have begun to consider COPD as a disease 
associated with systemic inflammation. By explaining the link between inflammation-related 
multimorbidity and COPD-specific outcomes, we strengthen the current understanding about 
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inflammation in COPD and provide a novel target area (systemic inflammation) to improve COPD-
specific outcomes. 
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CONCEPTUAL FRAMEWORK 
For the purposes of this study we adapted the conceptual framework from “Competing demands” 
model and operationalized the framework based upon our study requirements. The diagram (figure 
1) below details the basic version of the “competing demands” model originally used in assessing 
the impact of multimorbidity on preventive/primary care. (Jaén, Stange, & Nutting, 1994) It was 
later adapted by Klinkam et al in understanding the relationship between multimorbidity and care 
among individuals with depression. (Klinkman, 1997) The model described below contains four 
specific domains: a) the patient; b) the clinician; c) the practice ecosystem and d) the overall policy 
environment.  
The interplay between these characteristics eventually affects the care being provided to the 
patient. We were not able to determine any clinician characteristics due to unavailability of data. 
Competing demands from multimorbidity may lead to poorer COPD-specific outcomes compared to 
those without multimorbidity.  
 
 
 
  
Figure 1: “Competing Demands” Model on Impact of Multimorbidity on Health Outcomes 
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METHODS  
Study design 
 We utilized a retrospective longitudinal dynamic cohort design using administrative claims 
data for the years 2005 through 2008. Individuals with COPD were identified between 01/01/2006 
and 12/31/2007 (Index date Identification Period). Index date was recorded for each Medicaid 
beneficiary as the first observed inpatient or outpatient service date with COPD diagnosis.   Baseline 
period was considered as 12 months prior to this index date and follow up period was considered as 
12 months after the index date.    
 
 
 
 
 
 
 
Data Source 
Medicaid Analytic eXtract (MAX) (2005-2008) 
Medicaid analytic extract (MAX) files are prepared and produced by the Centers for 
Medicare and Medicaid Services with the help of Research and Data Assistance Center (ResDAC) 
for performing research on healthcare utilization and outcomes among Medicaid beneficiaries. States 
administering the Medicaid program are required to report annual, person-level data via Medicaid 
Statistical Information System (MSIS) for the Medicaid beneficiaries to the CMS. These person 
level files provide information about beneficiaries’ eligibility, their healthcare utilization and 
payment information. Several initiatives are taken by the agencies to maintain and improve the 
Index date 
Identification period 
12/31/2007 01/01/2005 12/31/2008 
 
Baseline period 
(1 year prior to index date) 
 
Follow-up period I 
(1 year from end index date) 
01/01/2006 
Figure 2: An example of description of study periods 
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quality of these datasets. (CMS, 2011; Hennessy, Leonard, Palumbo, Newcomb, & Bilker, 2007)We 
received separate files from CMS which were linked based on beneficiaries’ unique identification 
numbers. These included: enrollment (“personal summary”), inpatient and outpatient medical 
claims, and pharmacy claims files for beneficiaries. 
The personal summary file provided information on eligibility, demographics (age, gender, 
and race), managed care enrollment, and utilization summary. The other four files contained 
information on fee-for-service claims for services used. “Other therapy” included information 
regarding claims for Medicaid services provided at an outpatient level such as clinic services, 
physician services, etc. Information regarding services provided during hospitalizations was obtained 
from the “Inpatient file”. These files contain data such as hospitalization/outpatient services 
diagnoses codes, procedures, length of stay for each hospitalization and expenditures related to 
hospitalizations or other services. All the information regarding pharmacy or drug services was 
obtained from the “Prescription Drug” file. This file included information regarding utilization of 
prescription drugs by Medicaid beneficiaries including prescription fill date, days of supply, national 
drug code (NDC).  
We used data for beneficiaries residing in the following states: California (CA), Illinois (IL), 
New York (NY) and Texas (TX). The primary reason behind using this data was to obtain programs 
with lower Medicaid-managed care penetration rates so that more utilization characteristics would be 
captured. This provided us the ability to obtain maximum number of beneficiaries with fee-for-
service enrollments.  
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Area Resource File (ARF): 
 In addition to all the demographic characteristics and utilization variables obtained from the 
MAX files, we also determined each Medicaid beneficiary’s contextual county level variables using 
the Area Resource File (ARF). ARF is a comprehensive county-level dataset compiled by the 
Health Resources Service Administration’s Bureau of Health Professions. ARF contains more than 
6000 variables providing information about nation’s counties. The information contained within 
ARF includes type of health facilities in the various counties, number and type health professions, 
resource scarcity measures, health status, economic activity, health training programs, and 
socioeconomic and environmental characteristics. These files also include county codes and 
descriptors that allow its linkage with several secondary datasets such as MAX. The type of 
variables that were obtained from ARF included density of pulmonologist in beneficiary’s residing 
county. We used the county codes and state information to link MAX files with 2008 ARF file. All 
the ARF variables were obtained from the baseline period.   
Study Population 
Medicaid Beneficiaries with newly-diagnosed COPD 
Medicaid beneficiaries with diagnosed COPD were identified using MAX IP and OT files 
(physician office visits claims only). Baseline period were used to identify Medicaid Beneficiaries 
with COPD. Individuals with at least one inpatient visit or two 14 days apart outpatient visits 
(obtained using type of service codes) for COPD based on International Classification of Diseases, 
Ninth Revision, Clinical Modification (ICD-9-CM) codes for chronic bronchitis (491.xx), 
emphysema (492.xx), or unspecified chronic airway obstruction (496.xx) were considered to have 
diagnosed COPD. These diagnosis codes have been utilized in prior published research (codes 
491.xx, 492.xx and 496.xx) to identify COPD and evaluate medical treatment and health outcomes 
among individuals with COPD. (Dalal, Shah, D'Souza, Chaudhari, & Crater, 2012; Halpern et al., 
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2011; Make, Dutro, Paulose-Ram, Marton, & Mapel, 2012) Indeed, sensitivity and specificity of 
using ICD-9-CM codes to identify patients with COPD has been established. (Cooke et al., 2011; A. 
S. Gershon et al., 2009) A study conducted by Gershon et al reported that identifying COPD using 1 
or more ambulatory claims and/or 1 or more hospitalizations for COPD  resulted in a sensitivity of 
85.0% (95% CI: 77.0 to 91.0) and a specificity of 78.4% (95% CI: 73.6 to 82.7).  However, we will 
be used 1 inpatient or 2 outpatient claims to identify individuals with COPD in order to increase the 
specificity of the algorithm.  
Other inclusion criteria will included: a) 40-64 years (among young adults this age group is 
at highest risk of COPD); b) continuous eligibility during the baseline and follow-up period; c) no 
dual Medicaid/Medicare coverage (dual eligibility will represent high-cost and severe beneficiaries); 
d) enrolled in fee-for-service plans throughout the study observation period; e) Alive during the 
study observation period; and use of services (inpatient or outpatient). 
Dependent Variables  
Medication Receipt (Objective 1.1) 
According to various clinical practice guidelines pharmacologic treatment for individuals 
with COPD should include administration of maintenance bronchodilators and inhaled 
corticosteroids. Medication use among individuals with COPD was identified using the NDCs 
obtained from variety of sources including Food and Drugs Administration (FDA) register.  
Following indicator variables will be created 
i) Receipt of short-acting bronchodilators including beta agonists and inhaled anticholinergics 
(yes/no) 
ii) Receipt of long-acting bronchodilators including beta agonists and inhaled anticholinergics 
(yes/no) 
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iii) Receipt of any bronchodilator (short-/long-acting) categorized into four groups: 1)Short-
acting bronchodilator only; 2) long-acting bronchodilator only; 3) both; 4) none 
iv) Receipt of inhaled corticosteroid (yes/no) 
Long-Acting Bronchodilators: Treatment Persistence (Objective 1.1): 
Long-acting bronchodilators are considered as maintenance medications for individuals with 
COPD. Therefore, in addition to the receipt of medications, it is important to determine the impact of 
inflammation-related multimorbidity on the persistence with long-acting bronchodilators. We 
measured 180-day persistence among individuals who initiated with long-acting bronchodilators in 
the first 6-months of the follow-up period. Medication persistence was defined as continuous use i.e. 
without a 45-day gap in prescription refills of long-acting bronchodilators. Sensitivity analyses were 
conducted with varying gap periods i.e. 30-day gap (rigid measure) and 60-day gap (flexible 
measure). Time to discontinuation was calculated by subtracting the first discontinuation date (first 
date after initiation of pre-specified gap period) from the index date. For individuals who did not 
discontinue the therapy during the 180-day observation period, time to discontinuation was recorded 
as 180 days.   
COPD-Specific healthcare utilization: (Objective 1.2) 
  Any healthcare claim with primary diagnosis of COPD identified using ICD-9-CM codes 
were considered as COPD-specific health care utilization. Following variables were identified as 
COPD-specific health care utilization: a) COPD-specific hospitalizations (yes/no), b) COPD-specific 
Emergency Room visits (yes/no); obtained from and inpatient and outpatient claims and c) COPD-
specific outpatient visits (high density/low density) determined by categorizing the number of 
COPD-specific outpatient visits above and below the median.   
COPD-Related healthcare utilization: (Objective 1.2) 
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  Healthcare claims with any COPD diagnosis identified using ICD-9-CM codes were 
considered as COPD-related health care utilization. Following variables were identified as COPD-
related health care utilization: a) COPD-related hospitalizations (yes/no), b) COPD-related 
Emergency Room visits (yes/no); obtained from and inpatient and outpatient claims  
COPD-specific healthcare expenditures (Objective 1.3) 
We also measured COPD- specific and COPD-related total healthcare, inpatient and 
outpatient expenditures including expenditures for inpatient, outpatient, and emergency room 
expenditures. COPD-specific expenditures were identified by identifying service claims with the 
primary diagnosis of COPD (inpatient and outpatient). To account for medical services inflation, 
expenditures in 2006 and 2007 were converted to 2009 dollars using the annual consumer price 
index for medical care services available from the Bureau of Labor Statistics. (BLS, 2013) 
Key Independent Variable: Inflammation-related Multimorbidity 
Binary indicator variables were created for the presence of arthritis, CVD, depression, 
diabetes and osteoporosis using the International Classification of Diagnosis – 9th Revision- Clinical 
Modification (ICD-9-CM) codes obtained from the Agency for Healthcare Research and Quality 
(AHRQ) - Clinical Classification Software. Any Medicaid beneficiary with COPD having greater 
than or equal to one inpatient or two outpatient visits for these conditions were considered as having 
the disease. In addition indicator variables were created for inflammation-related physical conditions 
and inflammation-related mental condition. Any Medicaid beneficiary having either of the following 
conditions: arthritis, CVD, diabetes and osteoporosis were considered as having inflammation-
related physical condition. Similarly, any individual with COPD having depression was considered 
as having inflammation-related mental condition.   
Operational definition: 
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Inflammation-related multimorbidity was further categorized into: 
1) COPD + Inflammation-related Physical Conditions + Inflammation-related Mental 
Condition (i.e. depression) 
2) COPD + Inflammation-related Physical Conditions  
3) COPD + Inflammation-related Mental Condition (i.e. depression) 
4) COPD only (without any chronic conditions). 
Other Independent Variables  
Based on the conceptual framework we have grouped the independent variables into the 
specific domain: 
a) Patient Characteristics: These variables included year of diagnosis (2006 vs. 2007), demographic 
characteristics such as gender (women, men), race (White, African Americans, Others), age in years 
(40-49, 50-59, 60-64), poverty eligibility (yes, no), medical eligibility (yes, no), number of other 
clinical conditions (none, 1-3, 4-6, >6), serious mental illness (yes, no), alcohol abuse (yes, no), 
substance abuse  (yes, no), tobacco use (yes, no) and polypharmacy (<10 drug classes, > 10 drug 
classes).  
b) Eco-system (county-level) Characteristics:  County-level variables from ARF files were used to 
obtain eco-system characteristics. Quartiles for density of above high school education, 
unemployment, poverty, primary care providers, and specialist care providers were created. Density 
of these county level characteristics was calculated by dividing total number of each characteristics 
by the total county population. This density was further converted into per 1000 people by 
multiplying 1000 with the density. Other ARF characteristics included pulmonologist density (high 
vs. low), cardiologist density (high vs. low), etc.  
d) Policy Environment: Each state administering Medicaid coverage to eligible beneficiaries has 
different policies; for example, states have restrictions on medications that can be covered. To 
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account for policy differences we included a dummy variable for the states (CA, IL, NY, TX) in our 
analyses.   
Statistical Analyses 
Bivariate Analyses 
Chi-square tests of independence were used to determine subgroup differences in categorical 
variables by inflammation-related multimorbidity among Medicaid beneficiaries with COPD. 
Bivariate differences in time to discontinuation of long-acting bronchodilators were tested using 
Kaplan-Meier estimators and log-rank tests were used to determine statistical significance. To test 
the relationship between continuous variables (example: healthcare expenditures) and inflammation-
related multimorbidity categories we used F-tests.  
Multivariate Analyses 
Binary and multinomial logistic regressions were used to examine the relationship between 
inflammation-related multimorbidity and medication receipt, long-acting bronchodilators persistence 
and COPD-specific healthcare utilization. Parameter estimates are represented as Adjusted Odds 
Ratio (AOR) with 95% confidence intervals (CI). The association between inflammation-related 
multimorbidity and time to discontinuation of long-acting bronchodilators was examined using Cox-
proportional hazards regression. Parameters estimates from these regressions are expressed as 
adjusted hazard ratios (aHR) and 95% confidence intervals (CI). The relationship between 
inflammation-related multimorbidity and healthcare expenditures among individuals with COPD 
were analyzed using generalized lineal model (GLM) with log-link function and gamma distribution. 
As many Medicaid beneficiaries did not have any COPD-specific healthcare expenditures, we used 
two-part models. The first part of the model predicted the probability of having healthcare 
expenditures and the second part of the model included GLM with log-link and gamma distribution 
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on healthcare expenditures for beneficiaries who had non-zero expenditures.  All analyses were 
conducted using SAS v9.3 (SAS Institute, Cary, NC). 
RESULTS 
The final study population (after applying all exclusion criteria) consisted of 19,060 
Medicaid beneficiaries aged between 40-64 years with newly diagnosed COPD. The algorithm used 
to define the study cohort is shown in Figure 1. Majority of the Medicaid beneficiaries with newly 
diagnosed COPD were women (59.5%), Whites (48.6%), in the age group 50-59 years (48.4%) and 
residents of CA (54.5%).  
I) Prevalence of Inflammation-related Multimorbidity 
Overall, among Medicaid beneficiaries with newly-diagnosed COPD (n = 19,060), 48.8% 
had inflammation-related physical multimorbidity, 6.7% had inflammation-related mental 
multimorbidity, 19.6% had both and 24.9% did not have any inflammation-related multimorbidity. 
With regards to individual inflammation-related chronic conditions among Medicaid beneficiaries 
with newly-diagnosed COPD, 17.9% had cardiovascular disease, 19.8% had diabetes, 12.3% had 
hyperlipidemia, 37.8% had hypertension, 35.8% had musculoskeletal disorders and 26.3% had 
depression.  
II) COPD Medication receipt  
Findings from the bivariate and multivariate analyses from analyses on COPD medication 
receipt with inflammation-related multimorbidity as the key independent variable are depicted in the 
Table 1 (main manuscript section). Approximately 64% Medicaid beneficiaries with newly-
diagnosed COPD used at least short-acting bronchodilator during the follow-up period. The rates of 
long-acting bronchodilators and inhaled corticosteroids were 39.2% and 43.3% respectively.  
Medicaid beneficiaries with inflammation-related mental multimorbidity were more likely to receive 
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short-acting bronchodilators (OR: 1.16 95%; CI: 1.02, 1.33), those with both physical and mental 
condition were less likely to receive long-acting bronchodilators (OR: 0.91; 95% CI: 0.84, 1.00) but 
were more likely to receive inhaled corticosteroids (OR: 1.12; 95% CI: 1.03, 1.22) compared to 
those with no multimorbidity.   
Findings from multivariable logistic regression on COPD medication receipt among 
Medicaid beneficiaries with newly diagnosed COPD revealed that those with inflammation-related 
physical conditions were significantly less likely to receive short-acting bronchodilators (AOR: 0.82; 
95% CI: 0.75, 0.89), long-acting bronchodilators (AOR: 0.86; 95% CI: 0.79, 0.93) and inhaled 
corticosteroids (AOR: 0.81; 95% CI: 0.75, 0.88) compared to adults with no multimorbidity. 
Similarly, those with both physical and mental multimorbidity were 26% less likely to receive short-
acting bronchodilators (AOR: 0.74; 95% CI: 0.66, 0.81), 26% less likely to use to long-acting 
bronchodilator (AOR: 0.74; 95% CI: 0.67, 0.82) and 22% less likely to use inhaled corticosteroids 
(AOR: 0.78; 95% CI: 0.71, 0.86) compared to those with no multimorbidity. In addition, certain 
patient characteristics, eco-system level variables and policy environment variables were 
significantly associated with COPD medication receipt.  
To understand the overall bronchodilator use among Medicaid beneficiaries with newly-
diagnosed COPD, we created an aggregate bronchodilator use variable with four categories (short 
acting only, long-acting only, both and none). Majority (47.2%) of beneficiaries with at least one 
bronchodilator use (n = 13,310) in the follow-up period were in the both bronchodilator use group. 
Findings from multinomial logistic regressions (Table 2, main manuscript section) revealed that 
adults with physical and both physical and mental multimorbidity were less likely to receive short-
acting bronchodilators only (AOR: 0.88; 95% CI: 0.79, 0.97; AOR: 0.80; 95% CI: 0.71, 0.91 
respectively) as compared to those with no multimorbidity. Similarly findings were observed for 
 [35] 
 
receipt of short-acting and long-acting bronchodilators. However, inflammation-related 
multimorbidity did not have any statistically significant association with receipt of long-acting 
bronchodilators only.  
III) Long-acting bronchodilator persistence (6 months) 
Out of 6,119 Medicaid beneficiaries who initiated on long-acting bronchodilator therapy 
during the follow-up period, 30.7% (n = 1,880) remained persistent (i.e. without any 45-day gap 
period) through 6 month follow-up after the index date. Subgroup differences in persistence rates by 
inflammation-related multimorbidity were examined using chi-square tests of independence. These 
results suggested that there was no difference in terms of overall persistence by inflammation-related 
multimorbidity. (Table 3, main manuscript section) Sensitivity analyses were performed by 
changing the allowable gap period to 30 days (strict persistence measure) and 60 days (flexible 
persistence measure). Similar bivariate findings as those obtained using 45-day gap allowance, were 
observed in the sensitivity analyses as well.  
Interestingly, the findings from the logistic regressions on flexible persistence measure 
revealed that Medicaid beneficiaries with inflammation-related mental condition were 25% less 
likely to be persistent (AOR: 0.75; 95% CI: 0.60-0.96), whereas those with both physical and mental 
condition were 19% less likely to remain persistent (AOR: 0.81; 95%CI: 0.68, 0.97) in the 6-month 
follow-up period. No statistically significant relationships were found between inflammation-related 
multimorbidity and persistence using 30-day and 45-day gap period.  
Kaplan-Meier estimates with log-rank tests and cox-proportional hazards model were 
conducted to understand the unadjusted and adjusted relationship between inflammation-related 
multimorbidity and time-to-discontinuation (in days) respectively. Specific findings from these 
analyses with regards to inflammation-related multimorbidity are presented in Table 3, main 
manuscript section. Median time-to-discontinuation of long-acting bronchodilators was lower for 
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Medicaid beneficiaries with mental condition (96.0 days, 95%CI: 87.9, 110.1), with physical 
condition (102.0 days, 95%CI: 93.9, 107.1) and those with both conditions (107.0 days, 95%CI: 
99.9, 114.0) compared to those with no multimorbidity (113.0 days, 95%CI: 105.0, 117.9). 
However, this difference was not statistically significant. Sensitivity analyses with different 
allowable gap period revealed similar results.  
Cox proportional hazards regression on time-to-discontinuation (in days) indicated that after 
adjusting for baseline characteristics and using 60-day allowable gap period to measure time-to-
discontinuation, individuals with inflammation-related physical condition only (aHR: 1.10; 95% CI: 
1.01, 1.20), inflammation-related mental condition only (aHR: 1.18; 95% CI: 1.03, 1.36) and both 
conditions (aHR: 1.14; 95% CI: 1.02, 1.36) had higher hazards of discontinuation as compared to 
those without any inflammation-related multimorbidity.  
IV) COPD-specific and COPD-related healthcare utilization 
Table 4 (main manuscript section) depicts the findings from bivariate and multivariate 
analyses on COPD-specific and COPD-related healthcare utilization. About 5.0% (n = 998) 
Medicaid beneficiaries with newly diagnosed COPD had at least 1 COPD-specific hospitalization, 
14.8% (n = 2,824) had COPD-specific emergency room visits and 43.7% (n = 7,200) had >1COPD-
specific outpatient visits. Bivariate analyses did not reveal any statistically significant associations 
between inflammation-related multimorbidity and COPD-specific healthcare utilization.  
However, findings from the logistic regressions that adjusted for baseline characteristics 
suggested that Medicaid beneficiaries with inflammation-related physical condition only (AOR: 
0.81; 95% CI: 0.68, 0.96) and those with both physical and mental condition (AOR: 0.80; 95% CI: 
0.65, 0.99) were less likely to have COPD-specific hospitalization compared to adults with no 
multimorbidity. Similar findings were obtained for the relationship between inflammation-related 
multimorbidity and COPD-specific emergency room visits.  
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Overall, 16.0% (n = 3,052) of beneficiaries had any COPD-related hospitalizations and 
21.4% (n = 4,092) had COPD-related Emergency Room visits. Statistically significant subgroup 
differences in rates of COPD-related healthcare utilization by multimorbidity categories were 
observed. Those with physical condition only (16.0%), mental condition only (15.4%) and both 
(20.9%) had significantly (p<0.001) higher rates of COPD-related hospitalization as compared to 
those without any inflammation-related multimorbidity (12.4%). However, adjusting for baseline 
characteristics showed that only those with both physical and mental conditions had significantly 
greater likelihood of COPD-related hospitalization (AOR: 1.26; 95% CI: 1.10, 1.44). Adjusted 
analyses also indicated that beneficiaries with physical conditions had lower likelihood of COPD-
related Emergency Room visits (AOR: 0.87, 95% CI: 0.79, 0.95).  
V) COPD-specific healthcare expenditures 
Average total of COPD-specific and COPD-related expenditures (referred to as COPD 
expenditures) in the 12-month follow up period among Medicaid beneficiaries with newly-diagnosed 
COPD was estimated to be $3,238 (SD: $12,396). Among users, average COPD-specific inpatient 
expenditures were estimated to be $7,223 (SD: $4,413) and COPD-specific outpatient expenditures 
were determined to be $425 (SD: $138). Table 5 (main manuscript section) contains mean (SD), 
median, parameter estimates, standard errors, and statistical significance represented as asterisks for 
total and types of COPD-specific expenditures by inflammation-related multimorbidity groups. As 
shown in the table average total COPD-specific expenditures were significantly higher among 
individuals with inflammation-related physical multimorbidity ($3,481 vs. $2,872; p<0.01). 
However, COPD-specific inpatient expenditures and COPD-specific outpatient expenditures were 
not different among different inflammation-related multimorbidity groups.  
Findings from GLM with log-link and gamma distribution (Table 5) among those with positive 
expenditures revealed that total COPD expenditures, COPD-specific inpatient expenditures and 
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COPD-specific outpatient expenditures were lower for adults with inflammation-related 
multimorbidity compared to those with no multimorbidity. 
DISCUSSION 
The current study examined the impact of inflammation-related multimorbidity of COPD 
medication use, long-acting bronchodilator persistence, COPD-specific healthcare utilization and 
expenditures among Medicaid beneficiaries with newly-diagnosed COPD. In this study cohort 
approximately three-forth individuals had inflammation-related multimorbidity. Although no study 
has comprehensively examined the prevalence of inflammation-related comorbidities among 
individuals with COPD, the rates for some of the individual conditions obtained from our analyses 
are somewhat consistent with those found in other studies that have evaluated comorbidity burden 
among individuals with COPD. (Schnell, 2012; Lin, Shaya, & Scharf, 2010)  
In this study, we found that after controlling for patient characteristics, Medicaid beneficiaries 
with newly-diagnosed COPD were less likely to receive COPD medications including 
bronchodilators and inhaled corticosteroids. Furthermore, findings from long-acting bronchodilator 
persistence analyses indicated that individuals with COPD and inflammation-related multimorbidity 
had increased hazards of discontinuation. It is plausible that due to competing demands from 
healthcare management of multimorbidity, COPD-medication utilization and treatment persistence 
may be reduced. Studies have suggested that certain COPD medications are associated with side-
effects that could complicate management of allied co-occurring conditions. For example 
bronchodilators such as long-acting beta agonists or inhaled anticholinergics are associated with 
cardiovascular complications such as unstable angina and myocardial infarction. (Au DH, 2004; 
Lemaitre, 2002; Macie C, 2008; Martin RM, 1998) Similarly, inhaled corticosteroids may increase 
blood glucose levels among those with pre-diabetes or diabetes. (Suissa S, 2010; Slatore CG, 2009)  
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Therefore, it is important to weigh the benefits and safety issues in the healthcare management of 
patients with COPD and inflammation-related multimorbidity. Clinical practice guidelines need to 
be developed for individuals with COPD and multimorbidity.  
Contrary to our hypotheses, the presence of inflammation-related multimorbidity was associated 
with lower COPD-specific healthcare utilization. Medicaid beneficiaries with newly-diagnosed 
COPD and inflammation-related physical conditions or both physical/mental conditions were less 
likely to have COPD-specific hospitalization and emergency room visits. These findings are 
consistent with a study that indicated that presence of diabetes and hypertension were associated 
with lower likelihood of COPD re-hospitalizations (McGhan et al 2007).  We can only speculate on 
the possible reasons behind our study findings.  It is possible that those with multimorbidity have 
greater hospitalizations for other conditions in which COPD may be diagnosed as comorbidity and 
thus COPD management may take place while being hospitalized for other chronic conditions. This 
was also reflected in our analyses of COPD-related hospitalizations which were measured as 
hospitalization with COPD as any of the nine diagnoses codes.  
Although inflammation-related physical multimorbidity was associated with higher average 
total COPD-specific expenditures as compared to those with no multimorbidity ($3,482 vs. $2,872; 
p<0.01), this relationship was reversed in multivariable analyses.  After controlling for baseline 
characteristics it was found that inflammation-related multimorbidity was associated with 
statistically significant lower COPD-specific total, inpatient and outpatient expenditures.   Again, 
these findings highlight the burden of co-occurring conditions in patients with newly diagnosed 
COPD and inflammation-related multimorbidity.  Management of inflammation-related 
multimorbidity may require resources and these patients may have expenditures that may not be 
specific to COPD.  Indeed, similar evidence has been documented among individuals with mental 
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illness among whom multimorbidity is highly prevalent. Among individuals with mental illness a 
greater proportion of expenditures often relate to conditions not related to mental health. (Banerjea R 
et al, 2008) 
STRENGTHS AND LIMITATIONS 
The advantages of our study are: the use of administrative claims data which provided us the 
ability to identify all the medical conditions using diagnosis codes, availability of prescription 
medication claims, analysis of a comprehensive set of COPD-specific outcomes, examination of a 
high-risk and low-income population and ability to track capture utilization over time. Our study was 
strengthened by linking Medicaid files with ARF to comprehensively adjust for healthcare 
environment that could have affected the relationship between inflammation-related multimorbidity 
and COPD-specific outcomes. Our study had some limitations such as limited generalizability due to 
inclusion of beneficiaries with fee-for-service claims only. The study also used data from only four 
states which may not provide a full understating of overall Medicaid population. We also excluded 
dual Medicare-Medicaid enrollees from our population which limits the overall generalizability. Due 
to unavailability of laboratory data we were not able to control for stage of COPD at diagnosis or 
confirm the diagnosis of COPD.  
Despite these limitations, to the best of our knowledge this the first study to extensively examine 
the relationship between inflammation-related multimorbidity and comprehensive set of COPD-
specific outcomes. Therefore, the findings from this study may guide clinical and policy decision 
making for management of COPD patients with inflammation-related multimorbidity.  
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TABLES AND FIGURES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure: Algorithm Describing Selection of Study Population 
 
2,422 beneficiaries died during the study 
observation period 
23,289 dual Medicare/Medicaid eligible 
7,025 individuals without continuous 
eligibility 
59,536 individuals with newly diagnosed Chronic 
Obstructive Pulmonary Disease (COPD) diagnosis 
between January 1, 2006, and December 31, 2007 in  
Medicaid Analytic eXtract Files 
57,114 beneficiaries with newly diagnosed COPD were 
alive during the entire study observation period 
3,589 enrollees with HMO plans 
23,211 Medicaid beneficiaries with fee-for-services plans 
4,151 enrollees aged <40 years or >64 
years 
19,060 Medicaid Beneficiaries with 
newly-diagnosed COPD 
33,825 individuals with no dual eligibility 
26,800 beneficiaries with continuous eligibility 
throughout study observation period 
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Table 1 
Numbers, Percentages, Odds Ratios, Adjusted Odds Ratios and 95% Confidence Intervals  
  Receipt of COPD Medication Use among Medicaid Beneficiaries with Newly-Diagnosed COPD  
Medicaid Analytic Extract, 2005-2008 
Short Acting Bronchodilator Use 
Unadjusted Logistic 
Regression on Receipt of 
COPD Medication  
Adjusted Logistic Regression 
on Receipt of COPD 
Medication 
  N Row % OR 95% CI Sig AOR 95% CI Sig 
  
        
Short Acting Bronchodilators 
TOTAL 12,177 63.9 
Inflammation-related Multimorbidity 
Physical Only 5,947 63.9 1.05 [ 0.98 ,  1.13] 0.82 [ 0.75 ,  0.89] *** 
Mental Only 850 66.3 1.16 [ 1.02 ,  1.33] * 1.01 [ 0.88 ,  1.16] 
Both 2,407 64.5 1.08 [ 0.99 ,  1.18] 0.74 [ 0.66 ,  0.81] *** 
None 2,973 62.8 
Long Acting Bronchodilators 
TOTAL 7,474 39.2 
Inflammation-related Multimorbidity 
Physical Only 3,676 39.5 0.99 [ 0.92 ,  1.06] 0.86 [ 0.79 ,  0.93] *** 
Mental Only 507 39.5 0.99 [ 0.87 ,  1.12] 0.89 [ 0.78 ,  1.02] 
Both 1,406 37.7 0.91 [ 0.84 ,  1.00] * 0.74 [ 0.67 ,  0.82] *** 
None 1,885 39.8 
Inhaled Corticosteroids  
TOTAL 8,260 43.3 
Inflammation-related Multimorbidity 
Physical Only 4,043 43.4 1.07 [ 0.99 ,  1.14] 0.81 [ 0.75 ,  0.88] *** 
Mental Only 567 44.2 1.10 [ 0.97 ,  1.24] 0.93 [ 0.82 ,  1.07] 
Both 1,666 44.6 1.12 [ 1.03 ,  1.22] * 0.78 [ 0.71 ,  0.86] *** 
None 1,984 41.9 
 
   
      
Note: Based on 19,060 Medicaid Beneficiaries with newly diagnosed COPD obtained from Medicaid Analytic eXtract 
files observed during 2005-2008. Asterisks represent significant group differences in likelihood of respective COPD 
medication use by inflammation-related multimorbidity compared to the reference group (None) obtained from 
Unadjusted and Adjusted Logistic Regression Analyses.  
Adjusted Logistic Regression Analyses controlled for cohort year, sex, race, age, state, poverty eligibility, number of 
other clinical conditions, serious mental illness, alcohol abuse, substance abuse, tobacco use, polypharmacy, county 
level variables including: above high school education density (quartiles),  unemployment density (quartiles), poverty 
density (quartiles), metro status, primary care shortage area, mental health shortage area, primary care provider density 
(quartiles), hospital beds density (quartiles), psychiatric hospital, pulmonologist density and cardiologist density. 
 
OR: Odds Ratio; AOR: Adjusted Odds Ratio; CI: Confidence Interval; Sig: Significance 
 
*** p < .001; ** .001 ≤ p < .01; * .01 ≤ p < .05 
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Table 2 
Number, Percentage, Adjusted Odds Ratio and 95% Confidence Interval from Multinomial 
Logistic Regression on Type of Bronchodilator Use  
among Medicaid Beneficiaries with Newly-Diagnosed COPD 
Medicaid Analytic Extract, 2005-2008 
Short Acting Bronchodilators Only 
  
N Row% AOR 95% CI Sig 
TOTAL 5,836 30.6 
   
  
     
Inflammation-related Multimorbidity 
  
 
Physical Only 2,870 30.8 0.88 [0.79, 0.97] ** 
 
Mental Only 397 30.9 1.01 [0.86, 1.20] 
 
 
Both 1,207 32.3 0.80 [0.71, 0.91] *** 
 
None 1,362 28.8 
   
Long Acting Bronchodilators Only 
TOTAL 1,133 5.9    
 
      
Inflammation-related Multimorbidity   
 
Physical Only 599 6.4 1.01 [0.85, 1.20]  
 
Mental Only 54 4.2 0.77 [0.56, 1.06]  
 
Both 206 5.5 0.85 [0.68, 1.06]  
 
None 274 5.8    
Both Bronchodilators 
TOTAL 6,341 33.3    
 
      
Inflammation-related Multimorbidity   
 
Physical Only 3,077 33.1 0.77 [0.70, 0.85] *** 
 
Mental Only 453 35.3 0.92 [0.78, 1.09] 
 
 
Both 1,200 32.1 0.63 [0.56, 0.72] *** 
 
None 1,611 34.0    
 
      
Note: Based on 19,060 Medicaid Beneficiaries with newly diagnosed COPD obtained from Medicaid Analytic eXtract 
files observed during 2005-2008. Asterisks represent significant group differences in likelihood of bronchodilator use by 
inflammation-related multimorbidity compared to the reference group (None) obtained from Multinomial Logistic 
Regression Analyses.  
Adjusted Logistic Regression Analyses controlled for cohort year, sex, race, age, state, poverty eligibility, number of 
other clinical conditions, serious mental illness, alcohol abuse, substance abuse, tobacco use, polypharmacy, county level 
variables including: above high school education density (quartiles),  unemployment density (quartiles), poverty density 
(quartiles), metro status, primary care shortage area, mental health shortage area, primary care provider density 
(quartiles), hospital beds density (quartiles), psychiatric hospital, pulmonologist density and cardiologist density. 
 
OR: Odds Ratio;  AOR: Adjusted Odds Ratio; CI: Confidence Interval; Sig: Significance 
 
*** p < .001; ** .001 ≤ p < .01; * .01 ≤ p < .05 
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Table 3 
Description of 180-day Long Acting Bronchodilator Persistence  among 
 Medicaid Beneficiaries with Newly-Diagnosed COPD who initiated Long Acting Bronchodilators (n = 6,119) 
Medicaid Analytic Extract, 2005-2008 
Persistence (30-day allowable gap) 
    N Row % AOR 95% CI Sig 
Median 
Time 95% CI Sig aHR 95% CI Sig 
TOTAL 1,308 21.4 
Inflammation-related Multimorbidity 
Physical Only 624 20.8 0.90 [0.76 , 1.06] 96.0 [92.1, 101.1] 1.08 [1.00 , 1.17] * 
Mental Only 85 20.9 0.84 [0.64 , 1.11] 93.0 [87.0, 104.1] 1.12 [0.99 , 1.27] 
Both 255 22.2 0.89 [0.73 , 1.10] 102.0 [95.1, 107.1] 1.08 [0.98 , 1.19] 
None 344 22.1 103.0 [96.9, 111.0] 
Persistence (45-day allowable gap) 
TOTAL 1,880 30.7 
Inflammation-related Multimorbidity 
Physical Only 917 30.5 0.95 [0.82 , 1.10] 102.0 [93.90, 107.1] 1.06 [0.98 , 1.15] 
Mental Only 120 29.5 0.84 [0.66 , 1.08] 96.0 [87.90, 110.1] 1.14 [0.99 , 1.30] 
Both 357 31.0 0.89 [0.74 , 1.07] 107.0 [99.90, 114.0] 1.09 [0.99 , 1.21] 
None 486 31.2 113.0 [105.00, 117.9] 
Persistence (60-day allowable gap) 
TOTAL 2,354 38.5 
Inflammation-related Multimorbidity 
Physical Only     1,143  38.1 0.87 [0.76 , 1.00] 103.0 [95.1, 108.0] 1.10 [1.01 , 1.20] * 
Mental Only        145  35.6 0.75 [0.60 , 0.96] * 96.0 [87.9, 113.1] 1.18 [1.03 , 1.36] * 
Both        440  38.2 0.81 [0.68 , 0.97] * 108.0 [99.9, 116.1] 1.14 [1.02 , 1.26] * 
  
None        626  40.2       114.0 [105.9, 123.9]         
 
   
   
  
    
 
Note: Based on 6,119 Medicaid Beneficiaries with newly diagnosed COPD who initiated long-acting bronchodilators, obtained from Medicaid Analytic eXtract files 
observed during 2005-2008. Asterisks represent significant group differences in likelihood of 180-days persistence, median time to discontinuation (measured in days) 
and hazards of discontinuation.  
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Adjusted Logistic Regression Analyses controlled for cohort year, sex, race, age, state, poverty eligibility, number of other clinical conditions, serious mental illness, 
alcohol abuse, substance abuse, tobacco use, polypharmacy, county level variables including: above high school education density (quartiles),  unemployment density 
(quartiles), poverty density (quartiles), metro status, primary care shortage area, mental health shortage area, primary care provider density (quartiles), hospital beds 
density (quartiles), psychiatric hospital, pulmonologist density and cardiologist density. 
 
OR: Odds Ratio;  AOR: Adjusted Odds Ratio; aHR: Adjusted Hazards Ratio; CI: Confidence Interval; Sig: Significance 
 
*** p < .001; ** .001 ≤ p < .01; * .01 ≤ p < .05 
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Table 4 
Number, Percentage, Adjusted Odds Ratio and 95% Confidence Interval from Logistic 
Regressions on COPD-specific and COPD-related Healthcare Utilization among 
Medicaid Beneficiaries with Newly-Diagnosed COPD 
Medicaid Analytic Extract, 2005-2008 
COPD-specific Hospitalizations 
    N Row % AOR 95% CI Sig 
TOTAL 998 5.2 
Inflammation-related Multimorbidity 
Physical Only 478 5.1 0.81 [ 0.68 ,  0.96] * 
Mental Only 72 5.6 1.01 [ 0.77 ,  1.33] 
Both 205 5.5 0.80 [ 0.65 ,  0.99] * 
None 243 5.1 
COPD-specific Emergency Room  visits 
TOTAL 2,824 14.8 
Inflammation-related Multimorbidity 
Physical Only          1,322  14.2 0.83 [ 0.75 ,  0.93] *** 
Mental Only             198  15.4 0.91 [ 0.76 ,  1.09] 
Both             591  15.8 0.85 [ 0.74 ,  0.97] * 
None             713  15.1 
COPD-specific Outpatient Visits 
TOTAL 7,200 43.7 
Inflammation-related Multimorbidity 
Physical Only          3,462  43.7 1.02 [ 0.94 ,  1.11] 
Mental Only             499  43.8 1.02 [ 0.89 ,  1.17] 
Both          1,448  44.9 1.02 [ 0.92 ,  1.13] 
  
None          1,791  42.7 
      
COPD-related Hospitalizations 
TOTAL 3,052 16.0 
Inflammation-related Multimorbidity 
Physical Only          1,486  16.0 1.12 [ 1.00 ,  1.25] 
Mental Only             198  15.4 1.06 [ 0.89 ,  1.28] 
Both             779  20.9 1.26 [ 1.10 ,  1.44] *** 
  
None             589  12.4 
      
COPD-related Emergency Room visits 
TOTAL 4,092 21.4 
Inflammation-related Multimorbidity 
Physical Only          1,943  20.9 0.87 [ 0.79 ,  0.95] ** 
Mental Only             293  22.8 1.02 [ 0.87 ,  1.19] 
Both             891  23.9 0.92 [ 0.82 ,  1.03] 
  
None             965  20.4 
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Note: Based on 19,060 Medicaid Beneficiaries with newly diagnosed COPD obtained from Medicaid 
Analytic eXtract files observed during 2005-2008. Asterisks represent significant group differences in 
likelihood of respective COPD-specific healthcare utilization by inflammation-related multimorbidity 
compared to the reference group (None) obtained from Adjusted Logistic Regression Analyses.  
Adjusted Logistic Regression Analyses controlled for cohort year, sex, race, age, state, poverty eligibility, 
number of other clinical conditions, serious mental illness, alcohol abuse, substance abuse, tobacco use, 
polypharmacy, county level variables including: above high school education density (quartiles),  
unemployment density (quartiles), poverty density (quartiles), metro status, primary care shortage area, 
mental health shortage area, primary care provider density (quartiles), hospital beds density (quartiles), 
psychiatric hospital, pulmonologist density and cardiologist density. 
 
OR: Odds Ratio;  AOR: Adjusted Odds Ratio; CI: Confidence Interval; Sig: Significance 
 
*** p < .001; ** .001 ≤ p < .01; * .01 ≤ p < .05 
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Table 5 
Mean, Standard Deviation and Parameter Estimates from Generalized Linear Models on   
Total and Type of COPD-specific Healthcare Expenditures  
among Medicaid Beneficiaries with Newly Diagnosed COPD   
Medicaid Analytic Extract, 2005-2008  
Total COPD-expenditures 
  
  Unadjusted Model Fully-adjusted Model 
    Mean (SD) Median  beta SE Sig  beta SE Sig 
TOTAL 
Intercept 2872.0 180.1 *** 7.47 0.19 *** 
Inflammation-related Multimorbidity 
Physical Only 3481.7 (14115.1) 312.7 609.8 221.2 ** -0.07 0.03 * 
Mental Only 2588.3 (8163.0) 340.4 -283.7 390.1 -0.20 0.05 *** 
Both 3317.6 (9517.5) 390.9 445.6 271.3 -0.26 0.04 *** 
None 2872.0 (11710.8) 314.0 
COPD-specific Inpatient Expenditures (Among Inpatient Users; n = 998) 
TOTAL 
Intercept 8418.11 739.50 *** 7.98 0.39 *** 
Inflammation-related Multimorbidity 
Physical Only 7180.7 (13391.5) 4340.0 -1237.40 908.22 -0.18 0.07 ** 
Mental Only 5888.8 (7417.5) 4472.0 -2529.30 1546.77 -0.37 0.11 *** 
Both 6373.8 (6093.9) 4200.0 -2044.30 1093.20 -0.26 0.09 ** 
None 8418.1 (12037.3) 4876.0 
COPD-specific Outpatient Expenditures (Among Outpatient Users; n = 16, 480) 
TOTAL 
Intercept 440.28 24.10 *** 6.76 0.15 *** 
Inflammation-related Multimorbidity 
Physical Only 425.4 (1376.6) 133.4 -14.83 29.80 -0.09 0.03 *** 
Mental Only 372.3 (1362.0) 142.7 -67.98 52.17 -0.19 0.04 *** 
Both 421.5 (1635.4) 147.0 -18.77 36.55 -0.15 0.03 *** 
  
None 440.3 (1852.4) 141.6 
        
 
   
      
Note: Based on data of 19,060 Medicaid Beneficiaries with newly diagnosed COPD obtained from Medicaid 
Analytic eXtract files observed during 2005-2008. Asterisks represent significant group differences in expenditures 
by inflammation-related multimorbidity compared to the reference group (None) obtained from Unadjusted and 
Adjusted Generalized Linear Model with Log-Link and Gamma Distribution.  
Adjusted Logistic Regression Analyses controlled for cohort year, sex, race, age, state, poverty eligibility, number 
of other clinical conditions, serious mental illness, alcohol abuse, substance abuse, tobacco use, polypharmacy, 
county level variables including: above high school education (quartiles),  unemployment density (quartiles), 
poverty density (quartiles), metro status, primary and, mental health shortage area, primary care provider density 
(quartiles), hospital beds density (quartiles), psychiatric hospital, pulmonologist and cardiologist density. 
 
SD: Standard Deviation; Sig: Significance; SE: Standard Errors 
*** p < .001; ** .001 ≤ p < .01; * .01 ≤ p < .05 
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CHAPTER 3: REAL-WORLD STUDY OF CLINICAL AND ECONOMIC OUTCOMES 
OF STATIN MEDICATIONS AMONG MEDICAID BENEFICIARIES WITH NEWLY-
DIAGNOSED COPD 
INTRODUCTION 
Currently the treatment for Chronic Obstructive Pulmonary Disease (COPD) focuses on 
reducing the frequency of acute exacerbations and relieving the symptoms of COPD such as 
shortness of breath (Global strategy for the diagnosis, management, and prevention on chronic 
obstructive pulmonary disease: 2013 update.2013) through acute and maintenance 
pharmacologic therapies as well as pulmonary rehabilitation. To date, no therapeutic options, 
which alter the prognosis of disease also known as disease modifying drugs for COPD treatment, 
have been established.  However, new insights into the pathophysiology of the disease have 
opened up opportunities to use therapeutic regimens that are currently available for circulatory 
diseases to treat COPD. (M. Cazzola, Ciaprini, Page, & Matera, 2007; Fabbri & Rabe, 2007) 
The main pathophysiology of COPD revolves around airways inflammation which limits 
normal flow of air through the lungs. (Górska, Maskey-Warzechowska, & Krenke, 2010; Rabe et 
al., 2007) Inflammation in COPD can be caused because of lung exposure to risk factors such as 
smoking and air pollution (indoor, outdoor and/or occupational).(Global strategy for the 
diagnosis, management, and prevention on chronic obstructive pulmonary disease: 2013 
update.2013) As per the conventional theories inflammation should be limited only to the 
pulmonary system. However, evidence has been growing regarding the extra-pulmonary 
inflammation also known as systemic inflammation (Matera, Calzetta, Rinaldi, & Cazzola, 2012; 
Nussbaumer-Ochsner & Rabe, 2011; Vogelmeier & Wouters, 2011) and COPD is also being 
considered as a disease associated with systemic inflammation (P. J. Barnes & Celli, 2009; 
Fabbri & Rabe, 2007; Sevenoaks & Stockley, 2006). Systemic inflammation in COPD can be 
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due to the ‘spillover’ effect of high concentration of inflammatory mediators in the lungs (P. J. 
Barnes, 2010) or due to the high prevalence of inflammation-related multimorbidity among 
individuals with COPD. (P. J. Barnes & Celli, 2009) For example, highly prevalent chronic 
conditions such as cardiovascular diseases, musculoskeletal disorders, depression and diabetes 
mellitus have been linked to systemic inflammation outside the lungs among individuals with 
COPD. (P. J. Barnes, 2010; M. Cazzola, Bettoncelli, Sessa, Cricelli, & Biscione, 2010; M. 
Cazzola et al., 2012) Recently, it has been documented that individuals with COPD are more 
likely to have certain chronic conditions with common inflammatory pathway as compared to 
individuals without COPD. These conditions include depression (20.6% vs. 12.5%), coronary 
heart disease (12.7% vs. 6.1%), congestive heart failure (12.1% vs. 3.9%), and stroke (8.9% vs. 
4.6%). (Schnell et al., 2012) Unfortunately, the current acute and maintenance pharmacologic 
therapies for COPD management do not specifically target the systemic inflammation. (M. 
Cazzola et al., 2007; Matera et al., 2012) Therefore, it is important to evaluate the effects of other 
inflammation reducing medications such as 3-hydroxy 3-methylglutaryl coenzyme A reductase 
inhibitors (HMG CoA reductase inhibitors) commonly known as statins, that may alter the 
disease prognosis among individuals with COPD.  
 Inability of Current Medications to Treat Systemic Inflammation 
Medications commonly used for acute and maintenance COPD management include 
bronchodilators and corticosteroids. (Global strategy for the diagnosis, management, and 
prevention on chronic obstructive pulmonary disease: 2013 update.2013) Indirect evidence 
exists that these medications are potent in treating pulmonary inflammation and thus may be 
helpful in relieving symptoms of COPD. Some experiments on animals have provided evidence 
that currently available inhalation therapies can reduce levels of systemic inflammatory 
mediators. (Suda et al., 2011) However, these results were not consistent with those observed in 
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a large multicenter randomized controlled trial. (Sin et al., 2008) Findings from this trial revealed 
that the combination of inhaled corticosteroid and long acting beta-2-agonist reduced pulmonary 
inflammation leading to improvements in COPD symptoms but these medications did not reduce 
systemic inflammation. It has also been suggested that inhalation therapies may have limited 
systemic effects due to their mode of administration. (M. Cazzola et al., 2007; Vogelmeier & 
Wouters, 2011) In this context, researchers have been exploring the potential utility of other 
medications that may lead to reduction in systemic inflammation among individuals with COPD. 
Statins and Anti-Inflammatory Properties 
Statins, a class of cholesterol lowering drugs have demonstrated their effectiveness in 
prevention and management of cardiovascular diseases. (Baigent et al., 2005) Based on the 
review of in vitro as well as in vivo studies Schönbeck and Libby (Schonbeck & Libby, 2004) 
concluded that statins also have anti-inflammatory functions. In a study conducted by Lee et al 
(2005), it was found that the inflammation caused by smoking in lungs of rats was alleviated by 
lipophilic statin, specifically simvastatin. (J. Lee et al., 2005) In humans, researchers using a 
randomized controlled trial have shown that pravastatin (hydrophilic statin) use significantly 
reduced levels of inflammatory biomarkers. (T. Lee, Lin, & Chang, 2008) The evidence has also 
been supported by preclinical models that have revealed the pleiotropic/anti-inflammatory 
therapeutic benefits attributable to statins. (Takahashi et al., 2008) These facts derived from 
several mechanistic studies suggest that statin use has emerged as a novel therapeutic 
intervention for individuals with COPD. (Walsh, 2008)  
Statin use and Improved Outcomes among individuals with COPD 
Since early 2000, evidence of beneficial impact of statins on outcomes among individuals 
with COPD has become available. One randomized trial (T. Lee et al., 2008) and some 
observational studies have been conducted (Blamoun et al., 2008; Huang et al., 2011; Ishida et 
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al., 2007; Keddissi et al., 2007; Lawes et al., 2012) to examine the role of statins in COPD 
management.   Most of these studies have provided evidence of beneficial effects of statins in 
improving lung function, (Keddissi et al., 2007), exercise  time as a measure of health status (T. 
Lee et al., 2008) and reducing COPD exacerbations (Blamoun et al., 2008) and COPD-related 
hospitalizations (Mancini Huang), all-cause (Frost, Petersen, Tollestrup, & Skipper, 2007; Lawes 
et al., 2012; Lawes et al., 2012; Mancini et al., 2006; Søyseth et al., 2007; Søyseth, Brekke, 
Smith, & Omland, 2007)and COPD-specific mortality. (Frost et al., 2007)  
In retrospective cohort study using Veteran’s Affairs data among individuals with COPD, 
investigators have shown that statin use (including simvastatin, lovastatin, atorvastatin and 
fluvastatin) was associated with improved lung function as measured by slower decline 
pulmonary function compared no statin use. (Keddissi et al., 2007) Similarly, investigators of a 
randomized controlled trial among individuals with COPD found that pravastatin use for 6 
months significantly increased exercise time from baseline as compared to placebo group 
suggesting improvements in health status. (T. Lee et al., 2008)  
Reductions in COPD exacerbations have also been observed among statin users 
compared to non-users. In a study based on hospitalized COPD patients in a regional medical 
center (n = 185), investigators reported that individuals not receiving statins were approximately 
twice as likely to experience COPD exacerbation (Adjusted Odds Ratio (AOR): 2.35; 95% CI: 
1.01-5.50) and 10 times as likely to require intubation for exacerbation (AOR: 10.36; 95% CI: 
2.77–38.76) compared to non-users of statins. (Blamoun et al., 2008) This study was limited by 
its small sample size, inability to adjust for a variety of risk factors which may affect the 
relationship between statin use and COPD-related health outcomes such as co-morbidities. 
Similarly, a study using Veterans Affairs hospital patients (n = 418) with COPD revealed that 
 [60] 
 
individuals without statin use reported significantly higher mean of COPD exacerbations as 
compared to those with statin use (0.17 ± 0.31 vs. 0.11 ± 0.26; p = 0.01). (Keddissi et al., 2007)  
Likelihood of COPD-specific hospitalizations has been shown to be lower among users 
of statins compared to non-users of statins. Findings from a time-matched nested case-control 
study on effects of statin use on elderly individuals COPD, indicated that compared to no statin 
use, any statin use was associated with reduced likelihood of COPD related hospitalization 
irrespective of their cardiovascular risk (HI CV risk- RR: 0.71; 95% CI: 0.56-0.91 and low CV 
risk - RR: 0.71; 95% CI: 0.64-0.77). (Mancini et al., 2006)These findings were consistent with 
those obtained from nationwide cohort study in Taiwan. (Huang et al., 2011)This study reported 
that among 6,252 newly diagnosed individuals with COPD statin use significantly decreased 
hazards of COPD-related hospitalization (HR: 0.66; 95% CI: 0.60–0.74) compared to no statin 
use.  
Need for the Study 
COPD is generally considered as an irreversible disease with current medications 
focusing towards improving the symptoms associated with COPD. (GOLD, young, matera) 
Based on the healthy people goals for 2020 it has been suggested that improvements in COPD 
management should include reducing hospitalizations associated with COPD. (Healthy people 
2020: Goals for respiratory diseases.2013) Moreover, hospitalizations for COPD are considered 
to be preventable and thus are used as a metric to measure quality of care. (Quality indicator user 
guide: Prevention quality indicators (PQI) composite measures version 4.3.2011) Current, 
COPD medications have not been shown to alter the prognosis of disease mainly because of their 
inability to target and treat systemic inflammation. The healthy people 2020 goals for COPD 
specifically mention the need for developing novel treatments for COPD which can improve the 
overall prognosis of disease.  (Healthy people 2020: Goals for respiratory diseases.2013) 
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Therefore, there is need to generate evidence on novel therapies that may positively impact 
systemic inflammation and therefore modify the course of COPD.  
In this context, Statins, due to their anti-inflammatory properties are being evaluated as a 
novel therapy to manage COPD. (Young, Hopkins, & Eaton, 2009) However, evidence regarding 
health outcomes such as healthcare utilization and expenditures associated with statin therapy 
among individuals with COPD is limited. In addition, the currently available studies have several 
limitations which restrict our ability to better understand the relationship between statin therapy 
and COPD-specific health outcomes. First, the study conducted to assess the impact of statin use 
among veterans with COPD had limited sample size (n = 418) and only represented hospitalized 
patients who were either former or current smokers. (Keddissi et al., 2007) The other studies that 
evaluated the use of statins for improving COPD-specific outcomes had several shortcomings 
such as non-generalizability to US population (Huang et al., 2011; Mancini et al., 2006) and 
conducted on individuals with COPD and cardiovascular risk. (Mancini et al., 2006)  
   COPD is a disease associated with systemic inflammation and therefore has been linked 
with high rates of inflammation-related multimorbidity. Researchers using NHANES data have 
reported that 96% of individuals with COPD have at least one co-occurring conditions. (Schnell 
et al., 2012) Therefore, while studying the effect of statins on healthcare utilization among 
individuals with COPD and generating evidence base on the novel therapies for individuals with 
COPD, it is important to understand whether statin therapy can improve outcomes high-risk and 
more vulnerable population i.e. those with inflammation-related multimorbidity.  
This study is highly timely and innovative in providing important evidence on the 
association between novel approaches (statin therapy) for COPD management and COPD-
specific outcomes.   In addition, randomized clinical trials routinely exclude those with 
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multimorbidity and therefore using data from real-world settings is required to generate 
generalizable evidence for the management of individuals with multimorbidity. Our study is 
hypothesis generating and will provide the necessary foundation for future research and perhaps 
randomized clinical trials evaluating the effectiveness of statin therapy among individuals with 
COPD.  
An important contribution of our study is providing knowledge on the association 
between statin therapy and COPD-specific outcomes among young adults, specifically Medicaid 
beneficiaries. Enrollees in the Medicaid plans comprise of high-risk vulnerable population that 
have high rates of multimorbidity. In fact, Medicaid beneficiaries with COPD have very high 
rates of inflammation-related multimorbidity. Researchers using the Maryland Medicaid 
database have reported that beneficiaries with COPD had higher prevalence of diabetes mellitus 
(27.7%), congestive heart failure (17.9%) and cerebrovascular disease (10.7%). (Lin, Shaya, & 
Scharf, 2010)Therefore, proving the benefits of statins among high-risk and vulnerable 
population of Medicaid beneficiaries with COPD will strengthen the evidence in the area of 
COPD management. 
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CONCEPTUAL FRAMEWORK 
In this study we used an adaption of Economic Clinical and Humanistic Outcomes Model 
(ECHO). The ECHO model is described in the Figure below.  
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Description of ECHO Model 
ECHO Model: ECHO model identifies, various pathways which affects the economic, clinical 
and humanistic outcomes 
The theoretical framework provided in the ECHO model has been proposed by Kozma et al 
(Kozma, Reeder, & Schulz, 1993) in 1993 and adapted in protocol development guideline for 
observational comparative effectiveness research by Agency for Healthcare Research and 
Quality.  The model describes pathways which are associated with relationship between 
treatments and health outcomes. This model also depicts that that the choice of treatment 
alternatives is affected by several external controls. These external controls include non-
modifiable factors such as race, gender, age and modifiable factors such as personal health 
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practices such as tobacco, alcohol and drug use. The model indicates that disease (COPD) affects 
clinical indicators and clinical outcomes (such as disease biomarkers, hospitalizations and 
others). On the other hand presence of external control affects treatment choices. Once the 
treatment is provided through various pathways the treatment improves clinical outcomes and 
can lead to reduction in healthcare expenditures (i.e. economic outcomes).  
METHODS  
Study design 
 Retrospective longitudinal dynamic cohort design using data from administrative claims 
of Medicaid beneficiaries was utilized. Multiple years of Medicaid Analytic eXtract (MAX) files 
(2005-2008) provided by the Centers for Medicare and Medicaid Services (CMS) were used to 
construct the study cohort. Individuals with COPD were identified between 01/01/2006 and 
12/31/2007 (Index date Identification Period). Receipt of statin medication and other baseline 
characteristics were identified in the baseline period which was defined as 12 months before the 
index date. One year period after index date was considered as the follow-up period. This period 
was used to assess COPD-specific healthcare utilization such as COPD-specific hospitalizations, 
COPD-specific ER visits and COPD-specific outpatient visits. Total healthcare and COPD-
specific healthcare expenditures were also identified during this period. 
 
 
 
 
 
Index date 
Identification period 
12/31/2007 01/01/2005 12/31/2008 
 
Baseline period 
(1 year prior to index date) 
 
Follow-up period I 
(1 year from end index date) 
01/01/2006 
Figure: An example of description of study periods 
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Data Source 
Medicaid Analytic eXtract (MAX) (2005-2008) 
Medicaid analytic extract (MAX) files prepared and produced by the Centers for 
Medicare and Medicaid Services with the help of Research and Data Assistance Center 
(ResDAC) for performing research on healthcare utilization and outcomes among Medicaid 
beneficiaries were used for this study. The data for Medicaid beneficiaries is collected via 
Medicaid Statistical Information System (MSIS). States administering the Medicaid program 
report annual, person-level data for the Medicaid beneficiaries to the CMS through MSIS. These 
person level files provided information about beneficiaries’ eligibility, their healthcare utilization 
and payment information. The quality of these files is maintained through series of initiatives 
taken by the CMS and ResDAC. (CMS, 2011; Hennessy, Leonard, Palumbo, Newcomb, & 
Bilker, 2007) We received five separate files (“personal summary (PS)”, “inpatient claims (IP)”, 
“other therapy claims (OT)”, “prescription drug claims (RX)” and “long-term care claims (LT)”) 
from CMS. For the purposed of this study we linked PS, IP, OT, RX files based on beneficiaries’ 
unique identification number. The PS files included information on eligibility, demographics, 
managed care enrollment, and utilization summary. The other three files provided information on 
fee-for-service claims data for services used. For example, the RX file included information 
regarding utilization of prescription drugs by Medicaid beneficiaries. This information includes, 
date of prescription filled, days of supply, national drug code (NDC) which were used to identify 
the receipt of statin therapy. We used data for beneficiaries residing in the following states: New 
York (NY), Texas (TX), Illinois (IL), and California (CA). The primary reason behind using this 
data was to obtain programs with lower Medicaid-managed care penetration rates so that more 
utilization characteristics would be captured. This provided us the ability to obtain maximum 
number of beneficiaries with fee-for-service enrollments.  
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Area Resource File (ARF): 
 In addition to all the demographic characteristics and utilization variables obtained from 
the MAX files, we also determined each Medicaid beneficiary’s contextual county level 
variables using the Area Resource File (ARF). ARF is a comprehensive county-level dataset 
compiled by the Health Resources Service Administration’s Bureau of Health Professions. ARF 
contains more than 6000 variables providing information about nation’s counties. The 
information contained within ARF includes type of health facilities in the various counties, 
number and type health professions, resource scarcity measures, health status, economic activity, 
health training programs, and socioeconomic and environmental characteristics. These files also 
include county codes and descriptors that allow its linkage with several secondary datasets such 
as MAX. The type of variables that were obtained from ARF included density of pulmonologist 
in beneficiary’s residing county. We used the county codes and state information to link MAX 
files with 2008 ARF file. All the ARF variables were obtained from the baseline period.   
Study Population 
Medicaid Beneficiaries with COPD 
Medicaid beneficiaries with diagnosed COPD were identified using MAX IP and OT 
files (physician office visits claims only). Baseline period were used to identify Medicaid 
Beneficiaries with COPD. Individuals with at least one inpatient visit or two 14 days apart 
outpatient visits (obtained using type of service codes) for COPD based on International 
Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes for chronic 
bronchitis (491.xx), emphysema (492.xx), or unspecified chronic airway obstruction (496.xx) 
were considered to have diagnosed COPD. These diagnosis codes have been utilized in prior 
published research (codes 491.xx, 492.xx and 496.xx) to identify COPD and evaluate medical 
treatment and health outcomes among individuals with COPD. (Dalal, Shah, D'Souza, 
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Chaudhari, & Crater, 2012; Halpern et al., 2011; Make, Dutro, Paulose-Ram, Marton, & Mapel, 
2012) Indeed, sensitivity and specificity of using ICD-9-CM codes to identify patients with 
COPD has been established. (Cooke et al., 2011; A. S. Gershon et al., 2009) A study conducted 
by Gershon et al reported that identifying COPD using 1 or more ambulatory claims and/or 1 or 
more hospitalizations for COPD  resulted in a sensitivity of 85.0% (95% CI: 77.0 to 91.0) and a 
specificity of 78.4% (95% CI: 73.6 to 82.7).  However, we will be used 1 inpatient or 2 
outpatient claims to identify individuals with COPD in order to increase the specificity of the 
algorithm.  
Other inclusion criteria will included: a) 40-64 years (among young adults this age group 
is at highest risk of COPD); b) continuous eligibility during the baseline and follow-up period; c) 
no dual Medicaid/Medicare coverage (dual eligibility will represent high-cost and severe 
beneficiaries); d) enrolled in fee-for-service plans throughout the study observation period; e) 
Alive during the study observation period; and use of services (inpatient or outpatient). 
Dependent Variables  
COPD-Specific Outcomes 
  Any healthcare claim with primary diagnosis of COPD identified using ICD-9-CM codes 
were considered within COPD-specific outcomes. Following variables were identified as COPD-
specific outcomes: a) COPD-specific hospitalizations (yes/no); b) COPD-specific emergency 
room visits (yes/no); obtained from and inpatient and outpatient claims; and c) COPD-specific 
outpatient visits (low and high) derived by categorizing the number of COPD-specific outpatient 
visits greater than or equal to median and less than the median value.   
Total and COPD-specific Healthcare Expenditures 
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We also measured Total and COPD- specific inpatient and outpatient expenditures. 
COPD-specific expenditures were identified by identifying service claims with the primary 
diagnosis of COPD (inpatient and outpatient). Total expenditures were estimated by adding 
Medicaid payment per claim (inpatient, outpatient and prescription drugs) for each person. To 
account for medical services inflation, expenditures in 2006 and 2007 were converted to 2008 
dollars using the annual consumer price index for medical care services available from the 
Bureau of Labor Statistics. (BLS, 2013) 
Key Independent Variable 
Treatment Alternatives 
1. Statin Therapy  (Yes/No) 
Statin therapy was identified in the baseline period using National Drug Code (NDC). Any 
Medicaid beneficiary with at least one prescription of statin during the baseline period was 
considered as receiving statin therapy. 
2.  Long-term statin therapy (Long-term/short-term/no statin therapy) 
Individuals with long-term statin therapy were differentiated from those with short-term 
statin therapy. Medicaid beneficiaries with newly-diagnosed COPD having >120 days of statin 
supply during the baseline period were considered as receiving long-term therapy. Those with 
<120 days of statin supply were categorized as individuals with short-term statin therapy and 
those without any claim of statin  were grouped under no statin therapy.  
Clinical Severity (Inflammation-related multimorbidity) 
We created indicator variables for the presence of arthritis, CVD, depression, diabetes 
and osteoporosis using the International Classification of Diagnosis – 9th Revision- Clinical 
Modification (ICD-9-CM) codes. Any Medicaid beneficiary with COPD having greater than or 
equal to one inpatient or one outpatient visits for these conditions were considered as having the 
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disease. In addition indicator variables will be created for inflammation-related physical 
conditions and inflammation-related mental condition. Any Medicaid beneficiary having either 
of the following conditions: arthritis, CVD, diabetes and osteoporosis were grouped within 
inflammation-related physical conditions. Similarly, any individual with COPD and having 
depression were considered as having inflammation-related mental condition.  
Operational definition: 
Medicaid beneficiaries included in our study population were further grouped into one of the 
four multimorbidity categories as mentioned below: 
5) COPD + Inflammation-related Physical Conditions + Inflammation-related Mental 
Condition 
6) COPD + Inflammation-related Physical Conditions  
7) COPD + Inflammation-related Mental Condition 
8) COPD only (without any chronic conditions). 
 
To analyze the relationship between statin therapy, presence of inflammation-related 
multimorbidity and COPD-specific healthcare outcomes, we created a variable with four 
categories: a) statin therapy and inflammation-related multimorbidity; b) no statin therapy and 
inflammation-related multimorbidity; c) statin therapy and no inflammation-related 
multimorbidity and d) no statin therapy and no inflammation-related multimorbidity. This 
variable was entered in the final logistic regression analyses, which included adjustment for 
baseline characteristics.  
 
 [70] 
 
Other Independent Variables (External Controls) 
When examining the impact of treatment alternatives on clinical and economic outcomes, 
external controls may bias the relationship. Therefore, we adjusted for these external controls in 
the regression analyses. These variables included year of diagnosis (2006 vs. 2007), 
demographic characteristics such as gender (women, men), race (White, African Americans, 
Others), age in years (40-49, 50-59, 60-64), poverty eligibility (yes, no), medical eligibility (yes, 
no), number of other clinical conditions (none, 1-3, 4-6, >6), serious mental illness (yes, no), 
alcohol abuse (yes, no), substance abuse  (yes, no), tobacco use (yes, no) and polypharmacy (<10 
drug classes, > 10 drug classes). We additionally controlled for county-level characteristics 
obtained from the ARF. These variables included quartiles for density of above high school 
education, unemployment, poverty, primary care providers, and specialist care providers were 
created. Density of these county level characteristics was calculated by dividing total number of 
each characteristic by the total county population. This density was further converted into per 
1000 people by multiplying 1000 with the density. Other ARF characteristics included 
pulmonologist density (high vs. low), cardiologist density (high vs. low), etc. In addition to these 
variables, there is a possibility of bias in relationship between statin therapy and COPD-specific 
outcomes due to state policy variations. Therefore, we adjusted for fixed effects for state 
variations using dummy variable for the states (CA, IL, NY, TX) in our analyses.    
Statistical Analyses 
Inverse Probability of Treatment Weighting (IPTW) Technique 
 In order to account for selection bias due to observed differences in baseline characteristics 
among individuals with and without statin therapy, Inverse Probability of Treatment Weighting 
(IPTW) technique was used. This method allows us to calculate weights that are essentially the 
probability of an individual receiving the treatment (i.e. exposure in a nonrandomized study) 
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conditional on their observed stable covariates. Higher weights are assigned to individuals who 
are under-represented and vice-versa for individuals who are over represented. We adjusted for 
the probability weight that we obtained from the logistic/multinomial logistic regressions on 
statin therapy and duration of statin therapy respectively in order to control for the observed 
selection bias. This created a balance in terms of distribution of potential confounders across 
treatment levels.  
Bivariate Analyses 
Subgroup differences in statin therapy and duration of statin therapy were tested using 
Chi-square tests of independence. In addition, bivariate differences in COPD-specific healthcare 
outcomes between those with and without statin therapy were also tested using Chi-square tests 
of independence. F-tests were used to determine the relationship between statin therapy and 
continuous outcomes.  
Multivariate Analyses 
We used logistic regressions and multinomial logistic regressions to examine the factors 
associated with any statin and long-term statin therapy respectively. Multivariable logistic 
regressions with and without IPTW adjustment was be used to determine the relationship 
between statin therapy and COPD-specific outcomes when the dependent variables are 
categorical (example: COPD –specific hospitalizations). For analyzing expenditure outcomes we 
used multivariable GLM with log-link function and gamma distribution. As many Medicaid 
beneficiaries did not have any COPD-specific healthcare expenditures, we used two-part models. 
The first part of the model predicted the probability of having any COPD-specific utilization and 
the second part of the model included GLM with log-link and gamma distribution on healthcare 
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expenditures for beneficiaries who were users. All the analyses were conducted using SAS 9.3 
(SAS Institute, Cary, NC). 
RESULTS 
After applying the eligibility criteria as shown in Figure 1, the analytic cohort included 
19,060 Medicaid beneficiaries with newly-diagnosed COPD. Any statin therapy was observed in 
30.3% (n = 5,771) of the Medicaid beneficiaries, out of which three quarters of beneficiaries had 
long-term statin therapy defined as >120 days statin medication supply.  
Factors associated with Statin Therapy 
Several demographic and clinical factors were associated with statin therapy and duration 
of statin therapy among Medicaid beneficiaries with newly-diagnosed COPD. Females (AOR: 
0.92; 95% CI: 0.86, 0.99), African Americans (AOR: 0.56; 95% CI: 0.56, 0.67), younger adults 
in 40-49 years (AOR: 0.52, 95% CI: 0.47, 0.57) and 50-59 years (AOR: 0.72, 95% CI: 0.66, 
0.79) were less likely to receive statin therapy compared to males, whites, and older adults (60 – 
64 years). Beneficiaries with inflammation-related physical condition only (AOR: 3.6, 95% CI: 
2.85, 3.50) and those with both physical and mental conditions (AOR: 2.75, 95% CI: 2.44, 3.10) 
were approximately three times as likely to receive statins as compared to those with no 
multimorbidity. Medicaid beneficiaries with the presence of life-style risk factors such as alcohol 
abuse and substance abuse were less likely to receive statin therapy; whereas those with 
polypharmacy (AOR:3.82, 95% CI: 3.52, 4.14) were more likely to receive statins.  Similar 
results were observed from multinomial logistic regressions on duration of statin therapy (long-
term/short-term vs. no statin therapy) among Medicaid beneficiaries with newly-diagnosed 
COPD.  Detailed results from these analyses are presented in Table 1(a) and Table 1(b).  
Statin Therapy and COPD-specific Outcomes 
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As shown in Table 2, those with statin therapy had significantly lower rates of COPD-
specific hospitalizations (4.7% vs. 5.2%; p<0.05), COPD-specific ER visits (13.4% vs. 15.4%; 
p<0.001) and COPD-specific outpatient visits (41.4% vs. 44.7%; p<0.001) compared to adults 
without statin therapy. Similarly, beneficiaries with any duration of statin therapy (long-term or 
short-term) had lower rates of COPD-specific healthcare utilization. The reduction in COPD-
specific healthcare utilization was also observed even after controlling for baseline 
characteristics. Beneficiaries with statin therapy were 16% less likely to have COPD-specific 
hospitalization (AOR: 0.84; 95% CI: 0.71, 0.98), 11% less likely to have COPD-specific 
emergency room visit (AOR: 0.89; 95% CI: 0.81, 0.99) and 14% less likely to have COPD-
specific outpatient visit (AOR: 0.86; 95% CI: 0.80, 0.92). Analyses with duration of statin-
therapy revealed that only long-term statin therapy was associated with lower COPD-specific 
healthcare outcomes. Beneficiaries with long-term therapy of statin were less likely to have 
COPD-specific hospitalizations (AOR: 0.81, 95% CI: 0.71, 0.99), COPD-specific emergency 
room visits (AOR: 0.86; 95% CI: 0.77, 0.96) and COPD-specific outpatient visits (AOR: 0.84; 
95% CI: 0.78, 0.92).  
In order to control for selection bias in observed variables, we conducted same regression 
analyses after weighting with Inverse Probability Treatment Weights (IPTW) obtained from 
logistic and multinomial logistic regressions on statin therapy and duration of statin therapy 
respectively. These treatment weights were adjusted for the number of individuals in each 
category of statin therapy and duration of statin therapy. The results from these analyses are 
presented in Table 3. Even after using IPTW technique, individuals with statin therapy were 
significantly less likely to have COPD-specific healthcare outcomes. In fact, the magnitude of 
reduction and significance strength enhanced after controlling for selection bias using IPTW 
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technique. Moreover, after using IPTW technique short-term statin therapy also showed 
significant reduction in COPD-specific hospitalizations (AOR: 0.83; 95% CI: 0.75, 0.91). 
However, association between short-term statin therapy and COPD-specific emergency room 
visits and COPD-specific outpatient visits remained insignificant. We also conducted sensitivity 
analyses using unadjusted IPTW technique (using weights that were not adjusted for number of 
individuals who received statins). The results from sensitivity analyses were similar to those 
observed with adjusted IPTW technique. (Data not represented in tabular form) 
Statin Therapy, Inflammation-related Multimorbidity and COPD-specific Healthcare 
Utilization 
An analysis of relationship between statin therapy and COPD-specific healthcare 
outcomes in presence of inflammation-related multimorbidity revealed that beneficiaries with 
inflammation-related multimorbidity and statin therapy were less likely to have COPD-specific 
specific healthcare outcomes as compared to those with inflammation-related multimorbidity and 
no statin therapy. For example, beneficiaries with inflammation-related multimorbidity and statin 
therapy were 18% less likely to have COPD-specific hospitalization (AOR: 0.82; 95% CI: 0.70, 
0.97) as compared to those with inflammation-related multimorbidity and no statin therapy. 
Detailed results are presented in Table 4. 
Statin Therapy and Total and COPD-specific Healthcare Expenditures 
Findings from bivariate analyses on total and COPD-specific healthcare expenditures are 
reported in Table 5. For the ease of representation we have calculated ratio of means for overall 
and subgroup expenditures for selected characteristics. As shown in the table, individuals with 
statin therapy were not significantly different in average total healthcare expenditures than those 
without statin therapy ($36,215 vs. $35,724). Similarly, there was no difference in COPD-
specific outpatient expenditures between beneficiaries with or without statin therapy. However, 
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average COPD-specific inpatient expenditures (among users of inpatient services) were 
significantly lower among those who received statin therapy when compared with adults who did 
not receive statin therapy ($6,593 vs. $7,457; p<0.05). Interestingly, among beneficiaries with 
inflammation-related physical condition statin therapy was associated with lower average 
COPD-specific expenditures ($6,446 vs. $7,594; p<0.05) and higher average COPD-specific 
outpatient expenditures ($451 vs. $409; p<0.01)   
After controlling for baseline characteristics in the regression analyses with log-link 
function and gamma distribution (Table 6), it was found that statin therapy was not significantly 
associated with lower average COPD-specific inpatient and outpatient expenditures. 
Furthermore, long-term statin therapy was associated with higher average total healthcare 
expenditures ($9,394 vs. $8,759; β = 0.02; p<0.001), whereas short-term statin therapy was 
associated with lower ($7,902 vs. $8,759; β = -0.10; p<0.001) average total healthcare 
expenditures as compared to no statin therapy.  
DISCUSSION 
This retrospective observational study was conducted to evaluate the clinical and 
economic outcomes associated with statin therapy among individuals with newly diagnosed 
COPD in a real-world practice setting. Approximately 30% of Medicaid beneficiaries with 
newly-diagnosed COPD received statin medications during the baseline period. In this study, we 
found that even after controlling for baseline characteristics and observed selection bias using 
IPTW technique, beneficiaries with statin therapy were  24% less likely to have COPD-specific 
hospitalizations, 19% less likely to have COPD-specific ER and 14% less likely to have COPD-
specific outpatient visits among individuals with newly-diagnosed COPD. Our results are 
consistent with findings from a handful of studies that have evaluated effects of statins in terms 
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of COPD-related hospitalizations and found beneficial effects. (Mancini et al, 2006; Huang et al, 
2011) However, to the best of our knowledge this is the first study to examine the relationship 
between statin therapy and COPD-specific outcomes including both clinical and economic 
outcomes. Furthermore, this is the only study to assess the impact of duration of statin therapy 
among individuals with newly-diagnosed COPD. Findings from this study indicate that 
beneficial impact of statin is directly related to duration of statin therapy. Statistically significant 
reduction COPD-specific emergency room visits and outpatient visits were only observed among 
beneficiaries who had >120 days of statin medication supply during the baseline period.  
In addition, our study findings also revealed that statin therapy was beneficial for adults 
with COPD and inflammation-related multimorbidity (Table 4) as compared to those with 
inflammation-related multimorbidity and no statin therapy.  A plausible explanation could be 
found in the anti-inflammatory properties of statin therapy.  Biologically, statin therapy has 
shown anti-inflammatory properties by reducing inflammatory biomarkers. (Forrester JS et al, 
2007; Gross NJ et al, 2012) As COPD is being recognized as disease of systemic inflammation 
with high levels of inflammatory biomarkers (P. J. Barnes & Celli, 2009; Fabbri & Rabe, 2007; 
Sevenoaks & Stockley, 2006), the results from our analyses suggest that the biological benefits 
of statin medications in reducing systemic inflammation may be spilling over to reduce COPD-
specific complications.   
Our results indicate that reduction in COPD-specific healthcare outcomes with statin 
therapy did not translate into statistically significant reduction in total or COPD-specific 
inpatient or outpatient expenditures. It is plausible that due to inclusion of prescription drug costs 
in evaluating total expenditures may have offset any cost reduction due to lower healthcare 
utilization. However, while assessing COPD-specific expenditures, prescriptions costs were not 
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included. Future studies with longer follow-up period are required to ascertain whether statin 
therapy is associated with any economic benefits among those with COPD.   
Findings from this study complement the prior evidence that suggests statin use is 
associated with improved lung function, COPD symptoms and exacerbations. (Blamoun et al., 
2008; Huang et al., 2011; Ishida et al., 2007; Keddissi et al., 2007; Lawes et al., 2012)  
Collectively, these findings warrant the evaluation of statin medications in randomized clinical 
trials (RCT) setting to establish the efficacy and safety of statin use among individuals with 
COPD. In fact, few randomized trials that were ongoing when we conceptualized the study have 
been recently completed. (Criner GJ et al, 2014; NJH, 2014; UHA, 2014) Findings from one of 
these large, prospective, multicenter randomized trials on evaluating the efficacy of simvastatin 
on reducing COPD exacerbations differ from the conclusions of our study. (Criner GJ et al, 
2014) This may be due to difference in the study population as the randomized controlled trial 
included individuals with moderate to severe COPD aged between 40-80 years, whereas our 
study included newly diagnosed COPD patients between 40-64 years of age. Moreover, 
randomized controlled trial specifically evaluated efficacy of simvastatin. Therefore, more robust 
evaluation of all statin medications is required in both RCT and real-world practice settings with 
longer follow-up to confirm the beneficial effects of statins that we observed in our study.  
STRENGTHS AND LIMITATIONS 
This study is first real-world observational analyses of clinical and economic outcomes 
associated with statin therapy among newly-diagnosed COPD patients in a US setting which 
increases the generalizability of our findings. The major strength of our study includes the use of 
administrative claims data which provided us the ability to identify all the medical conditions 
using diagnosis codes. The data also consisted of medication information with NDCs and days of 
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medication supply information which helps in determining duration of statin therapy. 
Furthermore, our study examines a high-risk and more vulnerable population in terms of 
Medicaid enrollees. The current study is different from any prior analyses as it evaluated the 
effects of statin therapy on COPD-specific outcomes.  
This study has few limitations such as inability to control for COPD-severity due to 
unavailability of laboratory data. Our study population was determined using ICD-9-CM codes 
rather than gold standard approach using spirometry laboratory values. However, the sensitivity 
and specificity of ICD-9-CM codes to identify COPD has been established in previous studies. 
The study only used data from only four states which may not provide a full understating of 
outcomes in overall Medicaid population. We also excluded dual Medicare-Medicaid and 
managed care enrollees from our population which limits the overall generalizability. Finally, 
our study is only generalizable to newly-diagnosed COPD patients and thus further research is 
required to evaluate the effectiveness of statin therapy among individuals with prevalent COPD. 
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TABLES AND FIGURES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure: Algorithm Describing Selection of Study Population 
  
2,422 beneficiaries died during the study 
observation period 
23,289 dual Medicare/Medicaid eligible 
7,025 individuals without continuous 
eligibility 
59,536 individuals with newly diagnosed Chronic 
Obstructive Pulmonary Disease (COPD) diagnosis 
between January 1, 2006, and December 31, 2007 in  
Medicaid Analytic eXtract Files 
57,114 beneficiaries with newly diagnosed COPD were 
alive during the entire study observation period 
3,589 enrollees with HMO plans 
23,211 Medicaid beneficiaries with fee-for-services plans 
4,151 enrollees aged <40 years or >64 
years 
19,060 Medicaid Beneficiaries with 
newly-diagnosed COPD 
33,825 individuals with no dual eligibility 
26,800 beneficiaries with continuous eligibility 
throughout study observation period 
5,771 Statin Users 13,289 Non Users 
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Table 1 (a) 
Number, Percentages, Adjusted Odds Ratio and 95% CI 
 from Logistic Regressions on Statin Therapy  
among Medicaid Beneficiaries with Newly-Diagnosed COPD  
Medicaid Analytic Extract, 2005-2008 
Statin Therapy 
    N Row % AOR 95% CI Sig 
TOTAL 5,771 30.3 
Cohort Year 
2005-2007    3,161  29.5 0.88 [ 0.82 ,  0.94] *** 
2006-2008    2,610  31.3 
Sex 
Women    3,646  32.2 0.92 [ 0.86 ,  0.99] * 
Men    2,125  27.5 
Race/Ethnicity 
White    2,935  31.7 
African American    1,231  24.2 0.61 [ 0.56 ,  0.67] *** 
Others    1,605  34.1 0.98 [ 0.90 ,  1.07] 
Age (in years) 
40-49    1,386  21.8 0.52 [ 0.47 ,  0.57] *** 
50-59    2,942  31.9 0.72 [ 0.66 ,  0.79] *** 
60-64    1,443  41.4 
State 
California    3,179  30.6 
Illinois    1,257  30.6 1.07 [ 0.97 ,  1.19] 
New York       854  32.7 1.22 [ 1.07 ,  1.38] ** 
Texas       481  24.8 0.87 [ 0.74 ,  1.02] 
Poverty Eligibility 
Yes    5,366  30.7 1.12 [ 0.95 ,  1.31] 
No       405  25.6 
Medical Eligibility 
Yes       512  25.1 0.91 [ 0.79 ,  1.06] 
No    5,259  30.9 
Inflammation-related Multimorbidity 
Physical Only    3,639  39.1 3.16 [ 2.85 ,  3.50] *** 
Mental Only       184  14.3 1.01 [ 0.84 ,  1.22] 
Both    1,345  36.0 2.75 [ 2.44 ,  3.10] *** 
None       603  12.7 
  
 
(Continued) 
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Table 1 (a) 
Number, Percentages, Adjusted Odds Ratio and 95% CI 
 from Logistic Regressions on Statin Therapy  
among Medicaid Beneficiaries with Newly-Diagnosed COPD  
Medicaid Analytic Extract, 2005-2008 
Statin Therapy 
    N Row % AOR 95% CI Sig 
TOTAL 5,771 30.3 
Number of Other Clinical Conditions 
None         74  15.6 
1-3       835  23.5 1.23 [ 0.93 ,  1.63] 
4-6    1,268  28.3 1.15 [ 0.87 ,  1.52] 
>6    3,594  34.0 0.97 [ 0.74 ,  1.28] 
Serious Mental Illness 
Yes    1,299  26.2 0.92 [ 0.85 ,  1.00] 
No    4,472  31.7 
Alcohol Abuse 
Yes       318  17.4 0.58 [ 0.50 ,  0.67] *** 
No    5,453  31.6 
Substance Abuse 
Yes       457  17.3 0.52 [ 0.46 ,  0.59] *** 
No    5,314  32.4 
Tobacco Use 
Yes       675  26.6 0.98 [ 0.88 ,  1.10] 
No    5,096  30.8 
Polypharmacy 
Yes    4,361  44.2 3.82 [ 3.52 ,  4.14] *** 
No    1,410  15.3 
ARF Variables (County Level) 
Above HS Education Density 
Q1    3,168  31.5 
Q2       846  30.8 0.93 [ 0.81 ,  1.06] 
Q3    1,116  29.0 0.88 [ 0.77 ,  1.01] 
Q4       641  26.6 0.89 [ 0.75 ,  1.06] 
Unemployment Density 
Q1    4,248  30.0 
Q2       804  31.3 1.00 [ 0.85 ,  1.17] 
Q3       515  29.0 0.79 [ 0.64 ,  0.97] * 
Q4       204  36.4 1.02 [ 0.75 ,  1.38] 
  
    
(Continued) 
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Table 1 (a) 
Number, Percentages, Adjusted Odds Ratio and 95% CI 
 from Logistic Regressions on Statin Therapy  
among Medicaid Beneficiaries with Newly-Diagnosed COPD  
Medicaid Analytic Extract, 2005-2008 
Statin Therapy 
    N Row % AOR 95% CI Sig 
TOTAL 5,771 30.3 
Poverty Density 
Q1       423  26.7 
Q2       758  28.1 1.03 [ 0.85 ,  1.23] 
Q3    1,075  30.6 1.13 [ 0.95 ,  1.34] 
Q4    3,515  31.2 1.02 [ 0.84 ,  1.23] 
Metro 
Yes    4,984  30.2 0.89 [ 0.77 ,  1.04] 
No       787  31.1 
PCP Shortage 
Yes    5,561  30.4 1.03 [ 0.84 ,  1.25] 
No       210  27.3 
Mental Health Specialist Shortage 
Yes    5,148  30.2 0.92 [ 0.80 ,  1.06] 
No       623  31.1 
PCP Density 
Q1       261  32.5 
Q2    1,025  31.9 0.99 [ 0.79 ,  1.24] 
Q3       805  29.8 0.88 [ 0.69 ,  1.13] 
Q4    3,680  29.8 0.79 [ 0.58 ,  1.06] 
Hospital Beds Density 
Q1       315  31.5 
Q2       911  29.3 1.00 [ 0.82 ,  1.22] 
Q3    3,306  30.9 1.08 [ 0.88 ,  1.33] 
Q4    1,239  29.2 1.03 [ 0.83 ,  1.27] 
Psychiatric Hospital  
Yes    3,699  30.6 1.05 [ 0.92 ,  1.19] 
No    2,072  29.8 
Pulmonologist Density 
High    3,979  29.7 1.10 [ 0.94 ,  1.29] 
Low    1,792  31.6 
Cardiologist Density 
High    3,750  30.1 1.11 [ 0.95 ,  1.30] 
Low    2,021  30.7 
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Note: Based on 19,060 Medicaid Beneficiaries with newly diagnosed COPD obtained from Medicaid 
Analytic eXtract files observed during 2005-2008. Asterisks represent significant group differences in 
likelihood of statin therapy, long-term vs. short-term statin therapy by beneficiary characteristics 
compared to the reference group (None) obtained from Adjusted Logistic and Adjusted Multinomial 
Logistic Regression Analyses respectively.  
Adjusted Logistic Regression Analyses controlled for cohort year, sex, race, age, state, poverty 
eligibility, inflammation-related multimorbidity number of other clinical conditions, serious mental 
illness, alcohol abuse, substance abuse, tobacco use, polypharmacy, county level variables including: 
above high school education density (quartiles),  unemployment density (quartiles), poverty density 
(quartiles), metro status, primary care shortage area, mental health shortage area, primary care provider 
density (quartiles), hospital beds density (quartiles), psychiatric hospital, pulmonologist density and 
cardiologist density. 
 
OR: Odds Ratio; AOR: Adjusted Odds Ratio; CI: Confidence Interval; Sig: Significance 
 
*** p < .001; ** .001 ≤ p < .01; * .01 ≤ p < .05 
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Table 1 (b) 
Number, Percentages, Adjusted Odds Ratio and 95% CI  
from Multinomial Logistic Regressions on Duration of Statin Therapy 
among Medicaid Beneficiaries with Newly-Diagnosed COPD 
Medicaid Analytic Extract, 2005-2008 
  
Long-term Statin therapy Short-term Statin therapy 
  
N Row % AOR 95% CI Sig N 
Row 
% AOR 95% CI Sig 
TOTAL 4,343 22.8 
 
  
1,428 7.5 
 
  
            
Cohort Year 
 
         
 
2005-2007 2,377 22.2 0.87 [ 0.81 ,  0.94] *** 784 7.3 0.91 [ 0.81 ,  1.02] 
 
 
2006-2008 1,966 23.6 
   
644 7.7 
   
Sex 
 
         
 
Women 2,714 23.9 0.87 [ 0.80 ,  0.94] *** 932 8.2 1.08 [ 0.96 ,  1.22] 
 
 
Men 1,629 21.1 
   
496 6.4 
   
Race/Ethnicity 
 
         
 
White 2,320 25.0 
   
615 6.6 
   
 
African American 818 16.1 0.52 [ 0.47 ,  0.58] *** 413 8.1 0.92 [ 0.79 ,  1.07] 
 
 
Others 1,205 25.6 0.92 [ 0.84 ,  1.02] 
 
400 8.5 1.17 [ 1.01 ,  1.35] * 
Age (in years) 
 
         
 
40-49 973 15.3 0.45 [ 0.40 ,  0.50] *** 413 6.5 0.76 [ 0.64 ,  0.90] ** 
 
50-59 2,199 23.8 0.67 [ 0.61 ,  0.73] *** 743 8.0 0.95 [ 0.82 ,  1.11] 
 
 
60-64 1,171 33.6 
   
272 7.8 
   
State 
 
         
 
California 2,384 22.9 
   
795 7.6 
   
 
Illinois 917 22.3 1.10 [ 0.98 ,  1.23] 
 
340 8.3 1.00 [ 0.84 ,  1.18] 
 
 
New York 687 26.3 1.35 [ 1.17 ,  1.56] *** 167 6.4 0.87 [ 0.70 ,  1.10] 
 
 
Texas 355 18.3 0.86 [ 0.72 ,  1.03] 
 
126 6.5 0.89 [ 0.68 ,  1.16] 
 
Poverty Eligibility 
 
         
 
Yes 4,061 23.2 1.21 [ 1.01 ,  1.46] * 1,305 7.5 0.90 [ 0.70 ,  1.17] 
 
 
No 282 17.8 
   
123 7.8 
   
Medical Eligibility 
 
         
 
Yes 367 18.0 0.92 [ 0.78 ,  1.09] 
 
145 7.1 0.89 [ 0.70 ,  1.14] 
 
 
No 3,976 23.4 
   
1,283 7.5 
   
Inflammation-related Multimorbidity 
 
      
 
Physical Only 2,778 29.8 3.56 [ 3.16 ,  4.02] *** 861 9.3 2.35 [ 1.98 ,  2.78] *** 
 
Mental Only 124 9.7 1.00 [ 0.80 ,  1.25] 
 
60 4.7 1.04 [ 0.77 ,  1.41] 
 
 
Both 1,033 27.7 3.12 [ 2.72 ,  3.59] *** 312 8.4 2.01 [ 1.64 ,  2.45] *** 
 
None 408 8.6 
   
195 4.1 
   
  
      
(Continued) 
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Table 1 (b) 
Number, Percentages, Adjusted Odds Ratio and 95% CI  
from Multinomial Logistic Regressions on Duration of Statin Therapy 
among Medicaid Beneficiaries with Newly-Diagnosed COPD 
Medicaid Analytic Extract, 2005-2008 
  
Long-term Statin therapy Short-term Statin therapy 
  
N Row % AOR 95% CI Sig N 
Row 
% AOR 95% CI Sig 
TOTAL 4,343 22.8 
 
  
1,428 7.5 
 
  
Number of Other Clinical Conditions 
 
      
 
None 51 10.8 
   
23 4.9 
   
 
1-3 623 17.6 1.32 [ 0.96 ,  1.83] 
 
212 6.0 1.03 [ 0.66 ,  1.62] 
 
 
4-6 947 21.2 1.22 [ 0.88 ,  1.69] 
 
321 7.2 1.00 [ 0.64 ,  1.56] 
 
 
>6 2,722 25.8 1.03 [ 0.75 ,  1.42] 
 
872 8.3 0.85 [ 0.54 ,  1.32] 
 
Serious Mental Illness 
 
        
 
Yes 998 20.1 0.98 [ 0.90 ,  1.08] 
 
301 6.1 0.77 [ 0.67 ,  0.89] *** 
 
No 3,345 23.7 
   
1,127 8.0 
   
Alcohol Abuse 
 
         
 
Yes 209 11.5 0.51 [ 0.44 ,  0.61] *** 109 6.0 0.76 [ 0.61 ,  0.95] * 
 
No 4,134 24.0 
   
1,319 7.7 
   
Substance Abuse 
 
         
 
Yes 293 11.1 0.45 [ 0.39 ,  0.52] *** 164 6.2 0.70 [ 0.58 ,  0.84] *** 
 
No 4,050 24.7 
   
1,264 7.7 
   
Tobacco Use 
 
         
 
Yes 470 18.5 0.90 [ 0.80 ,  1.02] 
 
205 8.1 1.21 [ 1.03 ,  1.43] * 
 
No 3,873 23.4 
   
1,223 7.4 
   
Polypharmacy 
 
         
 
Yes 3,355 34.0 4.19 [ 3.82 ,  4.59] *** 1,006 10.2 3.00 [ 2.62 ,  3.44] *** 
 
No 988 10.7 
   
422 4.6 
   
ARF Variables (County Level) 
Above HS Education Density 
 
       
 
Q1 2,327 23.1 
   
841 8.4 
   
 
Q2 638 23.2 0.95 [ 0.81 ,  1.10] 
 
208 7.6 0.88 [ 0.70 ,  1.10] 
 
 
Q3 876 22.8 0.95 [ 0.82 ,  1.10] 
 
240 6.2 0.70 [ 0.55 ,  0.89] ** 
 
Q4 502 20.8 0.95 [ 0.78 ,  1.14] 
 
139 5.8 0.75 [ 0.56 ,  1.01] 
 
Unemployment Density 
 
        
 
Q1 3,166 22.4 
   
1,082 7.6 
   
 
Q2 607 23.6 0.98 [ 0.82 ,  1.16] 
 
197 7.7 1.07 [ 0.81 ,  1.42] 
 
 
Q3 406 22.9 0.79 [ 0.63 ,  0.99] * 109 6.1 0.77 [ 0.54 ,  1.10] 
 
 
Q4 164 29.3 1.02 [ 0.73 ,  1.42] 
 
40 7.1 1.00 [ 0.59 ,  1.71] 
 
  
         
(Continued) 
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Table 1 (b) 
Number, Percentages, Adjusted Odds Ratio and 95% CI  
from Multinomial Logistic Regressions on Duration of Statin Therapy 
among Medicaid Beneficiaries with Newly-Diagnosed COPD 
Medicaid Analytic Extract, 2005-2008 
  
Long-term Statin therapy Short-term Statin therapy 
  
N Row % AOR 95% CI Sig N 
Row 
% AOR 95% CI Sig 
TOTAL 4,343 22.8 
 
  
1,428 7.5 
 
  
Poverty Density 
 
         
 
Q1 339 21.4 
   
84 5.3 
   
 
Q2 577 21.4 0.97 [ 0.79 ,  1.18] 
 
181 6.7 1.25 [ 0.90 ,  1.74] 
 
 
Q3 827 23.6 1.09 [ 0.90 ,  1.32] 
 
248 7.1 1.25 [ 0.91 ,  1.72] 
 
 
Q4 2,600 23.1 1.00 [ 0.81 ,  1.23] 
 
915 8.1 1.09 [ 0.77 ,  1.55] 
 
Metro 
 
         
 
Yes 3,720 22.5 0.86 [ 0.73 ,  1.02] 
 
1,264 7.6 1.00 [ 0.77 ,  1.31] 
 
 
No 623 24.6 
   
164 6.5 
   
PCP Shortage 
 
         
 
Yes 4,188 22.9 1.16 [ 0.93 ,  1.44] 
 
1,373 7.5 0.73 [ 0.53 ,  1.01] 
 
 
No 155 20.1 
   
55 7.1 
   
Mental Health Specialist Shortage 
 
       
 
Yes 3,854 22.6 0.94 [ 0.80 ,  1.09] 
 
1,294 7.6 0.88 [ 0.69 ,  1.12] 
 
 
No 489 24.4 
   
134 6.7 
   
PCP Density 
 
         
 
Q1 205 25.5 
   
56 7.0 
   
 
Q2 770 24.0 0.96 [ 0.75 ,  1.22] 
 
255 7.9 1.11 [ 0.75 ,  1.65] 
 
 
Q3 629 23.3 0.89 [ 0.68 ,  1.17] 
 
176 6.5 0.86 [ 0.56 ,  1.32] 
 
 
Q4 2,739 22.2 0.81 [ 0.58 ,  1.12] 
 
941 7.6 0.75 [ 0.45 ,  1.28] 
 
Hospital Beds Density 
 
        
 
Q1 242 24.2 
   
73 7.3 
   
 
Q2 704 22.6 1.04 [ 0.83 ,  1.29] 
 
207 6.7 0.89 [ 0.63 ,  1.25] 
 
 
Q3 2,431 22.7 1.08 [ 0.86 ,  1.36] 
 
875 8.2 1.05 [ 0.74 ,  1.49] 
 
 
Q4 966 22.8 1.05 [ 0.83 ,  1.32] 
 
273 6.4 0.95 [ 0.66 ,  1.36] 
 
Psychiatric Hospital 
 
        
 
Yes 2,739 22.6 1.03 [ 0.89 ,  1.18] 
 
960 7.9 1.12 [ 0.91 ,  1.38] 
 
 
No 1,604 23.1 
   
468 6.7 
   
Pulmonologist Density 
 
        
 
High 2,959 22.1 1.06 [ 0.89 ,  1.26] 
 
1,020 7.6 1.23 [ 0.93 ,  1.62] 
 
 
Low 1,384 24.4 
   
408 7.2 
   
Cardiologist Density 
 
        
 
High 2,797 22.4 1.12 [ 0.94 ,  1.33] 
 
953 7.6 1.08 [ 0.82 ,  1.42] 
 
 
Low 1,546 23.5 
   
475 7.2 
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Note: Based on 19,060 Medicaid Beneficiaries with newly diagnosed COPD obtained from Medicaid 
Analytic eXtract files observed during 2005-2008. Asterisks represent significant group differences in 
likelihood of statin therapy, long-term vs. short-term statin therapy by beneficiary characteristics 
compared to the reference group (None) obtained from Adjusted Multinomial Logistic Regression 
Analyses respectively.  
Adjusted Multinomial Logistic Regression Analyses controlled for cohort year, sex, race, age, state, 
poverty eligibility, inflammation-related multimorbidity number of other clinical conditions, serious 
mental illness, alcohol abuse, substance abuse, tobacco use, polypharmacy, county level variables 
including: above high school education density (quartiles),  unemployment density (quartiles), poverty 
density (quartiles), metro status, primary care shortage area, mental health shortage area, primary care 
provider density (quartiles), hospital beds density (quartiles), psychiatric hospital, pulmonologist 
density and cardiologist density. 
 
OR: Odds Ratio; AOR: Adjusted Odds Ratio; CI: Confidence Interval; Sig: Significance 
 
*** p < .001; ** .001 ≤ p < .01; * .01 ≤ p < .05 
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Table 2 
Number, Percentage, Adjusted Odds Ratio and 95% Confidence Interval from Logistic 
Regressions on COPD-specific Healthcare Utilization among 
Medicaid Beneficiaries with Newly-Diagnosed COPD (n = 19, 060) 
Medicaid Analytic Extract, 2005-2008 
COPD-specific Hospitalizations 
N Row % Sig AOR 95% CI Sig 
TOTAL 998 5.2 
Statin therapy * 
Yes 270 4.7 0.84 [ 0.71 ,  0.98] * 
No 728 5.5 
Duration of Statin therapy 
Long-term 204 4.7 * 0.84 [ 0.71 ,  0.99] * 
Short-term 66 4.6 0.81 [ 0.62 ,  1.05] 
No Use 728 5.5 
COPD-specific ER visits 
TOTAL 2,824 14.8 
Statin therapy *** 
Yes 775 13.4 0.89 [ 0.81 ,  0.99] * 
No 2,049 15.4 
Duration of Statin therapy *** 
Long-term 564 13.0 0.86 [ 0.77 ,  0.96] ** 
Short-term 211 14.8 0.99 [ 0.85 ,  1.16] 
No Use 2,049 15.4 
COPD-specific Outpatient Visits 
TOTAL 7,200 43.7 
Statin therapy *** 
Yes 2,032 41.4 0.86 [ 0.80 ,  0.92] *** 
No 5,168 44.7 
Duration of Statin therapy *** 
Long-term 1,515 41.2 0.84 [ 0.78 ,  0.92] *** 
Short-term 517 41.8 0.90 [ 0.80 ,  1.02] 
No Use 5,168 44.7 
Note: Based on 19,060 Medicaid Beneficiaries with newly diagnosed COPD obtained from 
Medicaid Analytic eXtract files observed during 2005-2008. Asterisks represent significant 
group differences in likelihood of COPD-specific healthcare utilization by statin therapy and 
duration of statin therapy compared to the reference group (None) obtained from Adjusted 
Logistic Regression analyses. 
Adjusted Logistic Regression Analyses controlled for cohort year, sex, race, age, state, 
poverty eligibility, inflammation-related multimorbidity number of other clinical conditions, 
serious mental illness, alcohol abuse, substance abuse, tobacco use, polypharmacy, county 
level variables including: above high school education density (quartiles),  unemployment 
density (quartiles), poverty density (quartiles), metro status, primary care shortage area, 
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mental health shortage area, primary care provider density (quartiles), hospital beds density 
(quartiles), psychiatric hospital, pulmonologist density and cardiologist density. 
 
OR: Odds Ratio; AOR: Adjusted Odds Ratio; CI: Confidence Interval; Sig: Significance 
 
*** p < .001; ** .001 ≤ p < .01; * .01 ≤ p < .05 
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Table 3 
Adjusted Odds Ratio and 95% Confidence Interval from Logistic Regressions on COPD-
specific Healthcare Utilization  
among Medicaid Beneficiaries with Newly-Diagnosed COPD (n = 19, 060) 
Inverse Probability Treatment Weight Adjustment 
Medicaid Analytic Extract, 2005-2008 
COPD-specific Hospitalizations 
    AOR 95% CI Sig 
Statin therapy 
Yes 0.76 [ 0.66 ,  0.87] *** 
No 
Duration of Statin therapy 
Long-term 0.73 [ 0.66 ,  0.80] *** 
Short-term 0.83 [ 0.75 ,  0.91] *** 
No Use 
COPD-specific ER visits 
Statin therapy 
Yes 0.81 [ 0.75 ,  0.89] *** 
No 
Duration of Statin therapy 
Long-term 0.75 [ 0.67 ,  0.83] *** 
Short-term 0.95 [ 0.81 ,  1.11] 
No Use 
COPD-specific Outpatient Visits 
Statin therapy 
Yes 0.86 [ 0.80 ,  0.91] *** 
No 
Duration of Statin therapy 
Long-term 0.84 [ 0.77 ,  0.90] *** 
Short-term 0.89 [ 0.79 ,  1.00] 
  
No Use       
Note: Based on 19,060 Medicaid Beneficiaries with newly diagnosed COPD obtained from 
Medicaid Analytic eXtract files observed during 2005-2008. Asterisks represent significant group 
differences in likelihood of COPD-specific healthcare utilization by statin therapy and duration of 
statin therapy compared to the reference group (None). 
Adjusted Logistic Analyses controlled for cohort year, sex, race, age, state, poverty eligibility, 
inflammation-related multimorbidity number of other clinical conditions, serious mental illness, 
alcohol, substance abuse, tobacco use, polypharmacy, county variables including: above high 
school education  (quartiles),  unemployment density (quartiles), poverty density (quartiles), 
metro status, primary care shortage area, mental health shortage area, primary care provider 
density (quartiles), hospital beds density (quartiles), psychiatric hospital, pulmonologist density 
and cardiologist density. 
OR: Odds Ratio; AOR: Adjusted Odds Ratio; CI: Confidence Interval; Sig: Significance 
 
*** p < .001; ** .001 ≤ p < .01; * .01 ≤ p < .05 
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Table 4 
Adjusted Odds Ratio and 95% Confidence Interval from Logistic Regressions on COPD-specific 
Healthcare Utilization among Medicaid Beneficiaries with Newly-Diagnosed COPD (n = 19, 060) 
Medicaid Analytic Extract, 2005-2008 
COPD-specific Hospitalizations 
    AOR 95% CI Sig 
Inflammation-related Multimorbidity/Statin therapy  
MM and Statin therapy 0.82 [ 0.70 ,  0.97] * 
MM and no Statin therapy 
No MM and Statin therapy 0.98 [ 0.67 ,  1.46] 
No MM and no Statin therapy 1.17 [ 0.98 ,  1.39] 
COPD-specific Emergency Room visits 
Inflammation-related Multimorbidity/Statin therapy  
Statin and MM 0.90 [ 0.81 ,  0.99] * 
No Statin and MM 
Statin and no MM 0.99 [ 0.77 ,  1.27] 
No statin and no MM 1.17 [ 1.05 ,  1.31] ** 
COPD-specific Outpatient Visits 
Inflammation-related Multimorbidity/Statin therapy  
Statin and MM 0.85 [ 0.78 ,  0.92] *** 
No Statin and MM 
Statin and no MM 0.88 [ 0.73 ,  1.05] 
  
No statin and no MM 0.95 [ 0.87 ,  1.03]   
Note: Based on 19,060 Medicaid Beneficiaries with newly diagnosed COPD obtained from Medicaid 
Analytic eXtract files observed during 2005-2008. Asterisks represent significant group differences in 
likelihood of COPD-specific healthcare utilization by statin therapy/multimorbidity interaction 
categories compared to the reference group (No statin and no multimorbidity) obtained from Adjusted 
Logistic Regression analyses.  
Adjusted Logistic regressions controlled for cohort year, sex, race, age, state, poverty eligibility, 
inflammation-related multimorbidity number of other clinical conditions, serious mental illness, 
alcohol abuse, substance abuse, tobacco use, polypharmacy, county level variables including: above 
high school education density (quartiles),  unemployment density (quartiles), poverty density 
(quartiles), metro status, primary care shortage area, mental health shortage area, primary care 
provider density (quartiles), hospital beds density (quartiles), psychiatric hospital, pulmonologist 
density and cardiologist density. 
MM: Inflammation-related multimorbidity; OR: Odds Ratio; AOR: Adjusted Odds Ratio; CI: 
Confidence Interval; Sig: Significance 
 
*** p < .001; ** .001 ≤ p < .01; * .01 ≤ p < .05 
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Table 5 
Mean, Standard Deviation, Ratio of Means of Expenditures Between Statins 
Users and Non-Users (Selected Characteristics) 
among Medicaid Beneficiaries with Newly-Diagnosed COPD 
Medicaid Analytic Extract, 2005-2008 
Total Healthcare Expenditures 
    Statin therapy No Statin therapy 
    Mean SD Mean  SD ROM Sig 
ALL 36,215 38,329 35,724 43,549 1.01 
Inflammation-related Multimorbidity 
Physical Only 35,867 40,956 36,956 45,196 0.97 
Mental Only 35,450 25,875 33,129 31,999 1.07 
Both 39,610 35,451 41,955 51,163 0.94 
  
None 28,120 24,660 28,224 33,538 1.00 
COPD-specific Inpatient Expenditures 
ALL 6,593 5,814 7,457 13,032 0.88 * 
 
       
Inflammation-related Multimorbidity     
 
Physical Only 6,446 5,573 7,594 16,204 0.85 * 
 
Mental Only 4,434 2,537 6,151 7,973 0.72  
 
Both 6,958 6,417 6,143 5,969 1.13  
 
None 7,556 6,761 8,535 12,590 0.89  
COPD-specific Outpatient Expenditures 
ALL 429 1,380 423 1,631 1.01  
 
       
Inflammation-related Multimorbidity     
 
Physical Only 451 1,554 409 1,252 1.10 ** 
 
Mental Only 349 865 376 1,429 0.93  
 
Both 405 1,082 431 1,878 0.94  
 
None 377 968 450 1,948 0.84 ** 
 
       
Note: Based 19,060 Medicaid Beneficiaries with newly diagnosed COPD 
obtained from Medicaid Analytic eXtract files observed during 2005-2008. 
Asterisks represent significant differences in average total and average COPD-
specific healthcare expenditures by statin therapy obtained from unadjusted 
GLM among those with positive expenditures. 
SD: Standard Deviation; ROM: Ratio of Means Sig: Significance 
 
*** p < .001; ** .001 ≤ p < .01; * .01 ≤ p < .05 
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Table 6 
Description of Total and COPD-specific healthcare expenditures among Medicaid 
Beneficiaries with Newly Diagnosed COPD  
among Medicaid Beneficiaries with Newly-Diagnosed COPD 
Medicaid Analytic Extract, 2005-2008  
Total Healthcare Expenditure 
    
Adjusted β SE Exp (β) Sig 
Intercept 9.08 0.11         8,739  *** 
Statin therapy 
Yes 0.03 0.02         8,979  
  
No         
Intercept 9.08 0.11         8,759  *** 
Duration of Statin therapy 
Long-term 0.07 0.02         9,394  *** 
Short-term -0.10 0.03         7,902  *** 
  
No use 
COPD-specific Inpatient Expenditures (n = 998) 
Intercept 8.00 0.39         2,966  *** 
Statin therapy 
Yes -0.08 0.06         2,751  
  
No         
Intercept 7.98 0.40         2,929  *** 
Duration of Statin therapy 
Long-term -0.09 0.07         2,684  
Short-term -0.04 0.10         2,809  
  
No use         
COPD-specific Outpatient Expenditures 
Intercept 6.76 0.15            865  *** 
Statin therapy 
Yes -0.01 0.02            857  
  
No         
Intercept 6.76 0.15            866  *** 
Duration of Statin therapy 
Long-term 0.02 0.03            882  
Short-term -0.09 0.04            792  * 
  
No use         
Note: Based on 19,060 Medicaid Beneficiaries with newly diagnosed COPD obtained 
from Medicaid Analytic eXtract files observed during 2005-2008. Asterisks represent 
significant group differences in expenditures by statin therapy and duration of statin 
therapy compared to the reference group (None) obtained from Unadjusted and Adjusted 
Generalized Linear Model with Log-Link and Gamma Distribution.  
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GLM analyses controlled for cohort year, sex, race, age, state, poverty eligibility, 
inflammation-related multimorbidity number of other clinical conditions, serious mental 
illness, alcohol abuse, substance abuse, tobacco use, polypharmacy, county level variables 
including: above high school education density (quartiles),  unemployment density 
(quartiles), poverty density (quartiles), metro status, primary care shortage area, mental 
health shortage area, primary care provider density (quartiles), hospital beds density 
(quartiles), psychiatric hospital, pulmonologist density and cardiologist density. 
 
Exp: Exponentiation SE: Standard Error; Sig: Significance; β: Parameter Estimates 
 
*** p < .001; ** .001 ≤ p < .01; * .01 ≤ p < .05 
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CHAPTER 4: ANTIDEPRESSANTS, INHALED CORTICOSTEROIDS, STATINS AND 
NEW-ONSET DIABETES AMONG MEDICAID BENEFICIARIES WITH NEWLY-
DIAGNOSED COPD 
INTRODUCTION 
 Chronic Obstructive Pulmonary Disease (COPD) is an inflammatory disease linked to 
persistent and progressive airflow limitation. (Górska, Maskey-Warzechowska, & Krenke, 2010; 
Rabe et al., 2007)  COPD is increasingly being recognized as “chronic systemic inflammatory 
syndrome” (Fabbri & Rabe, 2007).  Individuals with COPD have high levels of inflammatory 
biomarkers that may be either due to the spill-over effect from the pulmonary inflammation or 
due to overall “systemic” inflammation caused by presence of inflammation-related chronic 
conditions such as arthritis, cardiovascular diseases (CVD), depression, diabetes and 
osteoporosis.  (P. J. Barnes & Celli, 2009; Fabbri & Rabe, 2007) 
 COPD is primarily managed through pharmacological treatment. Therefore it is not 
surprising that use of respiratory disease medications has been growing.  The global markets for 
respiratory disease medications has been increasing and is expected to grow at a compound 
annual growth rate of 4.4% to reach $47.1 billion by 2017. (Lehr, 2012) Similarly, the use of 
medications to treat inflammation-related multimorbidity among individuals for COPD has been 
increasing. Statins used among individuals with cardiovascular diseases and antidepressants used 
among those with depression are the most prescribed classes of medication in the United States 
(US). (Mann, Reynolds, Smith, & Muntner, 2008; Mojtabai & Olfson, 2011; Olfson & Marcus, 
2009; Paulose-Ram, Safran, Jonas, Gu, & Orwig, 2007)  Both these medications are extensively 
used among younger adults as well. (Mann et al., 2008; Olfson & Marcus, 2009) There are many 
reasons for multiple medication use among those with COPD.  In general, medication use among 
COPD has been increasing (Lehr, 2012) individuals with COPD are more likely to have 
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multimorbidity compared to those without COPD and the likelihood of multiple medication use 
increases with presence of multimorbidity. (Schnell et al., 2012)  Using a cross-sectional study 
among individuals with COPD (n = 126,283), researchers have reported that 98% of individuals 
received at least one prescription of “non-respiratory drugs”. In the same study, 64% 
cardiovascular medication and 8% depression medication use was reported.  (Anecchino et al., 
2007)  
 Although, generally regarded as safe, concerns about adverse effects have been raised 
about some of these medications in recent years. Specifically, antidepressants, inhaled 
corticosteroids (ICS) and statins have been linked with new-onset diabetes. (Bhattacharjee, 
Bhattacharya, Kelley, & Sambamoorthi, 2013; O'Byrne et al., 2012; Sattar et al., 2010; Suissa, 
Kezouh, & Ernst, 2010) New-onset diabetes has been linked with medication use because some 
of these medications can increase insulin resistance and decrease insulin secretion and thereby 
affecting the overall glucose metabolism. (Carvalho et al., 2004; Colbert & Stone, 2012; Nielsen 
et al., 2004) 
General Biological Correlates of Medications and New-Onset Diabetes 
Biological relationship between statin use and risk of developing diabetes has been 
poorly understood. Some investigators have suggested that lipophillic statins like atorvastatin 
and simvastatin may reduce insulin secretions and potentially affect glucose metabolism. 
(Colbert & Stone, 2012) With respect to insulin sensitivity or insulin resistance, the statin effects 
are different based on type of statins. (Kanda, Satoh, & Ichihara, 2003; Nakata et al., 2006), 
simvastatin and lovastatin reduces insulin sensitivity by affect cholesterol synthetic pathway; 
(Chamberlain, 2001; Koh, Sakuma, & Quon, 2011; Nakata et al., 2006) however, pravastatin has 
been shown the increase insulin sensitivity in rats and thereby reducing insulin resistance. 
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(Takagi et al., 2008) Additionally, muscle myopathy associated with statin use has also been 
suggested to increase the risk of new-onset diabetes. (Colbert & Stone, 2012)  
 Similarly, antidepressants may also increase the risk of new-onset diabetes by changes in 
body weight (Zimmermann, Kraus, Himmerich, Schuld, & Pollmächer, 2003) and modifications 
in the normal function of glucose homeostasis. (Carvalho et al., 2004; Fisfalen & Hsiung, 2003; 
Levkovitz et al., 2007) Other mechanisms include impairment of insulin secretion and changes in 
insulin sensitivity due to high affinity of antidepressants towards muscarinic receptors. (Jindal, 
2009) Although, no biological relationship exists between the use of inhaled corticosteroids, the 
use of oral corticosteroids has been shown to affect insulin resistance (Nielsen et al., 2004; 
Tappy et al., 1994) and reducing glucose uptake and thereby affecting glucose metabolism.  
(Rizza, Mandarino, & Gerich, 1982) Indeed some studies have also suggested that inhaled 
corticosteroid use is linked with higher serum glucose levels. (Slatore, Bryson, & Au, 2009) 
Therefore, ICS use may have similar effects that may lead to hyperglycemia.  
Medication Use and New-onset Diabetes:  Existing Evidence 
Antidepressants Use and New-onset Diabetes 
Investigators from a large randomized controlled trial have reported that antidepressant 
users had higher likelihood of developing diabetes compared to non-users. (Rubin et al., 2008) 
However, further studies have not conclusively determined the role of antidepressants in causing 
new-onset diabetes. Some evidence also indicates that rather than antidepressants, presence of 
depression is associated with new-onset diabetes. (Sambamoorthi, Ma, Findley, & Rust, 2012; 
Wilkins & Sambamoorthi, 2011) The growing prevalence of depression among COPD patients 
and potential use of antidepressants with other therapies make them vulnerable to incident 
diabetes. Therefore, while examining potential novel therapies for COPD, it is important to 
understand its safety issues in terms of new-onset diabetes.  
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Inhaled Corticosteroids Use and New-Onset Diabetes 
Inhaled corticosteroids (ICS) have also been evaluated with regards to development of 
type-2 diabetes among individuals with COPD due to the evidence related to hyperglycemia and 
incident diabetes associated with systemic corticosteroids.(Blackburn, Hux, & Mamdani, 2002; 
O'Byrne et al., 2012; Suissa et al., 2010) It has been indicated that ICS levels in the systemic 
circulations are low and thus may not cause the risk of incident diabetes. However, the evidence 
regarding the risk of new-onset diabetes associated with ICS use is inconclusive.  
A nested case-control study using the data from Quebec health insurance databases, 
Suissa et al reported that among 388,584 individuals with respiratory diseases, current ICS use 
was associated with 34% higher risk of incident diabetes compared to no current use of ICS (RR: 
1.34; 95% CI: 1.29-1.39). (Suissa et al., 2010) However, a major limitation of this study was the 
combined evaluation of asthma and COPD patients. (Suissa et al., 2010) It has been established, 
that the risk of incident diabetes is different among individuals with COPD than those with 
asthma. (Rana et al., 2004) Recently, a retrospective analysis of randomized controlled trials of 
budosenide, an ICS, indicated no statistically significant difference between users and non-users 
in terms of new-onset diabetes. (O'Byrne et al., 2012) Therefore the relationship between ICS 
use and new-onset diabetes remains uncertain. However, some studies have also reported higher 
blood glucose concentration with ICS use among individuals with diabetes. (Slatore et al., 2009) 
Therefore, while evaluating new-onset diabetes among individuals with COPD it is important to 
understand the role of ICS. 
Statins Use and New-onset Diabetes 
As per the USFDA labeling guidelines, statin medications may be linked with elevation 
of blood sugar levels (hyperglycemia) and risk of developing type-2-diabetes mellitus. (US FDA, 
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2012) Investigators of several large scale randomized controlled trials have reported inconsistent 
findings. For example, analysis of data from the Justification for the Use of Statins in Prevention: 
an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial revealed that among 17,802 
individuals randomly assigned to rosuvastatin or placebo, those in the rosuvastatin group had 
significantly higher rates of physician-reported incident diabetes cases as compared to those in 
the placebo group (3.0% vs. 2.4%; p= 0.01). (Ridker et al., 2008) This trial included individuals 
with low cardiovascular risk but high levels of inflammatory mediator C-reactive protein, a 
characteristic of smokers with COPD. (Ridker et al., 2008) On the contrary, findings from the 
large scale randomized trial of pravastatin (WOSCOPS - West of Scotland Coronary Prevention 
Study) suggested protective effects of pravastatin in reducing the risk of new-onset diabetes. The 
researchers reported that among men aged between 45-64 years, individuals randomized on 
pravastatin therapy had 20% reduced hazard of developing new-onset diabetes as compared to 
individuals on placebo (HR: 0.70; 95% CI: 0.50–0.99; p = 0.042). (Freeman et al., 2001) 
These findings have raised substantial concerns regarding the use of statins. Therefore, 
many meta-analyses of statin trials have been conducted to better understand the effects of statins 
on new-onset diabetes. Even though, these meta-analyses have also yielded conflicting results, a 
closer examination of the results in a recent review suggests that the results from these studies 
are highly dependent on data from the WOSCOPS Study. (Colbert & Stone, 2012) For example, 
meta-analysis of 5 statin trials by Coleman et al indicated that statin use is not associated with 
increased risk of incident diabetes (RR: 1.03; 95% CI: 0.89-1.19). However, the sensitivity 
analysis results after removing data from the WOSCOPS study revealed an increased risk of 
incident diabetes (RR: 1.14; 95% CI: 1.02-1.28). (Coleman, Reinhart, Kluger, & White, 2008) 
Similarly, investigators of a meta-analysis conducted in 2009 which additionally included results 
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from the JUPITER trial suggested that statin did not increase the risk of incident diabetes (RR: 
1.06; 95% CI: 0.93-1.25); however, removal of data from WOSCOPS study revealed an 
increased risk of incident diabetes with statin use as compared to placebo (RR: 1.13; 95% CI: 
1.03-1.23). (Rajpathak et al., 2009) Recently, several other meta-analyses have been conducted 
that included data from additional randomized controlled trials. The findings from a meta-
analysis conducted in 2010, which included 13 major trials’ data indicated a slightly higher risk 
of incident diabetes among statin users compared to individuals on placebo (RR: 1.09; 95% CI: 
1.02-1.17). (Sattar et al., 2010) Subsequent meta-analyses have confirmed these findings. (Mills 
et al., 2011; Preiss et al., 2011) 
These meta-analyses highlight the discrepancies in the findings related to statin use and 
new-onset diabetes. Moreover, the studies also raise an essential issue of studying the impact of 
individual statins as compared to collectively assessing the relationship between statin use and 
new-onset diabetes. Indeed, the subject of examining individual statin data has been emphasized 
in a recent review of literature on statin use and new-onset diabetes. (Colbert & Stone, 2012) 
Some clinical trials of specific statins have assessed the risk of developing new-onset 
diabetes with statin use. The results from trials that included Atorvastatin as investigational drug 
have shown that atorvastatin is associated with increased risk of new-onset diabetes when 
compared with placebo (Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) (Sever et al., 
2003) and Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL)) 
(Karam, Loney-Hutchinson, & McFarlane, 2008) but not when compared with an active control 
(Treating to new targets trial (TNT) (LaRosa et al., 2005) and Incremental Decrease in End 
Points Through Aggressive Lipid Lowering (IDEAL) study). (Pedersen et al., 2005) As 
mentioned earlier, rosuvastatin use has been associated with increased risk of new-onset diabetes 
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compared to placebo in the JUPITER trial; however, the Controlled Rosuvastatin Multinational 
Trial in Heart Failure (CORONA) (Kjekshus et al., 2007) study did not indicate higher risk of 
new-onset diabetes (RR: 1.13; 95% CI: 0.86 - 1.50). Similarly, simvastatin trials have also not 
indicated any relationship between drug use and incident diabetes. By contrast, one pravastatin 
trial (WOSCOPS) (Freeman et al., 2001) has indicated protective effects of pravastatin terms of 
incident diabetes; whereas, another pravastatin trial concluded that there was not a statistically 
significant relationship between pravastatin use and incident diabetes.  
Overall, based on the current understanding of medication use and new-onset diabetes 
suggests conflicting conclusions. Moreover, to date no study has examined the risk of new-onset 
diabetes associated with multiple medication use among individuals with COPD. Owing to the 
higher incidence of diabetes among individuals with COPD, it is important to comprehensively 
assess the safety of medications (new-onset diabetes) among individuals with COPD is required.  
Need for the Study 
 The prevalence of diabetes has been increasing affecting over 18 million Americans. 
(Geiss, 2012)  Diabetes is a preventable epidemic which costs about $174 billion in direct 
medical costs. A variety of avoidable risk factors are associated with new-onset diabetes such as 
multiple medication use. With the growing prevalence of multimorbidity, (Schnell et al., 2012) 
multiple medication use has become a reality (Anecchino et al., 2007) and it is essential to 
comprehensively evaluate the relationship between medication use and diabetes.  
Recently, antidepressants, ICS and statin use have been studied with respect to 
development of diabetes. As the individuals with COPD have high prevalence of inflammation-
related multimorbidity, the use of these medications is very high among those with COPD. 
Furthermore, the use of statins is also being evaluated for its role in COPD management. While 
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testing the effectiveness of statins as disease modifying therapy for individuals with COPD, it is 
important to examine any potential safety concerns. 
There are several important reasons for assessing the risk of new-onset diabetes among 
individuals with COPD. COPD is linked with chronic systemic inflammation, which is being 
recognized as a new risk factor for the development of type-2 diabetes. (Festa, D'Agostino, 
Tracy, & Haffner, 2002; Pradhan, Manson, Rifai, Buring, & Ridker, 2001; Spranger et al., 2003)  
Tobacco smoking is associated with higher levels of inflammatory mediators which may lead to 
other inflammation related diseases. Indeed, several investigators have pointed out the impact of 
pro-inflammatory cytokines on the pathogenesis of insulin resistance and type-2 diabetes. (Festa 
et al., 2002; Hu, Meigs, Li, Rifai, & Manson, 2004; Pradhan et al., 2001; Spranger et al., 2003) 
As the levels of these cytokines are elevated in individuals with COPD, the risk of developing 
type-2 diabetes may be more among individuals with COPD. (P. J. Barnes, 2000; Renauld, 2001) 
An analyses of data from prospective Nurses’ Health Study indicated that among 103,614 
females nurses, the risk of new-onset type-2 diabetes was significantly higher among those with 
COPD compared to those without COPD (RR: 1.8, 95%: CI 1.1–2.8). (Rana et al., 2004) Due to 
higher risk of new-onset diabetes among COPD patients, we need to evaluate new-onset diabetes 
as an important safety measure for all the medications used by those with COPD. 
This study provides important evidence regarding avoidable risk factors for new-onset 
diabetes. This study is timely because novel treatments such as statins are being evaluated for the 
management of COPD. Therefore, the findings from this study provide evidence about safety of 
statins in COPD as well as provide hypothesis for future randomized controlled trials.  
Furthermore, our study gives important policy implications in terms of management of 
Medicaid beneficiaries with COPD. With the help of this study, we evaluate the impact of 
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multiple medication use. Therefore, evidence regarding the adverse impact of management of co-
occurring conditions may help in designing effective and tailored disease management programs 
for Medicaid beneficiaries with COPD.  
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CONCEPTUAL FRAMEWORK 
For the purposes of this study we used the conceptual framework delineating the 
determinants of health. This model describes several risk factors that lead to development of 
chronic diseases. Thus it can be considered as a chronic disease incidence model. Due to the non-
availability of certain factors specifically mentioned in the original model, we used a modified 
“determinants of health” model. The model that guided us in determining the risk factors 
associated with new-onset diabetes is mentioned in Figure 1 below.  
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Figure 1: Conceptual Framework for Determinants of Health and Chronic disease incidence 
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Figure 1 describes a comprehensive view of various pathways that can increase the risk 
of new-onset diabetes. This model was originally designed as a chronic disease incidence model. 
However, as our study population comprises of individuals with a chronic disease (COPD), we 
have adapted this model and operationalized based on our requirements. The Determinants of 
Health and Chronic Disease Incidence model describes the relationship between societal factors, 
access to care variables, individuals’ health behavior, psychological factors and biological risk 
factors. Individuals’ non-modifiable characteristics also play an important role in determining the 
biological conditions. In our study an additional factor needs to be considered that these 
individuals already have a chronic disease and thus are at a higher risk of other co-occurring 
conditions.  The interplay between these factors causes disorders that require appropriate medical 
treatment. However, long term-use of therapeutic regimens may affect the normal bodily 
functions leading to further deterioration and causing illness (for example in this study we will 
be testing the association between statin use and new-onset diabetes). 
METHODS  
Study design 
 A retrospective longitudinal cohort design was used to determine the relationship 
between multiple medication use (antidepressants, ICS and statins) and new-onset diabetes.  For 
the purposes of this study data from administrative claims of Medicaid enrollees obtained from 
the Medicaid Analytic eXtract (MAX) (2005-2008) provided by the Centers for Medicare and 
Medicaid Services (CMS) was used. Medicaid beneficiaries with newly-diagnosed COPD were 
identified between 01/01/2006 to 12/31/2007. The first date with any inpatient or outpatient 
claim of COPD diagnosis was considered as the index date. One year prior to the index date was 
considered as the baseline period which. Beneficiaries with COPD or diabetes during this period 
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were excluded from the analyses. New-onset diabetes was identified during the follow-up period 
which was defined as 1 year after the index date.  
 
 
 
 
 
 
Data Source 
Medicaid Analytic eXtract (MAX) (2005-2008) 
For the purposes of this study we utilized the data from the Medicaid analytic extract 
(MAX). The files provided in the MAX administrative claims data are prepared and produced by 
the Centers for Medicare and Medicaid Services with the help of Research and Data Assistance 
Center (ResDAC). The primary purpose of producing these files is to supply information 
regarding healthcare utilization of Medicaid beneficiaries to researchers and policy maker. 
 The MAX files contain person-level data which is obtained via Medicaid Statistical 
Information System (MSIS) in which all the states administering Medicaid have to supply the 
information for the Medicaid beneficiaries to the CMS. These person level files provided 
information about beneficiaries’ eligibility and their healthcare utilization and payment 
information. Several initiatives are taken by the agencies to maintain and improve the quality of 
these datasets. (CMS, 2011; Hennessy, Leonard, Palumbo, Newcomb, & Bilker, 2007) We 
received separate files from CMS which were linked based on beneficiaries’ unique 
identification numbers. These files include enrollment (“personal summary”), inpatient and 
outpatient medical claims, and pharmacy claims files for beneficiaries. 
Index date 
Identification period 
12/31/2007 01/01/2005 12/31/2008 
 
Baseline period 
(1 year prior to index date) 
 
Follow-up period I 
(1 year from end index date) 
01/01/2006 
Figure: An example of description of study periods 
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The personal summary file provided information on eligibility, demographics (age, 
gender, and race), managed care enrollment, utilization summary and Medicaid payments. Three 
other files were used to capture the information regarding beneficiaries’ fee-for-service claims. 
From the “Other therapy” file we collected information regarding claims for Medicaid services 
provided at an outpatient level such as clinic services, physician services, home health and lab 
services. Enrollees’ information regarding services provided during hospitalizations was 
obtained from the “Inpatient file”. All the information regarding pharmacy or drug services was 
captured from the “Prescription Drug” file. This file included information regarding utilization of 
prescription drugs by Medicaid beneficiaries such as date of prescription filled, days of supply, 
national drug code (NDC).  
 We used data for beneficiaries residing in the following states: New York (NY), Texas 
(TX), Illinois (IL), and California (CA). The primary reason behind using this data was to obtain 
programs with lower Medicaid-managed care penetration rates so that more utilization 
characteristics would be captured. This provided us the ability to obtain maximum number of 
beneficiaries with fee-for-service enrollments.  
Area Resource File (ARF): 
 In addition to all the demographic characteristics and utilization variables obtained from 
the MAX files, we also determined each Medicaid beneficiary’s contextual county level 
variables using the Area Resource File (ARF). ARF is a comprehensive county-level dataset 
compiled by the Health Resources Service Administration’s Bureau of Health Professions. ARF 
contains more than 6000 variables providing information about nation’s counties. The 
information contained within ARF includes type of health facilities in the various counties, 
number and type health professions, resource scarcity measures, health status, economic activity, 
health training programs, and socioeconomic and environmental characteristics. These files also 
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include county codes and descriptors that allow its linkage with several secondary datasets such 
as MAX. The type of variables that were obtained from ARF included density of pulmonologist 
in beneficiary’s residing county. We used the county codes and state information to link MAX 
files with 2008 ARF file. All the ARF variables were obtained from the baseline period.   
Study Population 
Medicaid Beneficiaries with newly-diagnosed COPD 
Medicaid beneficiaries with newly-diagnosed COPD were identified using MAX IP and 
OT files (physician office visits claims only). Baseline period was used to identify Medicaid 
Beneficiaries with newly-diagnosed COPD. Individuals with at least one inpatient visit or two 14 
days apart outpatient visits (obtained using type of service codes) for COPD based on 
International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) 
codes for chronic bronchitis (491.xx), emphysema (492.xx), or unspecified chronic airway 
obstruction (496.xx) were considered to have diagnosed COPD. These diagnosis codes have 
been utilized in prior published research (codes 491.xx, 492.xx and 496.xx) to identify COPD 
and evaluate medical treatment and health outcomes among individuals with COPD. (Dalal, 
Shah, D'Souza, Chaudhari, & Crater, 2012; Halpern et al., 2011; Make, Dutro, Paulose-Ram, 
Marton, & Mapel, 2012) Indeed, sensitivity and specificity of using ICD-9-CM codes to identify 
patients with COPD has been established. (Cooke et al., 2011; A. S. Gershon et al., 2009) A 
study conducted by Gershon et al reported that identifying COPD using 1 or more ambulatory 
claims and/or 1 or more hospitalizations for COPD  resulted in a sensitivity of 85.0% (95% CI: 
77.0 to 91.0) and a specificity of 78.4% (95% CI: 73.6 to 82.7).  However, we will be used 1 
inpatient or 2 outpatient claims to identify individuals with COPD in order to increase the 
specificity of the algorithm.  
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Other inclusion criteria will included: a) no COPD diagnoses during baseline period; b) 
no diabetes diagnoses (ICD-9-CM: 250.x2) during the baseline period; c) 40-64 years (among 
young adults this age group is at highest risk of COPD); d) continuous eligibility during the 
baseline and follow-up period; e) no dual Medicaid/Medicare coverage (dual eligibility will 
represent high-cost and severe beneficiaries); f) enrolled in fee-for-service plans throughout the 
study observation period; g) Alive during the study observation period; and use of services 
(inpatient or outpatient). 
Dependent Variable (New-onset diabetes) 
New-onset diabetes was identified in the follow-up period for beneficiaries who were 
diabetes free in the year prior to baseline year. Any Medicaid beneficiary who had at least 1 
inpatient or 2 outpatient claims for diabetes based on ICD-9-CM diagnosis (250.x2) were 
considered as having new-onset diabetes 
Key Independent variables 
Multiple Medication Use 
Antidepressants, ICS and statins were identified using National Drug Codes (NDC) recorded 
in pharmacy claims. Although, identifying medication use is difficult using administrative claims 
data, any receipt of these medications was considered as use of medications.  
3. Any Statin use (Yes/No) 
 Adults with at least one prescription of statin during the baseline period were considered 
as statin users. 
4. Statin Type (Hydrophilic vs. Lipophilic Statins) 
 Statins were further grouped based upon their chemical nature. Statins with lipophilic 
characteristics (Atorvastatin, Cerivastatin, Fluvastatin, Lovastatin, Pitavastatin, and Simvastatin) 
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were classified as lipophilic statins and those with hydrophilic properties (Pravastatin, 
Rosuvastatin) were grouped as hydrophilic statins.  
5. Any ICS use (Yes/No) 
 ICS use was identified during the follow-up period as our population consisted of 
individuals with newly-diagnosed COPD and thus we did not have many cases with ICS use in 
the baseline period.  
6. Any Antidepressants use (Yes/No) 
Antidepressant prescriptions were identified during baseline. 
7. Long-term use (Antidepressants and Statins) 
Medicaid beneficiaries with newly-diagnosed COPD having >120 days of supply for these 
medications during the baseline period were considered as long-term users. Those with <120 
days of supply were categorized as short-term users and those without any use in the baseline 
period were considered as non-users.  
8. Inflammation-related multimorbidity:  
We created indicator variables for the presence of arthritis, CVD, depression, and 
osteoporosis using the International Classification of Diagnosis – 9th Revision- Clinical 
Modification (ICD-9-CM) codes. Any Medicaid beneficiary with COPD having greater than or 
equal to one inpatient or one outpatient visits for these conditions were considered as having the 
disease. In addition indicator variables were created for inflammation-related physical conditions 
and inflammation-related mental condition. Any Medicaid beneficiary having either of the 
following conditions: arthritis, CVD, and osteoporosis were considered as having inflammation-
related physical condition. Similarly, any individual with COPD having depression were 
considered as having inflammation-related mental condition.   
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Operational definition: 
Medicaid beneficiaries included in our study population were categorized into one of the four 
multimorbidity groups as mentioned below: 
9) COPD + Inflammation-related Physical Conditions + Inflammation-related Mental 
Condition (i.e. depression) 
10) COPD + Inflammation-related Physical Conditions  
11) COPD + Inflammation-related Mental Condition (i.e. depression) 
12) COPD only (without any chronic conditions). 
Other Independent Variables  
1. Individual Physical Makeup 
These variables include demographic characteristics such as age (will be grouped based 
on data), gender (female/male), race/ethnicity (Whites, African- Americans and Others).  
2. Community resources 
Community resources consist of variables regarding socioeconomic makeup of the 
society in which the Medicaid beneficiaries reside. These include variables such as median 
income at county level and county level education status. All the county level information 
was is obtained from the ARF. Variables included in this study were: Quartiles for density of 
above high school education, unemployment and poverty were created. Density of these 
county level characteristics was calculated by dividing total number of each characteristic by 
the total county population. This density was further converted into per 1000 people by 
multiplying 1000 with the density. Geographical Location 
Metro status was ascertained for each Medicaid beneficiary. All the Medicaid 
beneficiaries with COPD were categorized into metropolitan residents and non-metropolitan 
residents based county level information obtained from the ARF.  
3. Access to care variables 
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Access to care variables was identified as county level characteristics from the ARF. 
These characteristics included density of primary care providers in the county (Quartiles); 
density of specialist providers (Quartiles), primary care shortage area (yes/no) mental health 
shortage area (yes/no); hospital beds density (yes/no) pulmonologist density (high/low) and 
cardiologist density (yes/no)  
4. Health behavior 
Alcohol, illicit drug (substance abuse) and tobacco use were identified as health 
behaviors. These variables were identified using ICD-9-CM codes from Medicaid claims. 
ICD-9-CM codes for these conditions were obtained from AHRQ’s clinical classification 
software.  
5. Psychological Factor 
   Serious mental illness among Medicaid beneficiaries with COPD will be determined as 
psychological risk factor. Conditions included within serious mental illness were 
schizophrenia, bipolar disorder and psychoses. ICD-9-CM codes for these conditions were 
obtained from AHRQ’s clinical classification software.  
6. Biological Risk Factors 
Biological risk factor variables includes inflammation-related multimorbidity and other 
co-occurring conditions identified as number of other clinical conditions (categorized into: a) 
None, b) 1-3; c) 4-6; d >6 conditions. All these conditions were identified using ICD-9-CM 
codes obtained from AHRQ’s clinical classification software. 
Statistical Analyses 
Bivariate Analyses 
Chi-square tests of independence were used to determine subgroup differences in 
antidepressant, ICS and statin prescriptions and new-onset diabetes. Results from unadjusted 
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logistic regressions are also presented for better understanding of bivariate relationship between 
specific medication use categories and new-onset diabetes.   
Multivariate Analyses 
We used multivariable logistic regression to examine the relationship between any 
antidepressants, ICS and statins use and new-onset diabetes after controlling for comprehensive 
set of risk factors as described in the Methods section. SAS v 9.3 (SAS Institute, Cary, NC) was 
used for all the analyses. 
RESULTS 
Overall, 6.3% (n = 967) Medicaid beneficiaries with newly-diagnosed COPD had new-
onset diabetes during the follow-up period. In the study population, 47.8% individuals received 
antidepressants, 24.3% received statins and 42.9% received ICS. The bivariate differences in 
medication use by selected beneficiary characteristics are presented in Table 1. 
Antidepressants, ICS, Statins, and New-Onset Diabetes 
 Table 2 describes the unadjusted and adjusted relationship between any antidepressants, 
statins and ICS use and new-onset diabetes. Rates of new-onset diabetes were not significantly 
different between antidepressants users and non-users (6.5% vs. 6.2%). However, beneficiaries 
with statin use had significantly higher rates of new-onset diabetes compared to those without 
statin use (9.2% vs. 5.4%; p<0.001). Similarly, individuals with ICS use had significantly higher 
rates of new-onset diabetes compared to those without ICS use (7.4% vs. 5.5%; p<0.001).  After 
controlling for baseline characteristics beneficiaries who received statins and ICS were 48% 
(AOR: 1.48; 95% CI: 1.27, 1.72) and 23% (AOR: 1.23; 95% CI: AOR: 1.07, 1.47) more likely to 
have new-onset diabetes as compared to their counterparts without these medications.  
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 In order to assess the relationship between combined medication categories and new-
onset diabetes, we created a variable with the following categories: 1) all three medications; 2) 
antidepressant/statins; 3) antidepressants/ICS; 4) statins/ICS; 5) statins only; 6) ICS only; and 7) 
none of these medications.  Findings from bivariate and multivariate analyses with combined 
medication categories are presented in Table 3.  Adults with all three medications were 
significantly more likely to have new-onset diabetes (AOR: 1.56; 95% CI: 1.18, 2.05) compared 
to those without any of these three medications.  Adults who used statins combination with 
antidepressants and ICS or only ICS were more likely to have new-onset diabetes compared to 
those without any medications.  Other combinations which did not include statins were not 
associated with new-onset diabetes.  
Type of Statins and New-Onset Diabetes 
The findings from analyses on new-onset diabetes with type of statins are presented in 
Table 4. As number of non-elderly Medicaid beneficiaries with new-onset diabetes in the “both 
hydrophilic and lipophilic” was very small (n = 9), we removed individuals with “both 
hydrophilic and lipophilic” from the analyses. Therefore, the analyses on type of statins included 
15,128 Medicaid beneficiaries with newly-diagnosed COPD who did not receive both types of 
statins.  We observed no statistically significant relationships between types of statins and new-
onset diabetes.  
Duration of Antidepressants, Statin Use and New-Onset Diabetes 
Duration of medication use (antidepressants) did not have a statistically significant 
association with new-onset diabetes.  Adults with both long-term (AOR: 1.44, 95% CI: 1.22, 
1.70) and short-term statin use (AOR: 1.58, 95% CI: 1.25, 1.99) were more likely to have new-
onset diabetes compared to those without any statin use.  
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Secondary Analysis (Controlling for Selection Bias in Statin Use) 
As statin use was associated with new-onset diabetes, we also controlled for selection 
bias in unobserved variables.   For example, statin users may be different from non-users in 
terms of genetic risk factors or presence of pre-diabetic condition. To control for this selection 
bias, we conducted secondary analyses with instrumental variable regression. We used county-
level variables obtained from the ARF including poverty status (categorized into quartiles) and 
density of pulmonologist in a county in selection equation that predicted the presence/absence of 
statin use. The model on new-onset diabetes included all independent variables mentioned in the 
methods section. This analysis was conducted using STATA v. 11. The instrumental variable 
approach revealed that statin use was not associated with new-onset diabetes (parameter estimate 
= 0.15; p = 0.613). 
DISCUSSION 
Using a retrospective longitudinal dynamic cohort design, we examined the relationship 
between commonly used medications such as antidepressants, ICS, and statins and new-onset 
diabetes among Medicaid beneficiaries with newly-diagnosed COPD. For the purposes of these 
analyses we used Medicaid claims data from multiple years (2005-2008).  To the best of our 
knowledge, this is the first observational study to examine this relationship using Medicaid 
claims data of non-elderly adults with newly-diagnosed COPD.  Therefore, we cannot directly 
compare the study results with any prior studies. 
In our study, after controlling for baseline characteristics, we did not observe a 
statistically significant association between antidepressant use and new-onset diabetes.  These 
results are consistent with findings using data from general population (not specific to COPD).  
For example, no significant association between antidepressants and new-onset diabetes was 
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found in previous studies (Sambamoorthi, Ma, Findley, & Rust, 2012; Wilkins & Sambamoorthi, 
2011; Bhattacharrya R, 2014). Recently, a review on glucose metabolism and antidepressant 
medications has suggested that the relationship between antidepressant use and new-onset 
diabetes may vary by type of antidepressants. Therefore, it is plausible that deleterious effects of 
non-adrenergic antidepressants are negated by beneficial effects of mono-amine oxidase 
inhibitors with regards to glucose metabolism. (Hennings JM, 2012) Therefore, further analyses 
are required between type of antidepressant use and new-onset diabetes. Moreover, to draw 
conclusive evidence, randomized controlled trials among those with COPD are required to 
determine the safety of antidepressant in terms of new-onset diabetes. 
As statins are being investigated as novel therapeutic agents among individuals with 
COPD, we also examined the relationship between statins and new-onset diabetes.  Our primary 
analyses revealed that adults who had any statin use were more likely to have new-onset diabetes 
compared to those without statins. However, once we controlled for selection bias due to 
unobserved characteristics the statistically significant association disappeared. Although, no 
specific study has examined the risk of new-onset diabetes among COPD patients, randomized 
controlled trials and meta-analyses have yielded conflicting results. A meta-analysis including 
the data from WOSCOPS study has shown that statin use did not increase the risk of new-onset 
diabetes. (Rajpathak et al., 2009)  Whereas, another set of analyses have reported that statin use 
is associated with greater risk of new-onset diabetes. (Sattar et al., 2010; Mills et al., 2011; Preiss 
et al., 2011)  Therefore, more research is required in high-risk populations such as in our study to 
strengthen the knowledge base of the safety of these medications.  As statins are being 
investigated for their use in COPD, clinical trials should include new-onset diabetes as a safety 
outcome.  
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We also tested for the relationship between ICS and new-onset diabetes among newly-
diagnosed COPD patients. However, as our population consisted of only newly-diagnosed cases, 
we could only test for exposure to ICS and new-onset diabetes in the same follow-up period.  We 
did not find an association between ICS and new-onset diabetes when we combined all three 
medications and derived a combination variable with 7 categories. Our findings are different 
from those observed in a retrospective cohort study using Quebec Health Insurance database, 
which included patients with any respiratory disease. (Suissa, 2010)  The inconsistent findings 
could be due to differences in study populations.  
Overall, the findings from our study indicated that after controlling for baseline 
characteristics and selection bias, medication use (antidepressants, ICS and statins) was not 
associated with increased risk of new-onset diabetes when compared to those who did not 
receive any of these medications. However, as the prevalence of diabetes is increasing and 
individuals with COPD are at a greater risk of having new-onset diabetes due to systemic 
inflammation, continuous glucose monitoring for COPD patients may be needed.  In future, 
long-term observational studies and randomized controlled trials need to be conducted to 
evaluate the safety of above mentioned medications.  
STRENGTHS AND LIMITATIONS 
 There are many advantages to this study.  Use of Medicaid claims data enabled us to 
track individuals over two years and adopt a longitudinal design.  Clinical diagnoses with ICD9 
codes provided information on medical conditions.  Prescription drug claims facilitated 
identification of specific drugs and the precise time in which they were prescribed enabling us to 
calculate duration of medication use. The study also employed statistical tools that controlled for 
selection bias due to unobserved characteristics.   
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 An important limitation of this study is lack of generalizability, as we included only fee-
for-service claims of Medicaid beneficiaries living in four states. We only observed prescriptions 
for specific medications and cannot determine use of these medications. Furthermore, 
unavailability of laboratory data limited our ability to control for important confounders such as 
cholesterol levels and baseline blood glucose levels. Additionally we did not have the data for 
body mass index which is an important predictor of new-onset diabetes.    
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TABLES 
Table 1 
Number, Percentages of Mediation Use 
among Medicaid Beneficiaries with Newly-Diagnosed COPD  
Medicaid Analytic Extract, 2005-2008 
Any AD Use Any Statin Use Any ICS Use 
N Row % Sig N Row % Sig N Row % Sig 
TOTAL 7,313 47.8 3,720 24.3 6,554 41.4 
Cohort * 
2005-2007 4,148 48.0 2,041 23.6 3,746 43.4 
2006-2008 3,165 47.6 1,679 25.3 2,808 42.2 
Sex *** *** *** 
Women 4,853 54.6 2,299 25.9 4,209 47.4 
Men 2,460 38.4 1,421 22.2 2,345 36.6 
Race/Ethnicity *** *** *** 
White 4,121 53.9 2,005 26.2 3,372 44.1 
African American 1,527 37.6 755 18.6 1,645 40.5 
Others 1,665 46.6 960 26.9 1,537 43.0 
Age (in years) *** *** 
40-49 2,787 51.9 934 17.4 2,262 42.1 
50-59 3,470 47.6 1,883 25.8 3,129 42.9 
60-64 1,056 40.3 903 34.4 1,163 44.4 
State *** *** *** 
California 4,055 48.0 2,100 24.9 3,481 41.2 
Illinois 1,548 48.0 764 23.7 1,455 45.1 
New York 1,104 51.8 566 26.5 1,188 55.7 
Texas 606 40.8 290 19.5 430 29.0 
Income Eligibility ** *** + 
Yes 6,753 48.2 3,471 24.8 5,976 42.7 
No 560 43.7 249 19.4 578 45.1 
Medical Eligibility *** 
Yes 814 48.1 338 20.0 740 43.7 
No 6,499 47.8 3,382 24.9 5,814 42.8 
Inflammation-related Multimorbidity *** *** 
Physical Only 2,601 40.0 2,087 32.1 2,787 42.8 
Mental Only 1,011 78.8 184 14.3 567 44.2 
Both 2,245 81.4 846 30.7 1,216 44.1 
None 1,456 30.7 603 12.7 1,984 41.9 
 
       
(Continued) 
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Table 1 
Number, Percentages of Mediation Use 
among Medicaid Beneficiaries with Newly-Diagnosed COPD  
Medicaid Analytic Extract, 2005-2008 
Any AD Use Any Statin Use Any ICS Use 
N Row % Sig N Row % Sig N Row % Sig 
TOTAL 7,313 47.8 3,720 24.3 6,554 41.4 
Number of Other Clinical Conditions *** *** *** 
None 135 30.6 61 13.8 143 32.4 
1-3 1,209 37.9 641 20.1 1,244 39.0 
4-6 1,618 42.8 894 23.6 1,579 41.7 
>6 4,351 55.3 2,124 27.0 3,588 45.6 
Serious Mental Illness *** *** *** 
Yes 2,514 62.2 856 21.2 1,403 34.7 
No 4,799 42.7 2,864 25.5 5,151 45.8 
Alcohol Abuse *** *** *** 
Yes 828 53.4 217 14.0 569 36.7 
No 6,485 47.2 3,503 25.5 5,985 43.6 
Substance Abuse *** *** 
Yes 1,286 57.3 295 13.1 950 42.3 
No 6,027 46.2 3,425 26.3 5,604 43.0 
Tobacco Use *** *** 
Yes 1,176 56.7 439 21.2 922 44.5 
No 6,137 46.4 3,281 24.8 5,632 42.6 
Polypharmacy *** *** *** 
Yes 4,559 65.2 2,629 37.6 3,720 53.2 
No 2,754 33.2 1,091 13.1 2,834 34.2 
ARF Variables (County Level) 
Above HS Education Density *** *** *** 
Q1 3,621 45.6 1,999 25.2 3,239 40.8 
Q2 1,107 50.2 552 25.0 943 42.7 
Q3 1,593 50.1 767 24.1 1,449 45.6 
Q4 992 50.5 402 20.5 923 47.0 
Unemployment Density *** * *** 
Q1 5,263 46.5 2,734 24.1 4,683 41.3 
Q2 1,068 51.1 541 25.9 964 46.1 
Q3 741 52.1 318 22.4 686 48.3 
Q4 241 53.8 127 28.3 221 49.3 
Poverty Density ** ** *** 
Q1 647 50.5 270 21.1 585 45.7 
Q2 1,080 48.9 501 22.7 953 43.2 
Q3 1,409 49.8 689 24.4 1,286 45.5 
Q4 4,177 46.6 2,260 25.2 3,730 41.6 
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Table 1 
Number, Percentages of Mediation Use 
among Medicaid Beneficiaries with Newly-Diagnosed COPD  
Medicaid Analytic Extract, 2005-2008 
Any AD Use Any Statin Use Any ICS Use 
N Row % Sig N Row % Sig N Row % Sig 
TOTAL 7,313 47.8 3,720 24.3 6,554 41.4 
Metro *** 
Yes 6,222 47.0 3,202 24.2 5,673 42.9 
No 1,091 53.3 518 25.3 881 43.0 
PCP Shortage + 
Yes 7,003 47.8 3,586 24.5 6,288 42.9 
No 310 49.5 134 21.4 266 42.5 
Mental Health Specialist Shortage *** *** 
Yes 6,457 47.3 3,313 24.3 5,750 42.1 
No 856 52.1 407 24.8 804 48.9 
PCP Density *** *** 
Q1 321 50.8 161 25.5 326 51.6 
Q2 1,335 51.7 674 26.1 1,147 44.4 
Q3 1,136 51.8 527 24.0 1,025 46.7 
Q4 4,521 45.8 2,358 23.9 4,056 41.1 
Hospital Beds Density *** ** *** 
Q1 432 53.9 203 25.3 401 50.1 
Q2 1,230 49.2 560 22.4 1,092 43.6 
Q3 3,983 46.4 2,168 25.2 3,440 40.0 
Q4 1,668 49.2 789 23.3 1,621 47.8 
Psychiatric Hospital *** 
Yes 4,497 46.2 2,395 24.6 4,132 42.5 
No 2,816 50.7 1,325 23.9 2,422 43.6 
Pulmonologist Density *** * *** 
High 4,913 45.9 2,546 23.8 4,346 40.6 
Low 2,400 52.3 1,174 25.6 2,208 48.1 
Cardiologist Density *** *** 
High 4,601 46.1 2,401 24.1 4,094 41.0 
Low 2,712 51.1 1,319 24.9 2,460 46.4 
Note: Based on 15,287 Medicaid Beneficiaries with newly diagnosed COPD and diabetes-free during 
baseline period obtained from Medicaid Analytic eXtract files observed during 2005-2008. Asterisks 
represent significant group differences in beneficiary characteristics by medication use obtained from 
chi-square test.  
 
ICS: Inhaled Corticosteroids; HS: High School PCP: Primary Care Providers; Sig: Significance 
 
*** p < .001; ** .001 ≤ p < .01; * .01 ≤ p < .05 
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Table 2 
Number, Percentage, Unadjusted, Adjusted Odds Ratio and 95% Confidence Intervals  
from Logistic Regressions on New-Onset Diabetes  
among Medicaid Beneficiaries with Newly-Diagnosed COPD  
Medicaid Analytic Extract, 2005-2008 
New-Onset Diabetes 
N Row % OR 95% CI Sig AOR 95% CI Sig 
TOTAL 967 6.3 
Any Antidepressant Use 
Yes 475 6.5 1.06 [ 0.93 ,  1.20] 0.91 [ 0.78 ,  1.06] 
No 492 6.2  
Any ICS Use  
Yes 488 7.4 1.39 [ 1.22 ,  1.58] *** 1.23 [ 1.07 ,  1.47] ** 
No 479 5.5  
Any Statin Use  
Yes 344 9.2 1.79 [ 1.56 ,  2.05] *** 1.48 [ 1.27 ,  1.72] *** 
No 623 5.4 
Note: Based on 15,287 Medicaid Beneficiaries with newly diagnosed COPD who were diabetes-free during 
baseline period obtained from Medicaid Analytic eXtract files observed during 2005-2008. Asterisks represent 
significant group differences in likelihood of new-onset diabetes by antidepressant, ICS and statin use compared 
to the reference group (None) obtained from Unadjusted and Adjusted Logistic Regression Analyses.  
Adjusted logistic regressions controlled for cohort year, sex, race, age, state, poverty eligibility, inflammation-
related multimorbidity number of other clinical conditions, serious mental illness, alcohol abuse, substance abuse, 
tobacco use, polypharmacy, county level variables including: above high school education density (quartiles),  
unemployment density (quartiles), poverty density (quartiles), metro status, primary care shortage area, mental 
health shortage area, primary care provider density (quartiles), hospital beds density (quartiles), psychiatric 
hospital, pulmonologist density and cardiologist density in addition to medication use. 
 
ICS: Inhaled Corticosteroids; OR: Odds Ratio; AOR: Adjusted Odds Ratio; CI: Confidence Interval; Sig: 
Significance 
 
*** p < .001; ** .001 ≤ p < .01; * .01 ≤ p < .05 
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Table 3 
Number, Percentage, Unadjusted, Adjusted Odds Ratio and 95% Confidence Intervals  
from Logistic Regressions on New-Onset Diabetes  
Medicaid Beneficiaries with Newly-Diagnosed COPD 
Medicaid Analytic Extract, 2005-2008 
New-Onset Diabetes 
    N Row % OR 95% CI Sig AOR 95% CI Sig 
TOTAL 967 6.3 
Medication Use Categories 
All three 107 10.0 2.17 [ 1.69 ,  2.77] *** 1.56 [ 1.18 ,  2.05] ** 
AD/Statin 79 7.9 1.67 [ 1.27 ,  2.19] *** 1.29 [ 0.96 ,  1.74] 
AD/ICS 149 6.3 1.31 [ 1.05 ,  1.63] * 1.09 [ 0.86 ,  1.39] 
Statin/ICS 90 12.4 2.74 [ 2.11 ,  3.57] *** 2.06 [ 1.56 ,  2.72] *** 
AD only 140 4.9 0.99 [ 0.79 ,  1.24] 0.90 [ 0.71 ,  1.14] 
Statin only 68 7.3 1.54 [ 1.15,  2.04] ** 1.26 [ 0.94 ,  1.70] 
ICS only 142 5.9 1.22 [ 0.98 ,  1.53] 1.11 [ 0.88 ,  1.39] 
  None 192 4.9             
 
   
      
Note: Based on 15,287 Medicaid Beneficiaries with newly diagnosed COPD who were diabetes-free during 
baseline period obtained from Medicaid Analytic eXtract files observed during 2005-2008. Asterisks represent 
significant group differences in likelihood of new-onset diabetes by multiple medication use categories compared 
to the reference group (None) obtained from Unadjusted and Adjusted Logistic Regression Analyses.  
Adjusted logistic regressions controlled for cohort year, sex, race, age, state, poverty eligibility, inflammation-
related multimorbidity number of other clinical conditions, serious mental illness, alcohol abuse, substance abuse, 
tobacco use, polypharmacy, county level variables including: above high school education density (quartiles),  
unemployment density (quartiles), poverty density (quartiles), metro status, primary care shortage area, mental 
health shortage area, primary care provider density (quartiles), hospital beds density (quartiles), psychiatric 
hospital, pulmonologist density and cardiologist density in addition to medication use. 
 
AD: Antidepressants; ICS: Inhaled corticosteroids OR: Odds Ratio; AOR: Adjusted Odds Ratio; CI: Confidence 
Interval; Sig: Significance 
 
*** p < .001; ** .001 ≤ p < .01; * .01 ≤ p < .05 
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Table 4 
Number, Percentage, Unadjusted, Adjusted Odds Ratios and 95% Confidence Intervals  
from Logistic Regressions on New-Onset Diabetes with Type of Statin Use 
Medicaid Beneficiaries with Newly-Diagnosed COPD 
Medicaid Analytic Extract, 2005-2008 
New-Onset Diabetes 
    N Row % OR 95% CI Sig AOR 95% CI Sig 
TOTAL 958 6.3 
Type of Statin Use 
Lipophilic  292 9.5 1.06 [ 0.76 ,  1.48] 1.03 [ 0.73 ,  1.44] 
Hydrophilic 43 9.0      
  
None 623 5.4 0.58 [ 0.42 ,  0.80] *** 0.68 [ 0.49 ,  0.94] * 
 
Note: Based on 15,128 Medicaid Beneficiaries with newly diagnosed COPD who were diabetes-free during 
baseline period obtained from Medicaid Analytic eXtract files observed during 2005-2008. Asterisks represent 
significant group differences in likelihood of new-onset diabetes by type of statin use compared to the reference 
group (None) obtained from Unadjusted and Adjusted Logistic Regression Analyses.  
Adjusted logistic regressions controlled for cohort year, sex, race, age, state, poverty eligibility, inflammation-
related multimorbidity number of other clinical conditions, serious mental illness, alcohol abuse, substance abuse, 
tobacco use, antidepressants use,  Inhaled Corticosteroids use, polypharmacy, county level variables including: 
above high school education density (quartiles),  unemployment density (quartiles), poverty density (quartiles), 
metro status, primary care shortage area, mental health shortage area, primary care provider density (quartiles), 
hospital beds density (quartiles), psychiatric hospital, pulmonologist density and cardiologist density in addition to 
medication use. 
 
OR: Odds Ratio; AOR: Adjusted Odds Ratio; CI: Confidence Interval; Sig: Significance 
 
*** p < .001; ** .001 ≤ p < .01; * .01 ≤ p < .05 
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Table 5 
Number, Percentage, Unadjusted, Adjusted Odds Ratio and 95% Confidence Intervals  
from Logistic Regressions on New-Onset Diabetes  
Medicaid Beneficiaries with Newly-Diagnosed COPD 
Medicaid Analytic Extract, 2005-2008 
New-Onset Diabetes 
    N Row % OR 95% CI Sig AOR 95% CI Sig 
TOTAL 967 6.3 
Duration of AD Use 
Long-term 357 6.5 1.06 [ 0.92 ,  1.22] 0.91 [ 0.77 ,  1.07] 
Short-term 118 6.4 1.04 [ 0.84 ,  1.28] 0.92 [ 0.74 ,  1.14] 
No Use 492 6.2 
Duration of Statin Use 
Long-term 247 9.1 1.75 [ 1.50 ,  2.05] *** 1.44 [ 1.22 ,  1.70] *** 
Short-term 97 9.7 1.89 [ 1.51 ,  2.36] *** 1.58 [ 1.25 ,  1.99] *** 
  
No Use 623 5.4             
 
         
Note: Based on 15,287 Medicaid Beneficiaries with newly diagnosed COPD who were diabetes-free during 
baseline period obtained from Medicaid Analytic eXtract files observed during 2005-2008. Asterisks represent 
significant group differences in likelihood of new-onset diabetes by duration of antidepressant and statin use 
compared to the reference group (None) obtained from Unadjusted and Adjusted Logistic Regression Analyses.  
Adjusted logistic regressions controlled for cohort year, sex, race, age, state, poverty eligibility, inflammation-
related multimorbidity number of other clinical conditions, serious mental illness, alcohol abuse, substance abuse, 
tobacco use, ICS use, polypharmacy, county level variables including: above high school education density 
(quartiles),  unemployment density (quartiles), poverty density (quartiles), metro status, primary care shortage area, 
mental health shortage area, primary care provider density (quartiles), hospital beds density (quartiles), psychiatric 
hospital, pulmonologist density and cardiologist density in addition to medication use. 
 
ICS: Inhaled Corticosteroids; OR: Odds Ratio; AOR: Adjusted Odds Ratio; CI: Confidence Interval; Sig: 
Significance 
 
*** p < .001; ** .001 ≤ p < .01; * .01 ≤ p < .05 
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CHAPTER 5: SUMMARY AND CONCLUSIONS 
STUDY SUMMARY 
Chronic Obstructive Pulmonary Disease (COPD), characterized by persistent and 
progressive airflow limitation caused due to chronic inflammation in the lungs affects more than 
15 million Americans in the United States (CDC, 2012; Ford et al., 2013).  COPD is being 
increasingly recognized as a “chronic systemic inflammatory syndrome” due to presence of high 
levels of systemic and local inflammation. (Barnes & Celli, 2009) A recent study has established 
high prevalence of inflammation-related multimorbidity among individuals with COPD. (Schnell 
et al, 2012) Existing evidence suggests that presence of multimorbidity among individuals with 
COPD may pose challenges to COPD management (Tsiligianni, Kosmas, Van, & Tzanakis, 
2013).  However, no study till now had assessed its impact on COPD management, specifically 
treatment patterns among individuals with COPD. Furthermore, only a few studies have 
examined the role of co-existing chronic conditions on COPD-specific outcomes. The findings 
from these studies point towards negative impact of multimorbidity on COPD-specific outcomes; 
however, none of the studies until now had systematically evaluated the impact of inflammation-
related multimorbidity on COPD-specific outcomes. This led to the rationale for the Aim1, 
which examined the association between inflammation-related multimorbidity and COPD 
treatment patterns and COPD-specific outcomes such as COPD-specific healthcare utilization 
and healthcare expenditures among individuals with newly-diagnosed COPD.  We hypothesized 
that individuals with newly-diagnosed COPD and inflammation-related multimorbidity will have 
lower COPD-medication utilization and persistence. 
Furthermore, due to the presence of systemic inflammation among patients with COPD, 
current pharmacologic management is unable to alter the overall prognosis of the disease due to 
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their local pulmonary exposure. (M. Cazzola et al., 2007; Vogelmeier & Wouters, 2011) In this 
context, some prior studies had examined the beneficial effects of novel anti-inflammatory 
therapies such as statins in improving lung function, health status and COPD-related 
exacerbations among those with COPD. (Blamoun et al., 2008; Huang et al., 2011; Ishida et al., 
2007; Keddissi et al., 2007; Lawes et al., 2012) None of the studies were generalizable to US 
population and no study has systematically studied the role of inflammation-related 
multimorbidity on statin use and COPD-specific outcomes and expenditures. Therefore, the 
primary objective of Aim 2 was to examine the effectiveness of novel statin therapy in terms of 
clinical and economic outcomes among individuals with COPD in a real-world practice setting.  
Finally, as patients with COPD and inflammation-related multimorbidity are at an 
increased risk of developing new-onset diabetes (Rana et al., 2004), while examining 
effectiveness of statin therapies for COPD management, it is important to establish its safety in 
this population. Moreover, prior studies have suggested that patients with COPD often take 
multiple medications (Anecchino et al., 2007). These medications may include antidepressants, 
inhaled corticosteroids (ICS) and statins that have been associated with risk of new-onset 
diabetes. (Bhattacharjee, Bhattacharya, Kelley, & Sambamoorthi, 2013; O'Byrne et al., 2012; 
Sattar et al., 2010; Suissa, Kezouh, & Ernst, 2010) Thus, the primary objective of Aim 3 was to 
evaluate the association between antidepressants, ICS and statins and new-onset diabetes among 
individuals with newly-diagnosed COPD after controlling for comprehensive set of risk factors. 
For the purpose of these objectives we used the MAX data for years 2005 through 2008 
and conducted retrospective longitudinal analyses  
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SUMMARY OF FINDINGS 
Medicaid beneficiaries with newly-diagnosed COPD had very high prevalence of 
inflammation-related multimorbidity. Presence of inflammation-related multimorbidity was 
significantly associated with reduced COPD-medication utilization and decreased persistence on 
long-bronchodilators.  Our study findings suggest that COPD medication management may be 
poor due to competing demands arising from the presence of inflammation-related 
multimorbidity. Medicaid beneficiaries with inflammation-related multimorbidity were less 
likely to have COPD-specific utilization compared to those without any inflammation-related 
multimorbidity. These findings suggest that individuals with inflammation-related 
multimorbidity may have a greater need for non-COPD related care. 
Furthermore, findings from Aim 2 indicate that any statin use was associated with better 
COPD-specific outcomes compared to no statin use.  A closer examination of the data revealed 
that only those with long-term statin use have better outcomes as compared to those with no 
statin use. We also found that beneficiaries with inflammation-related multimorbidity and statin 
use had better COPD-specific outcomes compared to those with multimorbidity and no statin 
use.  These findings suggest that long-term statin use may reduce COPD-specific adverse 
outcomes.  Furthermore, statin use may be particular beneficial for those with inflammation-
related multimorbidity. Our study found that although statin use was associated with the risk of 
new-onset diabetes, the association was no longer significant in analyses that controlled for 
selection bias in unobserved characteristics.  Thus these findings indicate that the medications 
may be safe in terms risk of new-onset diabetes.   
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STUDY LIMITATIONS 
Our study had some limitations such as limited generalizability due to inclusion of 
beneficiaries with fee-for-service claims only. The study also used data from only four states 
which may not provide a full understating of overall Medicaid population. We also excluded 
dual Medicare-Medicaid enrollees from our population which limits the overall generalizability. 
Due to unavailability of laboratory data we were not able to control for stage of COPD at 
diagnosis or confirm the diagnosis of COPD. We only observed prescriptions for specific 
medications and cannot determine use of these medications. Furthermore, unavailability of 
laboratory data limited our ability to control for important confounders such as cholesterol levels 
and baseline blood glucose levels. Additionally we did not have the data for body mass index 
which is an important predictor of new-onset diabetes.    
Despite these limitations, to the best of our knowledge this the first study to extensively 
examine the relationship between inflammation-related multimorbidity and comprehensive set of 
COPD-specific outcomes. Therefore, the findings from this study may guide clinical and policy 
decision making for management of COPD patients with inflammation-related multimorbidity.  
UNIQUE CONTRIBUTIONS OF THE STUDY 
Our study aimed to fill the knowledge gap and provide real-world patterns about current 
pharmacologic management among those with inflammation-related chronic conditions and 
COPD. As there has been an increasing recognition for organizing care around the individuals 
rather than the disease (Kadam, 2012) an understanding of how care is delivered among 
individuals with multimorbidity will have important implications for the overall healthcare 
management of individuals with COPD. Our study also pioneered in the area of management of 
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COPD and provided important evidence that will help in developing clinical practice guidelines 
for those with COPD and multimorbidity. 
Our study contributed to a better understanding of a relationship between inflammation–
related multimorbidity and COPD-specific outcomes. COPD is often understood a disease with 
local inflammation. Therefore, most pharmacologic medications used in treating COPD focuses 
on reducing local inflammation and thereby improving only symptoms and not changing the 
course of disease progression. Recently, investigators have begun to consider COPD as a disease 
associated with systemic inflammation. By explaining the link between inflammation-related 
multimorbidity and COPD-specific outcomes, we strengthen the current understanding about 
inflammation in COPD and provide a novel target area (systemic inflammation) to improve 
COPD-specific outcomes. 
In this context, our study is highly timely and innovative as it examines the association 
between novel approaches (statin use) for COPD management and COPD-specific outcomes. 
Another important significance of our study is the use of real-world data that will provide 
information about individuals with multimorbidity as these individuals are excluded from 
randomized controlled trials.  Our study is also hypothesis generating and will provide the 
necessary foundation for future research and perhaps randomized clinical trials evaluating the 
effectiveness and safety of statin therapy among individuals with COPD.  
The use of data from the claims of Medicaid beneficiaries enhances the significance of 
this study. Enrollees in the Medicaid comprise of high-risk vulnerable population that have high 
rates of COPD and allied multimorbidity. Therefore, proving the real-world evidence about 
management of COPD and benefits and harms of current and novel therapies among high-risk 
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and vulnerable population of Medicaid beneficiaries with COPD will strengthen the evidence in 
the area of COPD management. 
IMPLICATIONS 
 Our study highlighted the high prevalence of inflammation-related multimorbidity among 
non-elderly low-income adults with newly-diagnosed COPD.   Our study findings confirm that 
multimorbidity is common even among the non-elderly and clinical practice and research studies 
need to examine multimorbidity across the entire life-course (Mercer SW, 2009)  
This finding also has implications for healthcare management of these individuals.  
COPD patients with inflammation-related multimorbidity will have competing demands and 
require care from multiple providers and specialists such as cardiologists, pulmonologists, 
mental health specialists, endocrinologists and others.  For individuals care needs to be organized 
around the patient rather than the disease (Kadam, 2012).  Furthermore, for individuals with 
multimorbidity, fee-for-service approach provides little incentive to coordinate care across 
multiple providers (Chronic Care: Making the Case for Ongoing Care).  Financial incentives to 
physicians for coordinating care are warranted.  In this context, Medicaid may want to adopt the 
Medicare policy initiative of paying physicians who manage care of patients with multimorbidity 
(DHHS, 2014).  Under this new initiative, physicians will be responsible for developing a 
comprehensive care plan that includes patients’ medical, psychological and social needs, monitor 
medication adherence, and coordinate care across multiple providers (DHHS, 2014) 
 In this study, we found that beneficiaries who received long-term use of statin 
medications were less likely to have COPD-specific adverse outcomes compared to no statin use.  
This finding has implications regarding the long-term adherence to therapies.  There is 
documented evidence of low-rates of long-term adherence to therapies in Medicaid population 
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(Kyanko, 2013).  Therefore, to realize the benefits of novel therapeutic agents such as statins for 
management of COPD, surveillance and programs need to be in place for encouraging long-term 
use of medications.    
The current study also evaluated the safety of antidepressants, ICS, and stains with regard 
to new-onset diabetes.  Our study did not find an association between these medications and risk 
of new-onset diabetes once we controlled for selection bias in unobserved variables.  Our study 
had not included many risk-factors (e.g. obesity, family history, and pre-diabetes).  These 
findings suggest the need to be cautious about making inferences from observational data 
without rigorous adjustments for selection bias.  
 Our study utilized Medicaid claims data on non-elderly adults with newly-diagnosed 
COPD. This has implication for improving access to care through expansion of Medicaid under 
the affordable care act.  In total, 27 states have adopted expanding insurance coverage through 
Medicaid expansion including California, Illinois and New York (states included in this study). 
Under this expansion, low-income non-elderly adults with incomes below 133% of federal 
poverty level are eligible to be enrolled in Medicaid.  Such expansion may include insurance 
coverage of non-elderly adults over age 40, similar to the population included in this study.  As 
these individuals are likely to have COPD, inflammation related multimorbidity, absolute 
number of individuals requiring care for these conditions will increase. Therefore, state Medicaid 
programs will need to specifically examine and solve the issue of provider shortage that may be 
created due to large influx of individuals with multimorbidity.  
DIRECTIONS FOR FUTURE RESEARCH 
Our research utilized retrospective claims data for years through 2005-2008, with 
rigorous analytical methods to understand the management of COPD among non-elderly adults 
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with newly-diagnosed diabetes.   Our research contributed to the nascent literature of 
multimorbidity among individuals with a specific disease namely COPD.   We documented the 
poor COPD management of individuals with inflammation-related multimorbidity and evaluated 
the benefits and safety of novel therapeutic agents such as statins for COPD management.  
However, future studies need to go beyond just documenting the existing problems in COPD 
management.  Randomized clinical trials are critical to establish the efficacy, effectiveness, and 
safety of novel therapeutic agents in management of COPD.  Furthermore, future research needs 
to focus on designing, developing and implementing evidence-based interventions for long-term 
adherence on medical therapies and improving health outcomes for individuals with COPD and 
inflammation-related multimorbidity. 
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